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ABSTRACT 
 
A variety of mechanisms act to prevent the inappropriate targeting of host tissues 
by the immune system, but these mechanisms can fail, leading to development of 
autoimmunity. Type 1 Diabetes is an autoimmune disease caused by T cell-mediated 
destruction of the insulin-producing beta cells in the pancreatic islets of Langerhans. This 
work focused on understanding islet-reactive CD4 T cells during Type 1 Diabetes 
progression by comparing T cell responses in diabetes-susceptible non-obese diabetic 
(NOD) mice to diabetes-resistant (B6.g7) mice. Our knowledge of how these cells are 
normally regulated and how that regulation breaks down leading to diabetes is limited 
due to a lack of reagents to track these cells in mice with normal T cell repertoires. The 
goal of this work was to develop models to study physiological numbers of islet-reactive 
CD4 T cells in mice in order to gain a better understanding of how these cells are 
regulated with an emphasis on one critical inhibitory pathway involving Programmed-
Death 1 (PD-1). Using these models, we showed that in diabetes-susceptible NOD mice, 
the majority of islet-reactive CD4 T cells become activated, but the pathogenic subset 
capable of contributing to disease was relatively small. Rather, the majority of the 
population was adequately controlled by the host through induction of T cell anergy. In 
diabetes-resistant mice, islet-reactive CD4 T cells were present, but failed to become  
activated and subsequently did not infiltrate the pancreas. The inhibitory receptor PD-1 
was important for suppressing CD4 T cell effector functions in NOD mice, including 
proliferation, trafficking to the pancreas, and localization within the pancreas. However,  
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blockade of PD-1 did not promote CD4 T cell trafficking to the pancreas in diabetes-
resistant mice. Unexpectedly, in NOD mice, PD-1 was predominantly involved in 
suppressing the functions of an activated effector population, not maintaining the anergic 
population. These findings provide new insight into the regulation of islet-reactive CD4 T 
cells, and show that PD-1 differentially contributes to the suppression of these cells.  
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CHAPTER 1: 
An overview of Type 1 Diabetes pathogenesis, including the role of CD4
+
 T cells, self 
tolerance mechanisms which act to restrain these cells, and the role of the PD-1 
pathway in regulating T cell functions
1
 
 
INTRODUCTION 
 The immune system has evolved to protect the host from a variety of pathogens 
including viruses, bacteria, and parasites, as well as tumor cells. Once activated, the 
immune system has the capacity to potently eliminate these harmful threats. A long 
standing problem in the immune system has been distinguishing what is harmful from 
what is not, and sparing the innocuous tissue while eliminating the threat from the body. 
There are a variety of mechanisms that the immune system has developed to distinguish 
between harmful and innocuous; however, these mechanisms are not always effective, 
resulting in the immune system targeting and destroying self tissues. Depending on the 
tissue that is targeted, a variety of different clinical outcomes occur, ranging from loss of 
function of an organ, deregulated production of different small molecules such as 
hormones, and, in the most severe cases, death. This inappropriate targeting of self 
tissues by the immune system is referred to as autoimmunity, and the range of diseases 
that fall into this category are diverse both in terms of severity and the tissues that are 
involved. The focus of the work presented herein is Type 1 Diabetes, an autoimmune 
disease characterized by loss of the insulin-producing beta cells in the pancreatic islets of 
Langerhans. The immune system selectively targets and destroys this population, 
2 
 
requiring Type 1 Diabetic patients to inject insulin daily for the remainder of their lives to 
regulate glucose metabolism. In this thesis, issues regarding the immune components 
responsible for the disease and the mechanisms that normally regulate these cells will be 
discussed, with a particular emphasis on one inhibitory pathway involving Programmed 
Death-1 (PD-1). Additionally, clinical perspectives will be addressed including potential 
cures for this devastating autoimmune disease. With a better understanding of how the 
self-specific immune response is controlled and why these regulatory mechanisms fail, 
we will enhance the possibility of developing a cure for Type 1 Diabetes.  
 
TYPE 1 DIABETES PATHOGENESIS  
Type 1 Diabetes in human patients 
 Type 1 Diabetes is an autoimmune disease that manifests when the adaptive 
immune system selectively targets and destroys the insulin-producing beta cells in the 
pancreatic islets of Langerhans. This aberrant autoimmune response leads to the 
permanent destruction of the insulin-producing cells, resulting in the requirement for 
Type 1 Diabetic patients to take exogenous insulin for the remainder of their lives to 
regulate glucose metabolism. While insulin therapy can be an effective way to regulate 
glucose metabolism, stringent control of blood glucose levels is difficult to maintain, 
which can lead to severe end organ damage in the kidney, eyes, peripheral nerves, and 
blood vessels. This organ damage can lead to kidney failure, blindness, peripheral 
neuropathy, coma and/or death (1, 2). Therefore, there is intense interest in the field to 
develop a cure for Type 1 Diabetes. A cure for Type 1 Diabetes will require both 
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restoration of beta cell mass so patients can produce their own insulin, as well as 
limitation of the anti-islet autoimmunity response. Issues involved in achieving this goal 
will be discussed in Chapter 5.  
Type 1 Diabetes is one of the most common chronic diseases in children in the 
United States. This form of the disease accounts for approximately 5-10% of diabetes 
cases, and is the most prevalent diabetes subtype observed under the age of 20 (2). Type 
1 Diabetes has also been referred to as juvenile onset diabetes due to the tendency of this 
disease to develop during childhood; however, it has become appreciated that Type 1 
Diabetes can develop at any age including adulthood, so the term juvenile onset is no 
longer widely used. Diabetes in children typically occurs either between 5-7 years of age 
or at or near puberty (2). Symptoms typically include polydipsia (chronic thirst), polyuria 
(increased urination), and polyphagia (increased hunger) and hyperglycemia (2). By the 
time patients are diagnosed, typically 80-90% of the insulin-producing beta cells have 
been destroyed (1). While these patients can retain some insulin production for the first 
year or two after diagnosis, they will ultimately require exogenous insulin for the 
remainder of their lives to maintain glucose homeostasis. Murine models of Type 1 
Diabetes show strong gender bias towards females developing the disease; however, this 
gender bias is not observed in human Type 1 Diabetes (2). The lack of gender bias in 
human diabetes is particularly interesting since most autoimmune diseases are more 
prevalent in women, and may be partially due to the early onset of the disease before 
puberty. Despite decades of research investigating this autoimmune response, the triggers 
that cause Type 1 Diabetes are still largely unknown. There is evidence for both genetic 
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and environmental components contributing to the disease, both of which will be 
discussed below. However, there are still several unresolved questions that remain in 
order to prevent or cure Type 1 Diabetes in humans.      
Genetics are the highest risk factor predisposing people to developing Type 1 
Diabetes. There is a high rate of familial transmission, which is particularly high for 
identical twins (35-40% concordance) (3-6). Additionally, there is a 7% increase in the 
risk of developing Type 1 Diabetes if a sibling has the disease, and a 6% increase for a 
child of a diabetic person (6). Furthermore, several genes have been associated with 
increased susceptibility to Type 1 Diabetes development. The highest associated genetic 
risk factor is MHC class II. For humans, combinations of the DRB1, DQA1, and DQB1 
genes heavily influence susceptibility to diabetes, with haplotypes HLA-DR4-DQ8 
(DRB1*0401-DQA1 *0301-DQB1 *0302) and HLA-DRB1*0301-DQA1*0501-
DQB1*0201 most commonly associated with diabetes (7-11). The HLA-DQ8 molecule is 
of particular interest because it contains an atypical non-aspartic acid mutation at position 
57 of the MHC class II beta chain which disrupts a salt bridge used for proper folding of 
the molecule. This mutation is also observed in the non-obese diabetic (NOD) mouse 
model of Type 1 Diabetes, where homozygous expression of this atypical MHC molecule 
is required for diabetes (12-14). Due to its role in antigen presentation to CD4
+
 T cells, 
MHC class II heavily impacts T cell selection in the thymus, which may bias towards 
selection of an autoreactive T cell repertoire. Additionally, MHC class II controls CD4
+
 T 
cell activation in the periphery, which may lead to aberrant activation of autoreactive T 
cells in diabetes-prone hosts (15). These two features likely both contribute to MHC 
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haplotype leading to enhanced susceptibility to developing Type 1 Diabetes. A variety of 
other genes have now been identified which increase the susceptibility to Type 1 
Diabetes. At least fifteen more loci in addition to MHC class II have been identified, 
though the functions of all of these polymorphisms are not fully characterized (11). 
Polymorphisms in the insulin gene (contains a variable nucleotide tandem repeat at the 5’ 
end of the gene) (16, 17), PTPN22 (11), IL-2RA (11),  and Cytotoxic T-Lymphocytes-
Associated Antigen-4 (CTLA-4) (presence of an alanine at codon 17 increases 
susceptibility to disease) (18, 19) have been identified to increase the risk of developing 
diabetes. However, the contribution of these genes is minor compared to MHC class II 
(11).    
While the genetic component of Type 1 Diabetes is widely appreciated, genetics 
cannot entirely account for disease development. For example, even though the genetic 
composition between identical twins is the same, the concordance is only 35-40%, 
leaving 60-65% discordance (3-5). Additionally, the disease frequency varies 
substantially between countries in a manner that cannot be explained by genetics, 
including immigrants from a country with a low frequency of diabetes acquiring a higher 
risk for diabetes development in the new country (20, 21). Hence, other factors must 
contribute to the development of Type 1 Diabetes, including the environment as well as 
stochastic factors that remain to be defined. Patients often have severe viral infections 
shortly before clinical symptoms of Type 1 Diabetes manifest, including rubella virus 
(22) and coxsackie B virus (23, 24). Other environmental factors that have been proposed 
to contribute to Type 1 Diabetes include diet and stress (25). Hormones have also been an 
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area of interest in Type 1 Diabetes due to the dramatically higher incidence of the disease 
in female NOD mice compared to male; however, since Type 1 Diabetes in humans often 
develops before puberty, it is less likely that sex hormones play a critical role in diabetes 
development in humans (2).  
The identification of Type 1 Diabetes as an autoimmune disease was critical for 
beginning to understand disease pathogenesis and continues to shape therapeutic 
strategies to manage the disease. Evidence to suggest that Type 1 Diabetes is autoimmune 
in nature comes from the presence of autoreactive T cells and autoantibodies specific for 
pancreatic islet antigens. Autoantibodies during Type 1 Diabetes in humans are better 
characterized than the islet-reactive T cell response, though production of peptide/Major 
Histocompatibility Complex (MHC) tetramer reagents to track antigen-specific T cells in 
humans is allowing us to gain a better understanding of this population as well. 
Autoantibodies against islet constituents including insulin, preproinsulin, and GAD are 
detectable in patients prior to diabetes onset (26-28). Importantly, levels of anti-insulin 
antibodies correlate with age of onset and rate of progression towards diabetes (29). In 
humans, CD4
+
 T cell responses to beta cell antigens including insulin, glutamic acid 
decarboxylase 65 kDa (GAD65), heat shock protein (HSP)-60 and HSP-70, insulinoma 
antigen (IA)-2, islet cell antigen (ICA)-69, and others, and CD8
+
 T cell responses to 
insulin, GAD65, IA-2, and islet amyloid polypeptide (IAPP) have been identified (30). 
There is a substantial effort from several groups including our own to further investigate 
the dynamics of these islet-antigen specific T cell populations in patients during pre-
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clinical stages as well as following diabetes onset in an effort to develop better therapies 
to inhibit these pathogenic T cell responses.  
In summary, Type 1 Diabetes is an autoimmune disease that typically develops 
early in life in humans and is caused by T cell-mediated destruction of the insulin-
producing beta cells in the pancreas. While the triggers leading to diabetes development 
remain unclear, genetics appear to play the most substantial role in diabetes risk. 
However, other factors including the environment, stress, and infections contribute to 
diabetes development as well. In order to cure diabetes, the insulin-producing cells must 
be replaced and the autoimmune response must be inhibited. Later sections will focus in 
detail on the regulation of the autoreactive T cell response using preclinical mouse 
models as well as potential immunotherapies to selectively inhibit autoreactive T cells in 
Type 1 Diabetic patients.  
  
The non-obese diabetic (NOD) mouse model for studying Type 1 Diabetes pathogenesis 
 The non-obese diabetic (NOD) mouse is the best characterized and most 
commonly used mouse model for studying Type 1 Diabetes (31, 32). The NOD mouse 
was developed over 30 years ago by Makino and colleagues in an attempt to isolate 
strains susceptible to developing cataracts (32, 33). The observation that this strain 
developed diabetes spontaneously, and subsequently the establishment that this mouse 
shared many similarities with human Type 1 Diabetes, has led to a wealth of information 
on how diabetes progresses and importantly how it can potentially be treated. Compared 
to the human disease, the NOD mouse has similar genetic linkages, pancreas-specific 
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autoantibodies, and aberrant activation of autoreactive CD4
+
 and CD8
+
 T cells. 
Additionally, many of the antigens involved in disease progression are shared between 
Type 1 Diabetic patients and the NOD mouse, including insulin and GAD65 (30). A 
critical advantage of the NOD mouse model is that the disease develops spontaneously, 
allowing investigation of the natural breakdown of self tolerance mechanisms. 
Furthermore, the similarities between the NOD mouse and human diabetes have allowed 
development of potential therapies to treat Type 1 Diabetes in the NOD mouse that have 
subsequently been translated into humans (31, 34). The characterization and use of 
different therapies targeted at immune regulation and prospective therapies will be further 
detailed in Chapter 5.  
 Diabetes incidence in NOD mice varies between mouse colonies, but it typically 
averages 60-80% for female mice and 20-30% for male mice by 30 weeks of age (32). 
However, there is evidence of immune cell infiltration of the pancreas by 3-4 weeks of 
age. The infiltration of the pancreas begins as peri-insulits, which is defined as 
mononuclear cell infiltrates surrounding the islet but not deeply penetrating within the 
islet, and eventually progresses to destructive insulitis as the protective barrier between 
the infiltrate and insulin-producing cells is lost and the T cells induce damage that leads 
to disease onset. All female NOD mice develop peri-insulitis; however, 100% of these 
mice do not develop the disease (31, 32). The inability to discern which mice would 
progress to clinical diabetes and which would not has made studying the events leading to 
Type 1 Diabetes difficult, particularly the imitating events that occur very early in life. 
However, recent imaging advances by Mathis and colleagues have made it possible to 
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determine which mice will eventually develop clinical disease months prior to symptom 
onset (35). This technology, termed MRI-MNP, employs non-invasive MRI imaging of 
magnetic nanoparticles (MNP). During diabetes development, insulitis results in 
inflammation that leads to vascular damage and leakage, which can be detected by the 
MRI. Using this technique, it can be determined whether a NOD is going to develop 
diabetes later in life by 6 weeks of age, demonstrating the importance of events early in 
life during Type 1 Diabetes pathogenesis (35). This technology will likely aid in further 
delineating the mechanisms that contribute to the loss of self tolerance in NOD mice, 
particularly the pathogenic events that occur early in life. 
 Autoimmune diseases develop due to the aberrant activation of a small portion of 
the adaptive immune system that is specific for self antigens. In Type 1 Diabetes, CD4
+
 
and CD8
+
 T cells as well as B cells all play indispensable roles during disease 
progression, which is most evident by NOD mice deficient in any one of these adaptive 
immune components being protected from developing Type 1 Diabetes (CD4
+
 T cell 
deficiency using CIITA knockout (KO) NOD (36), CD8
+
 T cell deficiency using 2m 
KO NOD (37, 38), and B cell deficiency using MT mice (39)). However, diabetes is 
considered a T cell-mediated autoimmune disease because disease can be transferred 
from one mouse to another using diabetogenic T cells but not serum autoantibodies (31).  
The primary role of B cells during diabetes development is thought to be antigen 
presentation to CD4
+
 T cells rather than autoantibody production, since B cells must 
express MHC class II for diabetes to develop and serum antibody transfer into B cell-
deficient NOD mice does not restore disease (40, 41). Additionally, NOD mice 
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engineered to contain B cells that express MHC class II but cannot secrete antibody 
developed both insulitis and diabetes, suggesting that antibody is not required for 
diabetes pathogenesis (42). For CD4
+
 T cells, there are a variety of different effector 
subsets that arise following antigen encounter, and these subsets are defined based on the 
cytokines they are capable of producing (Th1 cells produce IFN, Th2 cells produce IL-4, 
and Th17 cells produce IL-17) (43). During Type 1 Diabetes, IFN-producing Th1 cells 
are critical for disease progression, since IFN KO and IFNR KO mice on the NOD 
background are largely protected from developing diabetes (44, 45), and NOD.T-bet KO 
mice (the master transcription factor required for Th1 differentiation) are completely 
protected from developing Type 1 Diabetes (46). Th2 cytokines are thought to be 
protective during Type 1 Diabetes (47, 48), and the role of Th17 cells during disease 
progression remains controversial (49-51). However, the indisputable role for T cells in 
the pathogenesis of Type 1 Diabetes has led to a substantial interest in understanding how 
these cells escape deletion during development (central tolerance), how these cells are 
normally regulated (peripheral tolerance), why these cells become activated and destroy 
the pancreas, and how these self-destructive cells can be stopped.  
 
THE ROLE OF ISLET-ANTIGEN SPECIFIC CD4
+
 T CELLS DURING TYPE 1 
DIABETES DEVELOPMENT 
CD4
+
 T cells are required for Type 1 Diabetes development in NOD mice 
 The previous section outlined the indispensable roles of CD4
+
 and CD8
+
 T cells 
as well as B cells in Type 1 Diabetes development based on studies using NOD mice 
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deficient in any one of these subsets (36-39). While CD8
+
 T cells and B cells are 
important for the disease, our lab specifically focuses on understanding the pathogenic 
CD4
+
 T cell subset in this autoimmune response. Several lines of evidence support the 
importance of CD4
+
 T cells in Type 1 Diabetes. The MHC class II locus is the highest 
genetic susceptibility allele for Type 1 Diabetes in NOD mice and human patients, 
implicating CD4
+
 T cells as an important component in disease progression (31).  The H-
2
g7
 haplotype in NOD and HLA-DR3/4 and DQ8 haplotypes in humans are thought to 
enhance susceptibility to diabetes through mediating selection of a T cell repertoire that 
selects for diabetogenic clones and promoting aberrant activation of these pathogenic 
cells in the periphery (15, 52). The NOD MHC class II molecule H-2
g7
 differs from other 
mouse MHC class II molecules by having histidine and serine residues at positions 56 
and 57 of the beta chain, respectively, rather than the proline and aspartic acid residues 
that are typically found at these positions (53). Additionally, the H-2
g7
 haplotype encodes 
H-2A (g7), but does not encode H2-E due to a deletion in part of the gene encoding the 
alpha chain (54). In NOD mice, Type 1 Diabetes development requires homozygous 
expression of H-2
g7
 and the absence of the H2-E locus, highlighting the importance of 
this atypical MHC molecule in disease progression (12-14). A similar amino acid 
substitution is also observed in the human HLA-DQ8 haplotype which is highly 
associated with Type 1 Diabetes susceptibility (52). The histidine and serine residues 
disrupt a salt bridge in the MHC class II molecule, altering the nature of the peptides that 
preferentially bind as well as impacting the on/off rate of peptides once bound. The latter 
results in peptides bound to H-2
g7
 and HLA-DQ8 being abnormally unstable, causing loss 
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of peptides from the groove on the surface of antigen presenting cells (52, 55, 56). Some 
speculate that the abundance of empty MHC class II molecules on the surface of dendritic 
cells in the pancreas leads to loading of peptides derived from beta cell granules onto the 
surface of these cells, leading to the aberrant activation of diabetogenic T cells (56, 57). 
While the exact mechanism of diabetogenic T cell activation is still debated and will be 
discussed in detail in a later section, the critical role for the MHC class II haplotype in 
this process remains well established.   
In NOD mice, CD4
+
 T cells are required for Type 1 Diabetes pathogenesis. NOD 
mice deficient in MHC class II (CIITA KO mice) and subsequently CD4
+
 T cells are 
protected from diabetes development (36). Additionally, antibody-mediated depletion of 
CD4
+
 T cells prevents diabetes onset in NOD mice (58). Furthermore, in vitro activated 
diabetogenic CD4
+
 T cells are sufficient to induce Type 1 Diabetes in lymphoreplete 
mice (59), demonstrating that CD4
+
 T cells can be directly pathogenic during diabetes. 
The mechanism of diabetes induction in this case is likely cytokine mediated, since in 
vitro activated CD4
+
 T cells produce high levels of IFN This critical cytokine enhances 
the antigen presenting capacity of antigen presenting cells within the islet (60), and in 
cooperation with other cytokines including TNF and IL-1 can directly induce 
apoptosis in the insulin-producing beta cells (61-63). During spontaneous diabetes 
progression, CD4
+
 T cells likely play a more cooperative role in disease development 
rather than a directly pathogenic role. CD4
+
 T cells are known for providing help to 
activate both B cells and CD8
+
 T cells, two other immune constituents that are required 
for Type 1 Diabetes pathogenesis (37-39). Diabetogenic CD4
+
 T cells comprise the 
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majority of the early infiltrate in the pancreas of young NOD mice, and may be critical 
for the initiating events that subsequently lead to Type 1 Diabetes later in life (64). There 
is currently a substantial interest in the field in understanding the contribution of CD4
+
 T 
cells to diabetes with the hope of targeting this T cell subset for therapeutic benefit. 
  
A variety of pancreatic antigens are recognized by CD4
+
 T cells during Type 1 Diabetes 
 Diabetogenic CD4
+
 T cells are activated early in life in NOD mice and persist in 
the pancreas throughout the course of the disease. These cells recognize a variety of 
different pancreatic antigens, though the epitopes responsible for initiating as well as 
sustaining Type 1 Diabetes have been highly debated. There is interest in identifying 
which epitopes are important at which stages of disease so that these CD4
+
 T cells can be 
targeted using antigen-specific therapies, including antigen-coupled ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (ECDI)-fixed cells, which will be discussed later. 
Identifying which antigens are critical at different stages of disease is particularly 
problematic in the context of developing antigen specific therapy because antigens can 
vary between patients, requiring each therapy to be personalized, and there is evidence of 
epitope spreading, suggesting that the antigens targeted by the anti-islet T cell response 
change as disease progresses. Two of the major antigens recognized by CD4
+
 T cells 
early during the initiation of Type 1 Diabetes in NOD mice are GAD65 and insulin (30). 
Epitopes from GAD65 in NOD mice include amino acid residues 206-220, 247-266, 509-
528 and 524-543. Tolerizing three week old NOD mice against GAD65 by either 
immunizing intravenously or by intrathymic injections practically eliminated insulitis and 
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diabetes (65, 66), demonstrating the importance of GAD65 as an autoantigen during Type 
1 Diabetes. Importantly, the 247-266 and 206-220 epitopes have also been identified in 
human patients with Type 1 Diabetes. However, several reports strongly argue against 
GAD as an immunodominant antigen during Type 1 Diabetes. First, GAD65 KO NOD 
mice develop diabetes normally (67). Second, insulitis and diabetes developed normally 
when tolerance to GAD was induced by expressing it under the control of the invariant 
chain promoter (68). Third, there are substantial differences in GAD65 expression 
between humans and mice, with expression levels in NOD mice being substantially lower 
than humans (69). These studies have led to substantial resistance against GAD being an 
immunodominant epitope during Type 1 Diabetes. The majority of the field now 
acknowledges insulin as the major immunodominant antigen. While the evidence for this 
consensus will be discussed below in detail, the most substantial finding suggesting the 
importance of insulin came from mice where insulin was engineered to be a foreign 
antigen (70). Insulitis and diabetes were completely prevented in these mice, highlighting 
the importance of insulin in the initiation of diabetes (70). It should be noted, however, 
that whether other epitopes are essential for sustaining diabetes progression is still 
debated. Other autoantigens that serve as CD4
+
 T cell epitopes during Type 1 Diabetes 
include IA-2, HSP-60, ICA-69, S100 (30) and chromogranin A (71). However, these 
antigens appear to play less significant roles in diabetes progression than insulin or 
GAD65 (72).  
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Insulin is the major immunodominant antigen for spontaneous Type 1 Diabetes 
development in NOD mice and human patients 
 While the autoantigens responsible for the development of Type 1 Diabetes are 
still debated, several lines of evidence highlight the importance of the immune response 
against insulin during disease development. CD4
+
 and CD8
+
 T cell epitopes have been 
identified within the insulin protein, and anti-insulin autoantibodies are detectable in both 
NOD mice and diabetic patients (26, 64, 73-79). Importantly, insulin is the only diabetes-
associated autoantigen where autoantibodies correlate with age of onset and rate of 
disease progression (29) Work conducted in NOD mice strengthens the argument that 
insulin is a major immunodominant epitope both in terms of initiating the disease as well 
as sustaining the response through diabetes onset. T cells that react to insulin are 
detectable in the pancreas as early as 4 weeks of age (64), and persist in the pancreas long 
term as evidenced by their presence at weeks 5, 6, 7, 8, 9, and 12 weeks of age (80). 
Early work investigating insulin-specific T cells in the pancreas showed that in 12 week 
old mice the majority of T cells that responded to insulin were of the CD4
+
 T cell lineage 
(64), though a CD8
+
 T cell epitope within insulin (B chain 15-23) has been identified that 
can comprise up to 10% of CD8
+
 T cells infiltrating the pancreas (73, 81). Greater than 
90% of the insulin-specific CD4
+
 T cells in the pancreas respond specifically to the 9-23 
peptide from the insulin B chain (insB9-23) (74). Consequently, a substantial amount of 
work has been conducted to understand the role of diabetogenic CD4
+
 T cells specific for 
insB9-23 in NOD mice.  
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The importance of the T cell response directed against insulin, and more 
specifically the insB9-23 peptide, during Type 1 Diabetes progression has come from two 
key observations. The first observations came from genetic approaches to study the 
impact of insB9-23-specific CD4
+
 T cells during diabetes. First, Maki Nakayama and 
George Eisenbarth created a NOD mouse line that had the two genes that encode mouse 
insulin (mouse ins1 and ins2) knocked out, and transgenic expression of insulin 
containing a critical point mutation in the gene encoding the insulin B chain (alanine for 
the tyrosine at position 16) (70). This mutation does not impact the metabolic activity of 
insulin, allowing these mice to regulate glucose metabolism normally. However, previous 
work from this group had shown that the tyrosine at position 16 was required for insB9-23-
specific CD4
+
 T cell responses (82). Hence, the native mouse insulin peptide sequence is 
considered a foreign antigen in these mice. Using this mouse model, Nakayama made the 
seminal observation that when mouse insulin was a foreign antigen, NOD mice did not 
develop insulitis or Type 1 Diabetes, presumably due to the lack of induction of an 
efficient insB9-23-specific CD4
+
 T cell response (70). Introduction of one copy of either 
mouse insulin 1 or 2 into this transgenic line restores insulitis and diabetes, highlighting 
the importance of the immune response against mouse insulin in diabetes progression. If 
the other diabetes-associated epitopes were critical for disease initiation, insulitis and/or 
diabetes would have been observed in those mice (70). Further evidence that insB9-23-
specific T cells are required for diabetes progression comes from generation of a T cell 
receptor transgenic mouse specific for the 9-23 peptide. These transgenic mice, termed 
BDC12.4.1, develop Type 1 Diabetes with approximately 40% penetrance on a Rag-
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deficient background, demonstrating that when insulin-specific CD4
+
 T cells are the only 
T cell specificity in the mouse, diabetes can still develop (83). In this study transfer of 
insB9-23-specific T cells from the BDC12.4.1 mouse into lymphopenic NOD mice 
(NOD.scid) induced diabetes, further supporting the direct pathogenic role of this 
specificity during Type 1 Diabetes progression (83). These studies firmly established the 
importance of the insulin-specific CD4
+
 T cell response during Type 1 Diabetes 
development in NOD mice. 
The second key observation that has led to intense interest in targeting the anti-
insulin immune response in patients is that tolerogenic immunization against the insulin 
protein, the insB9-23 peptide, or variants of insB9-23 that have been modified to bind with 
high affinity to I-A
g7
 can prevent and/or reverse Type 1 Diabetes in NOD mice (59, 84-
86). Work using antigen coupled to apoptotic splenocytes using the chemical ECDI 
revealed a role for insB9-23 in the initiation of disease, since treating 4-6 week old mice 
with splenocytes coupled to insB9-23 or whole insulin protein could prevent disease later 
in life (85). Importantly, treating with cells coupled to GAD65509-528, GAD65524-543, or 
IGRP206-214 did not confer protection, highlighting the importance of the anti-insulin 
response early during the initiation of the disease (85). Interestingly, treating older pre-
diabetic NOD mice (19-21 weeks) with whole insulin coupled to apoptotic cells, but not 
insB9-23, prevented diabetes, suggesting that the insB9-23 epitope may be less important for 
sustaining disease progression in older mice (85). These results have been confirmed and 
extended using tolerogenic immunization (84, 86) with an insB10-23 peptide variant that 
had been modified to bind with higher affinity to I-A
g7
 (87). Zhang and Daniel 
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demonstrated that immunizing 4-6 week old NOD mice with this modified peptide could 
prevent diabetes, supporting the conclusion by Prasad and colleagues that the insulin B 
peptide is important for initiating disease (84, 86). However, Daniel and colleagues also 
showed that immunizing 12-14 week old NOD with the modified peptide could prevent 
diabetes, contrary to the conclusions made by Prasad using the natural 9-23 peptide 
coupled to apoptotic cells (84, 85). It is possible that modifying the insulin B peptide to 
increase stable binding to I-A
g7
 increased the potency of the tolerogenic stimulus in 
Daniel’s work compared to the natural peptide sequence in Prasad’s work, and this issue 
should be further pursued to determine the efficacy of using peptide variants for 
therapeutic benefit in patients with Type 1 Diabetes. Use of the whole protein as a 
tolerogenic stimulus should also be considered for therapeutic benefit, since work from 
our lab using whole insulin coupled to cells using ECDI reversed diabetes in 
approximately 50% of new onset diabetic NOD mice (59). Whether tolerogenic 
immunization with insB9-23 or variants of this peptide will be able to reverse diabetes in 
NOD mice remains to be investigated. Collectively, these data show that the immune 
response against insulin is important both early during the initiation of disease and late 
near and/or at disease onset. 
 
Antigen recognition by insB9-23-specific CD4
+
 T cells in vivo  
Activation of diabetogenic T cells is requisite for Type 1 Diabetes development; 
therefore, there is interest in understanding how these pathogenic cells get activated by 
autoantigen in vivo. The early events that lead to the activation of autoreactive T cells in 
19 
 
NOD mice and patients with Type 1 Diabetes are poorly understood; however, the most 
favored model is that T cells get activated in the pancreatic lymph node (LN) since naïve 
diabetogenic T cells proliferate in the pancreatic LN prior to observable insulitis (88, 89) 
and removal of the pancreatic LN (but not the spleen) prevents diabetes onset (90). 
Antigen can enter the pancreatic LN in two ways: (1) intra-islet dendritic cells can take 
up antigen from dying beta cells and migrate to the pancreatic LN (91), or (2) small 
particulate antigen may drain directly from the pancreas to the pancreatic LN through 
lymphatics (92). Evidence supporting migration of dendritic cells from the pancreas to 
the pancreatic LN comes from work using NOD.MIP-GFP mice (91, 93), where the gene 
encoding green fluorescent protein is under the control of the mouse insulin promoter 
(94). Intra-islet dendritic cells containing GFP could be detected in both the pancreas and 
pancreatic LN, and T cell-mediated inflammation promoted dendritic cell trafficking to 
the pancreatic LN (93). Importantly, dendritic cells isolated from islets were uniquely 
capable of activating diabetogenic T cells (57). Collectively, these data support a model 
where naïve diabetogentic T cells get activated in the pancreatic LN either by a migrating 
population of intra-islet dendritic cells or presentation of pancreatic antigen that had 
drained to the pancreatic LN and was presented by LN-resident dendritic cells.   
The source of the pancreatic antigen responsible for activating insB9-23-specific 
CD4
+
 T cells is atypical compared to other immune responses. Canonical CD4
+
 T cell 
activation occurs when whole proteins are broken down by antigen presenting cells such 
as dendritic cells, processed in the MIIC endocytic compartment, loaded onto MHC class 
II molecules, and presented on the cell surface. CD4
+
 T cells capable of responding to 
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antigens processed through this pathway are considered Type A cells. However, insB9-23-
specific CD4
+
 T cells in NOD mice do not potently respond to immunization with whole 
insulin protein, suggesting that the natural cleavage products of insulin presented on 
MHC class II do not efficiently activate this population in vivo (57). One hypothesis to 
explain this result is that cells which respond with high affinity to the natural cleavage 
products of insulin get deleted in the thymus. Rather, the pathogenic insB9-23-specific 
CD4
+
 T cells that contribute to diabetes pathogenesis escape deletion because they 
specifically respond only to the B9-23 peptide that is present in the pancreas which is not a 
natural cleavage product of insulin that arises in the thymus. The source of the insB9-23 
peptide that activates these cells comes from granules in beta cells that contain a high 
concentration of pre-processed peptides that are a by-product of insulin production (57). 
Cells that respond to specific peptide fragments but not natural cleavage products from 
the endogenous protein are referred to as Type B cells, and evidence suggests that insB9-
23-specific CD4
+
 T cells that are Type B in nature are pathogenic during Type 1 Diabetes 
(57). While it is still unclear whether the insulin peptides from beta cell granules are 
taken up by intra-islet dendritic cells and processed through the canonical MHC class II-
processing pathway or whether these peptides are directly loaded onto empty MHC class 
II molecules on the cell surface, it is generally agreed that these peptides serve as the 
main source of antigen responsible for activating insulin-specific CD4
+
 T cells in NOD 
mice. 
The importance of insulin-specific CD4
+
 T cells during the initiation and 
development of Type 1 Diabetes has generated substantial interest in investigating the 
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dynamics of insB9-23-specific CD4
+
 T cells during diabetes development in vivo. 
However, the field has been limited by the inability to track endogenous insulin-specific 
CD4
+
 T cells in unmanipulated NOD mice. Recent advances in the generation and use of 
peptide/MHC class II tetramer reagents have greatly improved our ability to track 
endogenous CD4
+
 T cell populations (95, 96). Of particular importance has been the 
development of enrichment techniques to improve the sensitivity of detecting incredibly 
rare antigen-specific populations in intact immune repertoires (95-97). Despite advances 
in detecting rare populations of cells, peptide binding registers remain an important issue 
when constructing peptide/MHC class II tetramer reagents. Due to the way MHC class II 
molecules form, the ends of the peptide-binding groove are open and therefore can 
accommodate peptides that are longer than the nine amino acid core that fits into the 
groove. Because a portion of the peptide can be found outside of the groove, the entire 
peptide can be frame-shifted along the MHC molecule. Each time the peptide frame shifts 
by one amino acid, the amino acid residues that stick out of the peptide binding groove 
and contact the T cell receptor change. Therefore, for one peptide, there are several 
different binding registers, and for each register the T cell receptor is encountering a 
completely different set of amino acid residues. When tracking antigen-specific CD4
+
 T 
cells, this issue of register is particularly problematic, since each frame shift will provide 
a unique peptide that is binding a unique population of T cells, and potentially not all 
populations of these T cells are involved in the immune response of interest. 
Groups led by John Kappler and Emil Unanue have extensively investigated the 
impact of different insB9-23 peptide binding registers on the insulin-specific CD4
+
 T cell 
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response. Three primary registers have been postulated for the insulin B9-23 peptide. 
Registers 1 (core segment 12-20 (VEALYLVCG) and 2 (core segment 13-21 
(EALYLVCGE) can stably bind I-A
g7
 (98). Register 3 (core segment 14-22 
ALYLVCGER) poorly binds I-A
g7
 due to a charge clash between the p9 anchor residue 
(arginine) and the positively charged p9 binding pocket unique to the NOD I-A
g7
 
molecule (87). Kappler and colleagues performed a series of modifications to the insB9-23 
peptide to stabilize binding to I-A
g7
. Modifying the amino acids at p1 and p9 of the 
nonomer core from the insB10-23 peptide to enhance binding to I-A
g7
 did not alter the 
ability of register 1 or 2 to bind I-A
g7
, but substantially enhanced binding of register 3 
(87). Only the mutation at p9 was required to enhance binding, likely due to the 
alleviation of the charge clash with the p9 binding pocket. Importantly, mutating register 
3 to allow strong binding I-A
g7
 caused the register 3 peptide to stimulate IL-2 production 
from more insulin-specific hydridomas than either register 1 or 2 (87). Further work by 
Kappler’s group highlighted the importance of register 3 in stimulating insulin-specific 
CD4
+
 T cells (99). In this study a series of tetramers were constructed with the insulin B 
peptide bound in register 3, but with a critical point mutation to mimic registers 1 and 2. 
Using these reagents, this group determined that the glutamic acid at B:21 (position 8 of 
the nonomer core in the peptide-binding groove for register 3) could either promote or 
inhibit binding to different insulin-specific hybridomas. Hence, the authors concluded 
that all insulin-specific CD4
+
 T cell hybridomas could recognize the register 3 peptide, 
though some favored the glutamic acid at B:21 (mimicking registers 2 and 3) while other 
were inhibited by it (mimicking register 1) (99). These data have caused a substantial 
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shift in the field to study insulin-specific CD4
+
 T cells capable of binding this modified 
register 3 peptide (insB10-23r3) (87, 99), though there is still some interest in register 1 and 
2 in stimulating these cells as well (100). Studies incorporating tetramers containing 
multiple binding registers are needed to understand this pathogenic population.  
 
CD4
+
 T cells from the BDC2.5 T cell receptor transgenic mouse are used to study Type 
1 Diabetes pathogenesis 
 The last specificity that will be discussed is the BDC2.5 T cell population which 
recognizes Chromogranin A. This specificity is discussed because it is used throughout 
the thesis as a model antigen-specific population. Like many of the other known 
diabetogenic T cell clones, the CD4
+
 T cell encoding the BDC2.5 T cell receptor was 
originally isolated from the islet infiltrate of a diabetic NOD mouse (101). Since T cells 
are thought to traffic to and get retained in the pancreas based on their specificity for 
pancreatic antigens and pathogenic potential during diabetes (102), it is often predicted 
that cells cloned out of the pancreas are important for disease progression. Creation of a 
CD4
+
 transgenic mouse encoding this diabetogenic T cell receptor confirmed the 
hypothesis that BDC2.5 T cells were pathogenic and could cause Type 1 Diabetes (103). 
Transfer of BDC2.5 T cells derived from either the original clones (104) or the transgenic 
mouse (103) accelerated diabetes onset in vivo. Due to its ability to transfer disease into 
pre-diabetic NOD mice, the BDC2.5 transgenic mouse has provided a model system used 
by several investigators for over twenty years to study CD4
+
 T cells during Type 1 
Diabetes (105). However, studying this population has been complicated by a lack of 
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knowledge of the natural antigen that this specificity recognizes. It was appreciated early 
after isolating this clone that unlike many of the other clones isolated from the pancreas 
within that time frame (64, 74), BDC2.5 T cells did not respond to insulin. These cells 
did, however, respond to pancreatic islet cells, beta cell extracts, and beta cell adenomas 
(106, 107). In 2001 Darcy Wilson’s group substantially enhanced the ability to study 
BDC2.5 T cells by constructing a library of “mimics of epitopes” or “mimetopes”, which 
are synthetic peptides that could be recognized by the BDC2.5 T cell receptor (108). This 
mimetope screen identified a series of peptide ligands that bound to the BDC2.5 T cell 
receptor with varying affinities, ranging from incredibly low to high (108). For the ten 
amino acid core that binds MHC class II, all of these peptides share the consensus 
sequence XXXPLWX(R/K)M(D/E). The presence of the amino acids P, L, W, R/K, and 
M at positions 4, 5, 6, 8, and 9, respectively, are required for activity; however, varying 
the amino acids as positions 1, 2, 3, and 7 provided a wide range of affinities for the T 
cell receptor that correlated with a range of stimulatory capacities (108). Many studies 
have relied on in vitro activation of BDC2.5 T cells with the high affinity mimetopes p31, 
p63, or PS3 (46, 59, 109, 110). However, the availability of low affinity mimetopes 
provides the opportunity to interrogate issues of affinity in diabetogenic T cell functions. 
Use of the mimetope library defined by Wilson and colleagues has generated 
substantial data on the biology of islet-reactive CD4
+
 T cells during Type 1 Diabetes; 
however, there was a need to identify the natural antigen recognized by this T cell 
population in order to gain a deeper understanding of how these cells became activated in 
vivo. While the specific peptide epitope that binds MHC class II is still debated (71, 109), 
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it is generally accepted that the natural antigen is contained within the protein 
Chromogranin A (71). This critical finding was evidenced by the inability of beta cell 
membranes isolated from Chromogranin A-deficient mice to stimulate IFN by BDC2.5 
T cells in vitro, while Chromogranin A-sufficient beta cell membranes stimulated 
substantial IFN production (71). The issue that remains debated is which exact peptide 
sequence from Chromogranin A is the natural epitope. Two candidate epitopes are WE14 
(Chg358-371) or Chg29-42. Haskins and colleagues identified WE14 as a potential 
candidate first based largely on searching for the consensus sequence identified by the 
mimetope library screen (71, 108). While multiple candidates were identified in 
Chromogranin A containing this consensus sequence, none of the candidates stimulated 
BDC2.5 T cells except WE14. WE14 is a natural cleavage product of Chromogranin A 
(Chg358-371), but the N terminal end of the peptide starts at position 5 of the consensus 
sequence from the mimetope screen, not position 1 (71). The authors speculated that the 
four N terminal amino acids that would normally occupy the peptide binding groove are 
simply missing in this case, with WE14 binding I-A
g7
 in an atypical manner by 
occupying only half of the binding groove (71). Other groups have not successfully 
repeated these results, failing to show that WE14 has any stimulatory capacity (109)(KEP 
unpublished observation). Considering the lack of reproducibility with WE14, Singh and 
colleagues proposed Chg29-42 as the natural epitope for BDC2.5 instead of WE14 (109). 
This peptide is derived from Vasostatin-1, another natural cleavage product of 
Chromogranin A (ChgA1-76). This peptide contains only three of the amino acids from 
the consensus sequence predicted from the mimetope library, but is better at stimulating 
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proliferation of BDC2.5 T cells in vitro than WE14 (109). Which peptide (if either) is the 
natural epitope remains debated. In Chapter 2 we developed a model that allowed us to 
study activation of BDC2.5 T cells without knowledge of the natural antigen, 
circumventing issues associated with identifying the natural ligand for this diabetogenic 
T cell receptor. 
 
MECHANISMS OF IMMUNOLOGICAL SELF TOLERANCE SUPPRESS 
AUTOIMMUNE ACTIVATION AND TYPE 1 DIABETES 
Overview of central and peripheral tolerance mechanisms 
 The lymphocyte receptors of T cells and B cells develop randomly to increase the 
likelihood that these cells will have a receptor capable of recognizing a diverse repertoire 
of foreign antigens. This process, which involves the rearrangement of small gene 
segments to provide incredible diversity, is independent of foreign antigen exposure. This 
random process of receptor development, coupled with the fact that lymphocyte receptors 
recognize ligands that are physically small (only four or five amino acids within a peptide 
bound to MHC contact the T cell receptor), creates a major problem for the adaptive 
immune system. The problem is that there is a high likelihood that lymphocyte receptors 
will recognize self antigens in the body rather than being specific for foreign antigens. In 
an attempt to protect self tissues from the potentially devastating effects of an anti-self or 
autoimmune response, mechanisms of central and peripheral tolerance have evolved to 
eliminate or restrain autoreactive cells. Central tolerance refers to events that occur 
during lymphocyte development in the central or primary lymphoid organs, including the 
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bone marrow for B cells and the thymus for T cells. The main mechanism of central 
tolerance involves deletion of autoreactive lymphocytes that bind with high affinity to 
antigens present in these primary lymphoid organs. Deletion of these cells is an effective 
mechanism of tolerance because it completely eliminates the risk of aberrant activation in 
the periphery. One unique mechanism in the thymus that promotes deletion of self-
reactive T cells is Aire, or autoimmune regulator (111-113). Aire is expressed in the 
thymic medulla by medullary thymic epithelial cells, and allows expression of self 
proteins in the thymus that are normally restricted to peripheral tissue sites, including 
insulin, thyroglobulin, and zona pellucida glycoprotein (111). The importance of Aire in 
promoting deletion of self-reactive T cells comes from aire knockout mice, which 
develop mutli-organ autoimmunity (111) and human patients with autoimmune 
polyendocrinopathy, candidiasis and ectodermal dysplasia (APECED), which manifests 
as the spontaneous development of autoimmunity in multiple endocrine organs (112, 113).  
An additional mechanism of central tolerance is lineage deviation to a regulatory 
phenotype. CD4
+
 T cells with a high affinity for self antigens expressed in the thymus 
can induce expression of the master transcription factor Foxp3 and subsequently acquire 
a regulatory phenotype rather than being deleted (114-116). Therefore, regulatory T cells 
(also referred to as Treg cells) that develop in the thymus not only reduce the number of 
autoreactive T cells, but these cells also substantially contribute to the regulation of 
conventional T cells in the periphery (117). The importance of Treg cells in regulating 
autoreactive T cells comes from mice that lack functional Foxp3, including the scurfy 
mutation (118) or Foxp3 KO mice (114, 115), which develop fatal multi-organ 
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autoimmunity early in life. A similar phenomenon is observed in human patients with 
loss of function mutations in Foxp3 (119, 120). These patients die early in life from 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 
which manifests as multi-organ autoimmunity due to a lack of Treg cells (119, 120). 
Consequently, central tolerance acts as a front line defense against autoimmunity, and 
defects in these tolerance mechanisms (e.g. Aire and Foxp3) result in devastating multi-
organ autoimmune disorders.  
 Despite the well-established role for central tolerance in reducing the frequency of 
potentially autoreactive T cells in the periphery, autoreactive T cells are present in the 
periphery of all healthy individuals (121-123). Therefore, mechanisms of peripheral 
tolerance are required to control these cells to prevent autoimmunity. Peripheral tolerance 
mechanisms include: antigen sequestration, ignorance, extrinsic regulation by Treg cells, 
intrinsic regulation by anergy, and clonal deletion. This section will provide a brief 
introduction to the different peripheral tolerance mechanisms, and a more detailed 
discussion of how these mechanisms contribute to regulation during Type 1 Diabetes will 
subsequently follow. 
Antigen sequestration results when tissue antigens are being isolated from the 
potentially autoreactive cells of the immune system. Naïve T cells and B cells circulate 
through the secondary lymphoid organs (lymph nodes and spleen), and are restricted 
from entering non-lymphoid tissues (124). Therefore, the likelihood that these cells will 
encounter tissue antigens is limited. Antigen sequestration is particularly important for 
sites of immune privilege, which either lack or have reduced lymphatic drainage to limit 
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the probability of antigen entering the secondary lymphoid organs (125). These sites 
include the brain, eye, testis, and the uterus during pregnancy. This sequestration leads to 
ignorance, or a lack of activation of autoreactive T cells in the periphery (125). However, 
since activated effector T cells are capable of infiltrating the majority of non-lymphoid 
tissues (124, 126, 127), the premise of antigen sequestration as a tolerance mechanism 
pertains mostly (though not exclusively) to naïve T cells.   
Treg cells mediate cell extrinsic regulation of other conventional T cells. There 
have been several mechanisms proposed for how Treg cells suppress, including: direct 
cytolysis, cytokine deprivation, inhibitory receptors (e.g. CTLA-4), suppression through 
cytokine release (e.g. IL-10, TGF, IL-35), and alteration of antigen presenting cells 
including promoting up-regulation of the immunosuppressive enzyme indoleamine 2,3-
dioxygenase (IDO) by antigen presenting cells (117). Through these mechanisms, Treg 
cells contribute to homeostatic control of the adaptive immune system, regulate cells at 
sites of inflammation to mitigate tissue damage, aid in the resolution of immune 
responses, and promote tolerance (117). The importance of the Treg cells in regulating 
the adaptive immune system is evidenced by the severe phenotype of mice lacking these 
cells (e.g. scurfy mice (118) and Foxp3-deficient mice (114, 115)) as described above, 
which develop severe multi-organ autoimmunity that results in death early in life. The 
role Treg cells during Type 1 Diabetes will be discussed in more detail in subsequent 
sections. 
The remaining three mechanisms of peripheral tolerance described herein 
manifest when autoreactive T cells encounter autoantigen in the periphery. First, these 
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cells can simply be deleted. This outcome typically occurs when T cell have a high 
affinity receptor for autoantigen, though this mechanism is likely uncommon during 
physiological conditions in vivo since most of these cells are deleted in the thymus. 
Second, CD4
+
 T cells can induce Foxp3 expression in the periphery, becoming adaptive 
or peripheral Treg cells. Treg cells that are induced in the periphery (rather than the 
thymus) have some redundant functions with thymic-derived Treg cells, though an 
important area of research is currently focused on how these cells differ (128). One 
notable difference is likely T cell receptor specificity: Since adaptive Treg cells develop 
post-selection in the thymus, these cells should have a unique set of T cell receptors 
compared to thymic Treg cells (129, 130). While evidence suggests that there is minimal 
overlap between the T cell receptor specificities between natural Treg cells and adaptive 
Treg cells (131), whether there is some overlap and the extent of that overlap is debated 
(132). The role of T cell receptor specificity in Treg suppression remains controversial, 
though some favor a model where antigen-specific Treg cells are better at suppressing 
conventional T cells of the same specificity than non-specific Treg cells (133). The third 
major fate is anergy induction, which leads to a state of functional hyporesponsiveness. 
Following anergy induction, cells persist long term rather than getting deleted, but upon 
reencounter with their cognate antigen fail to produce effector cytokines or proliferate 
(134). Since inducing T cell anergy is a goal of our lab to inhibit autoimmunity in 
patients, a more detailed discussion will follow in the next section. In summary, both 
central and peripheral tolerance mechanisms act to restrain potentially autoreactive T 
cells. Since central tolerance in incomplete, several mechanisms of peripheral tolerance 
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are needed to control these cells. Strategies to enhance peripheral tolerance 
therapeutically to inhibit autoreactive T cells in patients will be discussed in Chapter 5. 
 
Anergy is an important mechanism of peripheral tolerance used to restrain 
autoreactive T cells following autoantigen encounter 
Anergy is cell intrinsic mechanism of peripheral tolerance broadly defined as 
functional inactivation following exposure to antigen. These cells are impaired in cell 
division, differentiation, and cytokine production, particularly following secondary 
exposure to antigen. Rather than undergoing cell death, anergic cells live for an extended 
period of time in this hypofunctional state (134). The nomenclature involved in studying 
T cell anergy has become convoluted over the years, and now “anergy” can be 
subdivided into at least two different types defined by Schwartz as “clonal anergy” and 
“adaptive tolerance” or “in vivo anergy” (134). The requirement for antigen in the 
maintenance of anergy, the ability of IL-2 to reverse anergy, and the cellular events 
leading to anergy induction vary depending on the subtype of anergy being considered. 
Classical “clonal anergy” is caused when pre-activated T cells undergo incomplete 
secondary T cell activation, whereas “in vivo anergy” is typically caused when naïve T 
cells encounter antigen either in the absence of positive costimulation or in the presence 
of high levels of inhibitory signals such as PD-1 or CTLA-4. Clonal anergy can be 
maintained without antigen, while in vivo anergy requires the persistence of antigen to be 
maintained. Additionally, clonal anergy can typically be reversed by high doses of IL-2, 
while in vivo anergy cannot (134). Additional work is needed to identify the molecular 
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requirements involved in the induction and maintenance of anergy, with a focus on the 
safety and efficacy of exploiting anergy in patients to inhibit the function of autoreactive 
T cells. Since anergy is induced following stimulation through the T cell receptor, T cells 
can be shut off in an antigen-specific manner. This approach to inducing tolerance leaves 
patients far less immunocompromised than broad-spectrum non-antigen specific therapies 
targeted at wide spread immunosuppression such as corticosteroids. Therefore, 
investigators are actively pursuing ways to induce anergy clinically. As will be discussed 
in a later section, work from our lab has shown that treatment with antigen-coupled 
ECDI-fixed cells can induce anergy in islet-reactive CD4
+
 T cells to prevent and reverse 
Type 1 Diabetes (59), which could provide an exciting therapeutic platform to inhibit the 
autoimmune response in diabetic patients.  
  
Role of central versus peripheral tolerance mechanisms in controlling islet-reactive T 
cells during Type 1 Diabetes 
 The relative contribution of central and peripheral tolerance mechanisms to the 
control of diabetogenic T cells in NOD mice is controversial; however, it is clear that for 
the mice that develop Type 1 Diabetes both mechanisms ultimately fail. Defects in 
central tolerance in NOD mice lead to increased numbers of autoreactive T cells in the 
periphery, which periphery tolerance mechanisms fail to control in cases when diabetes 
develops. It had been speculated that defects in selection would be correlated with the I-
A
g7
 molecule because it directly impacts the peptides that select CD4
+
 T cells in the 
thymus. However, the MHC class I allele is not a diabetes susceptiblity locus, and CD8
+
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T cells are required for Type 1 Diabetes pathogenesis. Sprent and colleagues provided the 
first evidence that there were defects in negative selection in NOD mice, and this defect 
was independent of the I-A
g7
 allele (135). Rather, this defect was thought to be caused by 
enhanced expression of anti-apoptotic molecules following T cell receptor engagement 
such as caspase-8-homologous Fas-associated death-domain-like interleukin 1-
converting enzyme inhibitory protein (cFLIP), which antagonizes apoptosis induced by 
Fas-dependent negative selection (135). Work by Zucchelli and colleagues further 
supported the conclusion that there were defects in central tolerance in NOD, showing 
that deletion of self-reactive thymocytes was impaired in fetal thymic organ cultures 
derived from NOD compared to B6 mice expressing the NOD MHC class II allele (B6.g7 
mice) (136). Collectively, these data showed that clonal deletion during thymocyte 
development is impaired in NOD mice, which leads to increased numbers of autoreactive 
T cells in the periphery. 
Despite the growing evidence that defects in central tolerance lead to Type 1 
Diabetes development in NOD, the majority of the field continues to focus on defects in 
peripheral tolerance in these mice because it is more feasible to enhance peripheral 
tolerance to inhibit autoreactive T cell functions clinically than to alter central tolerance 
through thymic selection. Multiple pathways involved in peripheral tolerance are 
implemented in Type 1 Diabetes pathogenesis (31). Genes involved in costimulatory and 
inhibitory pathways are involved in diabetes development. Polymorphisms in CTLA-4 
have been associated with increased susceptibility to Type 1 Diabetes (18, 19), and 
blocking CTLA-4 in young NOD mice accelerates diabetes (137). Additionally, NOD 
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mice deficient in the inhibitory receptor PD-1, which is involved in the induction and 
maintenance of T cell tolerance (59), develop accelerated diabetes (138). NOD mice 
deficient in the positive costimulatory molecule CD28 develop accelerated diabetes, 
though this effect is due to defects in Treg cell development in the absence of CD28 
(139). Treg cells are important during Type 1 Diabetes development, since loss of this 
population exacerbates disease in NOD (139) and transfer of large numbers of Treg cells 
or therapies targeted at enhancing their function slows diabetes (133, 139-141). These 
findings have led to preclinical work and early clinical trials involving the adoptive 
transfer of Treg cells to induce tolerance in Type 1 Diabetes patients (133, 140, 142), 
which will be discussed in Chapter 5. In NOD mice, however, there are contradictory 
reports as to whether loss of suppressive capacity by Treg cells contributes to disease 
pathogenesis. Some studies have shown decreases in Treg cell numbers or function with 
age and subsequently disease progression in NOD mice (139, 143), and the idd3 diabetes 
susceptibility locus has polymorphisms in the genes encoding IL-2 and IL-21, which are 
involved in Treg homeostasis (144). However, work from the Mathis and Benoist group 
has suggested that Treg cells in NOD are not functionally impaired, but rather diabetes 
develops due to over-activity of conventional T cells, leading to their inability to be 
suppressed (145). These findings have important therapeutic implications for Treg cell-
based therapy for Type 1 Diabetes, which will be discussed further in Chapter 5.  
 
THE ROLE OF THE INHIBITORY RECEPTOR PROGRAMMED DEATH-1 
(PD-1) AND ITS LIGANDS IN REGULATING T CELL FUNCTIONS  
35 
 
Members of the CD28 superfamily regulate T cell activation and function 
T cell activation is a highly coordinated process that involves at least three 
distinct signals: (1) the T cell receptor binding peptide/MHC, (2) positive costimulatory 
signals such as CD28 on the T cell binding B7, and (3) signals from inflammatory 
cytokines such as IL-12 and Type I IFN that aid in effector differentiation (146, 147). 
This activation process is subject to a high degree of regulation to provide specificity to 
the adaptive immune response (through peptide/MHC) and limit immunopathology. 
Inhibitory receptors are critically involved in regulating initial T cell activation as well 
suppressing on-going effector responses. Two of the most well-characterized inhibitory 
receptors are CTLA-4 and PD-1, both of which belong to the CD28  superfamily of 
immune receptors (147). Unlike CD28, which is expressed on naïve T cells, CTLA-4 and 
PD-1 expression are specifically induced following T cell activation by peptide/MHC 
complexes, increasing the susceptibility of activated T cells to immune regulation. An 
interesting feature of PD-1 and its ligands are their broad expression patterns: CD28 and 
CTLA-4 are largely restricted to T cells, while PD-1 is expressed by T cells as well as B 
cells and some myeloid cells. CD28 and CTLA-4 share the ligands CD80 (or B7-1) and 
CD86 (or B7-2), which are largely restricted to antigen presenting cells (147). On the 
contrary, PD-1 has distinct ligands from CD28 and CTLA-4, including Programmed 
Death Ligand (PD-L) 1 and PD-L2. PD-L1 has an incredibly broad expression pattern, 
including antigen presenting cells, T cells, B cells, and several non-hematopoietic cell 
lineages including pancreatic islet cells, vascular endothelial cells, liver non-parenchymal 
cells including sinusoidal endothelial cells and Kupffer cells, keratinocytes, and placental 
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synctiotrophoblasts. PD-L2 is more restricted in its expression, and is largely limited to 
antigen presenting cells (148). Additionally, PD-L1 can interact with CD80, providing 
further complexity in terms of ligand interactions (149, 150). The broad distribution of 
PD-L1 suggests that this pathway plays a critical role in regulating PD-1-expressing T 
cells in both lymphoid and non-lymphoid tissues, and has made targeting this pathway an 
attractive therapeutic option to manipulate T cell responses at effector sites. 
While PD-1 and CTLA-4 are both inhibitory receptors expressed following 
activation, these pathways are not redundant in terms of regulating T cell functions. 
Differences between PD-1- and CTLA-4-mediated suppression were revealed by analysis 
of mice genetically deficient for either molecule. CTLA-4 KO mice die early in life from 
lymphoproliferative disease regardless of genetic background (151, 152). CTLA-4 
expressed by Treg cells is required to suppress lymphoproliferative disease (153), and 
supplementing CTLA-4-deficient mice with wild type regulatory T cells using bone 
marrow chimeras prevented lymphoproliferative disease, highlighting the importance of 
CTLA-4 on Treg cells (154). PD-1 KO mice do not develop lymphoproliferative disease; 
rather, these mice develop accelerated autoimmunity that is dependent on genetic 
background. C57Bl/6 mice develop a lupus-like nephritis (155), BALB/c mice develop 
dilated cardiomyopathy (156), and NOD mice develop accelerated Type 1 Diabetes (138). 
These data reveal important differences between PD-1 and CTLA-4, and suggest that 
CTLA-4 is more important in regulating the threshold for T cell activation, while PD-1 is 
more important in fine tuning effector responses, particularly in non-lymphoid tissues. 
This difference between these two inhibitory receptors has engendered the hypothesis 
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that blocking PD-1 therapeutically to enhance immunity will have less adverse side 
effects than CTLA-4. An additional discussion involving PD-1 blockade in clinical trials 
will follow in Chapter 5.  
 
Regulation of PD-1 and its ligands 
 The regulation of PD-1 and its ligands is an area of on-going investigation. 
However, it is clear that PD-1 on T cells is regulated at least in part by antigen 
engagement through the T cell receptor. PD-1 is not expressed on naïve T cells (157). 
Activation through the T cell receptor causes PD-1 to become expressed, and it is 
considered a marker of recent activation during acute antigen settings (157). Chronic 
antigen engagement causes PD-1 levels to remain sustained, and continual signaling 
through PD-1 can result in progressive loss of function leading to exhaustion (158, 159). 
Whether there are signals independent of antigen that can regulate PD-1 expression on T 
cells is unclear. Additionally, how PD-1 is regulated on other cell types, such as myeloid 
cells that lack antigen receptors, is also unclear.  
  Our understanding of how the PD-1 ligands are regulated is also limited, though 
both PD-L1 and PD-L2 appear to be induced by inflammation. Type I (IFN and IFN) 
and Type II (IFN) interferons induce the up-regulation of PD-L1 (160, 161), and IFN 
regulatory factor (IRF) binding sites (IRF-1) have been identified in the PD-L1 promoter 
(162). Additionally, pathways known to be activated during inflammation, including 
MyD88, TRAF6, MEK, and JAK2 have all been implicated in the induction of PD-L1 
(162, 163). Less is known about the regulation of PD-L2, but it can be induced by GM-
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CSF, IL-4, and IFN (164, 165). A better understanding of how PD-1 and its ligands are 
regulated will enhance our ability to exploit this pathway therapeutically.  
  
Mechanism of PD-1-mediated suppression 
 In order to deliver an inhibitory signal, PD-1 must be ligated in cis with the T cell 
receptor, meaning the PD-L and peptide/MHC must be expressed on the same cell to 
signal (166). This signaling mechanism is shared with CTLA-4, which must bind B7 on 
the same cell that is presenting MHC to the T cell in order to deliver an inhibitory signal 
(167). One hypothesis for why PD-1 must be engaged simultaneously with the T cell 
receptor is that the inhibitory effects delivered by PD-1 involve dephosphorylation of key 
signaling intermediates downstream of the T cell receptor that are phosphorylated in the 
activated state. Alternatively, PD-1 may counteract the positive signals associated with 
promoting T cell differentiation and survival, including those regulated by CD28 and IL-
2 (168-170). These models are not necessarily mutually exclusive, and it is likely that 
PD-1 acts to oppose several positive signals being delivered to activated T cells. PD-1 is 
a 55 kDa Type I transmembrane protein that contains two key tyrosine-containing 
signaling domains, one ITIM motif and one ITSM motif (148). Phosphatases SH2-
domain containing tyrosine phosphatase (SHP)-1 and SHP-2 can be recruited to the ITIM 
and ITSM of PD-1, leading to inhibition of T cell receptor-mediated phosphorylation of 
CD3ζ, ZAP70, and PKCθ (171, 172). Interestingly, despite the abundance of ITIM motifs 
in immunoreceptors, only the ITSM motif is required for PD-1 to inhibit T cell functions 
(169, 171). Ultimately PD-1 signaling inhibits PI3K (173) and Erk activity (171), leading 
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to decreases in cytokine production, proliferation, and survival. Despite advances in our 
knowledge of the mechanism of PD-1-mediated inhibition, additional studies are needed 
to fully elucidate the mechanism by which PD-1 controls T cell functions, particularly 
during chronic antigen settings where anti-PD-1 antibodies are being tested for use in 
humans to enhance immunity.   
 The downstream effect of PD-1 ligation is dampened effector T cell responses. 
Several in vitro and in vivo studies have described roles for PD-1 in suppressing 
proliferation and effector cytokine production and impairing survival (59, 169, 174-177). 
During acute antigen settings, PD-1 is important for dampening T cell effector functions 
to limit immune pathology. For example, during adenovirus infection, PD-1 KO mice 
clear the virus more rapidly, but also develop more severe hepatocellular damage than 
PD-1 sufficient mice (178). During persistent antigen settings such as chronic viral 
infections and malignancies, continued engagement of PD-1 by CD8
+
 T cells leads to a 
progressive loss of function referred to as exhaustion (148, 158, 159). This loss of 
function occurs in a hierarchical manner, with IL-2, cytotoxicity, and robust proliferation 
being lost early and TNF and IFN being lost later at more terminal stages of 
exhaustion (179). PD-1 blockade can restore functional capacity to a subset of exhausted 
T cells (158, 159, 180), providing a promising therapeutic avenue that will be discussed 
in more detail in Chapter 5. PD-1 and its ligands also function during autoimmunity, 
which will be discussed in the next section. However, whether the PD-1 pathway can be 
targeted therapeutically to inhibit T cell functions in patients with autoimmunity is 
unclear.     
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Role for PD-1 and its ligands during Type 1 Diabetes 
 PD-1 interacting with its ligand PD-L1 is important for slowing Type 1 Diabetes 
progression (137, 138, 174). NOD mice genetically deficient for either PD-1 (138) or PD-
L1 (174) develop accelerated diabetes, and blocking either PD-1 or PD-L1 with 
neutralizing antibodies accelerates the disease (137). Blocking PD-L2 does not accelerate 
diabetes, highlighting the importance of PD-1/PD-L1 interactions in disease progression. 
Interestingly, PD-1/PD-L1 blockade precipitates disease when administered to both 
young (4 weeks of age) and old (10 weeks of age) NOD mice, but the rate of disease 
onset is far more rapid in older mice (137). This result differs from CTLA-4, where 
administering neutralizing antibody only to extremely young mice (1 week of age) causes 
accelerated diabetes on the NOD background (137). Importantly, polymorphisms in the 
gene encoding PD-1 have been described in humans with susceptibility to developing 
Type 1 Diabetes (181), suggesting that perhaps PD-1 is less functional during human 
diabetes development. 
One interesting feature of the PD-1 pathway is the broad distribution of PD-L1 in 
both lymphoid and non-lymphoid tissue. Several lines of evidence suggest that PD-1 is 
controlling T cell effector functions in both the pancreas-draining LN and pancreas 
during Type 1 Diabetes. Removing the pancreatic LN prior to anti-PD-L1 treatment 
revealed interesting differences in PD-1-mediated regulation of young (3 weeks of age) 
versus old (10 weeks of age) NOD mice (182). When the pancreatic LN was removed at 
3 weeks of age, anti-PD-L1 no longer accelerated disease; however, when the pancreatic 
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LN was removed at 10 weeks of age, anti-PD-L1 accelerated disease similarly to control-
treat mice (182). This result suggested that the effector T cells in the pancreas of a 10 
week old NOD mouse were sufficient to induce diabetes, but were being actively 
regulated by PD-1/PD-L1 interactions in the islets. At 3 weeks of age there were likely 
few activated autoreactive T cells in the pancreas, rendering PD-1 blockade ineffective at 
accelerating disease. This work emphasizes the importance of PD-1 in the pancreas, but 
does not exclude a role for PD-1 in regulating autoreactive T cells in the pancreatic LN. 
Since PD-1 regulates activated T cells during antigen engagement, it is likely that PD-1 
acts in both the pancreatic LN and pancreas to suppress diabetogenic T cell functions. 
Evidence generated by our lab supports this idea, since anti-PD-L1 treatment induced the 
T cell stop signal in both the pancreatic LN and islets, an event associated with 
acquisition of potent effector functions. This stop signal was not induced in the non-
antigen containing inguinal LN, showing the importance of antigen in PD-1-mediated 
suppression (110). Hence, PD-1 acts to suppress T cells in both the pancreatic LN and 
pancreas. However, the temporal requirements for PD-1 may change during Type 1 
Diabetes progression due to the relative functional importance of suppression in the 
pancreatic LN versus the pancreas as disease progresses. 
Work from several groups has addressed the effect of anti-PD-L1 on Type 1 
Diabetes progression both in NOD mice as well as B6 mice expressing model antigens 
under the control of the insulin promoter, a model which provides a reductionist approach 
to studying antigen-specific T cell responses against islet antigens (182-186). By treating 
NOD mice deficient for B cells (NOD.MT), CD4+ T cells (NOD.CIITA KO), or CD8+ 
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T cells (NOD.2m KO), Guleria and colleagues demonstrated that CD4+ T cells and 
CD8
+
 T cells were required for anti-PD-L1 treatment to accelerate Type 1 Diabetes, but 
B cells were dispensable for this effect (182). Anti-PD-L1 caused increased proliferation 
of two islet-reactive CD4
+
 (BDC2.5 and 4.1) and one CD8
+
 (8.3) T cell receptor 
transgenic populations in the pancreatic LN but not the non-antigen containing inguinal 
LN (182). Interestingly, anti-PD-L1 did not influence survival measured by apoptosis 
(182), which contradicted predictions made based on PD-1 ligation preventing up-
regulation of the pro-survival molecule BclXL (169). Work using expression of the model 
antigen ovalbumin (OVA) under the rat insulin promoter (RIP-mOVA) on the B6 genetic 
background has further elucidated the role of PD-1/PD-L1 interactions in regulating islet-
reactive CD8
+
 T cell responses. Treating mice with anti-PD-L1 antibody, Martin-Orozco 
and colleagues observed a more substantial impact of PD-1 blockade on enhancing OVA-
specific (OT-1) CD8
+
 T cell granzyme B and IFN production than proliferation (185). 
Keir et al. utilized the same OT-1/RIP-mOVA model, but used OT-1 cells genetically 
deficient for PD-1 to show that the results obtained from Martin-Orozco and colleagues 
using anti-PD-L1 were due to the direct effect of PD-1 on the CD8
+
 T cell regulating 
functions (184). Interestingly, when PD-1 KO OT-1 cells were transferred into RIP-
mOVA
low
 mice, which express less than 1/30 of the OVA as the RIP-mOVA
high
 mouse 
used in the remainder of the study, PD-1-deficient OT-1 failed to proliferate or induce 
diabetes. If PD-1 KO OT-1 were activated in vitro and then transferred into RIP-
mOVA
low
 mice, diabetes was induced, suggesting that these cells were not intrinsically 
incapable of executing their effector functions (184). It could therefore be reasoned that if 
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antigen levels were sufficiently low in the pancreatic LN, then PD-1 would not be 
required for the induction of tolerance since the absence of PD-1 was not capable of 
overcoming this defect.  
While it is established that PD-1 can regulate islet-reactive T cells during Type 1 
Diabetes, an important unanswered question in the field is which cellular interactions are 
required for this regulation, particularly in the pancreas. As discussed earlier, PD-1 must 
signal in cis with the T cell receptor to inhibit T cell functions (166), meaning PD-L and 
peptide/MHC must be expressed by the same cell. CD8
+
 T cells recognize peptide 
presented on MHC class I, which is expressed by nearly all nucleated cells; therefore, any 
nucleated cell could theoretically deliver an inhibitory signal through PD-1 on a CD8
+
 T 
cell. On the contrary, CD4
+
 T cells recognize peptides presented on MHC class II, which 
is largely restricted to antigen presenting cells. It is therefore likely that only MHC class 
II-expressing cells (predominantly antigen presenting cells) will be capable of inhibiting 
CD4
+
 T cells through PD-1. Due to MHC restriction, we hypothesize that PD-L1 
expressed by hematopoietic cells (mostly dendritic cells, a subset of antigen presenting 
cells) will be essential for regulating islet-reactive CD4
+
 T cells, while PD-L1 expressed 
by either hematopoietic or non-hematopoietic cells (such as pancreatic islet cells) will be 
capable of regulating islet-reactive CD8
+
 T cells. Work conducted by Keir and colleagues 
investigated the role of PD-L1 on hematopoietic versus non-hematopoietic cells during 
Type 1 Diabetes (174). Selective ablation of PD-L1 on innate immune system cells 
accelerated diabetes compared to wild type controls (100% diabetic at 7 weeks versus 13 
weeks post-irradiation, respectively); however, this result was not statistically significant 
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and both groups eventually developed diabetes, yielding the interpretation by the authors 
that PD-L1 expressed by cells of the innate immune system (including antigen presenting 
cells) was not sufficient to suppress diabetes onset. To address the role of PD-L1 on non-
hematopoietic cells, PD-L1-deficient or -sufficient islets were transplanted into diabetic 
NOD recipients. In this setting, islets expressing PD-L1 survived longer than islet lacking 
PD-L1. The authors concluded from this result that PD-L1 in the islet was responsible for 
controlling autoreactive T cell functions (174). While this study was informative, it failed 
to address (1) the role of PD-1/PD-L1 in the pancreatic LN in regulating islet-reactive T 
cells, (2) which cell type in the islet had to express PD-L1 since both insulin-producing 
beta cells and intra-islet dendritic cells express this molecule and both were present in the 
transplant, and (3) the relative importance of PD-L1 on hematopoietic versus non-
hematopoietic cells in regulating islet-reactive CD4
+
 versus CD8
+
 T cells. A more 
thorough understanding of these issues is required in order to determine whether the PD-
1 pathway can be engaged to provide therapeutic benefit for Type 1 Diabetes patients.  
 
Associations between the PD-1 pathway and autoimmune diseases in humans 
In addition to the importance of PD-1 in suppressing autoimmunity in several 
murine models, there is increasing evidence that PD-1 is linked to autoimmunity in 
humans. Greater than 30 single-nucleotide polymorphisms (SNPs) have been identified in 
the human PD-1 gene, and several SNPs have been linked to susceptibility to 
autoimmunity in various populations. Autoimmune diseases in humans that have had 
SNPs identified in PD-1 include Type 1 Diabetes (181, 187) as well as systemic lupus 
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erythematosus (SLE) (188-191), multiple sclerosis (192), rheumatoid arthritis (191, 193, 
194), psoriasis (195), and ankylosing spondylititis (196). Additionally, enhanced 
expression of PD-1 has been described on T cells in the synovial fluid during rheumatoid 
arthritis (RA) and salivary glands during Sjogren’s syndrome (197-199). Interestingly, a 
splice variant of PD-1 was recently identified in patients with rheumatoid arthritis (200). 
This splice variant lacks the transmembrane domain, and is therefore secreted. Soluble 
PD-1 can be found in sera and synovial fluid from RA patients, and it is speculated that 
the soluble form interferes with the functions of the membrane bound form, leading to 
exacerbated disease. Understanding how these SNPs impact PD-1 functions in human 
cells will be important for exploiting this pathway clinically. It is critical to understand 
how PD-1 operates in humans to suppress autoimmunity, particularly since antibodies 
against this molecule are entering the clinic to enhance immunity in both chronic viral 
infections and tumors. Discussions in Chapter 5 will be dedicated to outlining the 
potential risks of blocking this pathway in patients. 
 
CONCLUSION 
 Type 1 Diabetes is an autoimmune disease caused by T cell-mediated destruction 
of the insulin-producing beta cells in the pancreatic islets. The NOD mouse is a well-
established model used to study the pathogenesis of Type 1 Diabetes since it shares many 
similarities with the human disease. Diabetes is caused by the adaptive immune system 
responding to a variety of pancreatic antigens, including insulin. CD4
+
 and CD8
+
 T cells 
as well as B cells are required for the disease, though this focus of this thesis is on 
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understanding the dynamics of islet-reactive CD4
+
 T cells. Diabetes results from defects 
in both central and peripheral tolerance mechanisms which normally act to restrain 
autoreactive lymphocytes in vivo. The inhibitory receptor PD-1 interacting with its ligand 
PD-L1 is an important mechanism of peripheral tolerance that suppresses autoreactive T 
cells during Type 1 Diabetes development in NOD mice. The work presented in this 
thesis aims to address how the PD-1 pathway regulates islet-reactive CD4
+
 T cell effector 
functions in the secondary lymphoid organs as well as the pancreas, and our ultimate goal 
is to determine the efficacy of targeting this pathway therapeutically to restore tolerance 
in Type 1 Diabetic patients.  
 
FOOTNOTES 
1
Portions of this work have been previously published. Reprinted from Annuals of the 
New York Academy of Sciences, Volume 1217, Brian T. Fife and Kristen E. Pauken, The 
role of the PD-1 pathway in autoimmunity and peripheral tolerance. p. 45-59. 
Copyright 2011 with permission from John Wiley and Sons (license number 
3184901097948) 
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CHAPTER 2:  
Development of a novel adoptive transfer model to track islet antigen-specific CD4
+
 
T cells following activation by endogenous autoantigen during Type 1 Diabetes
1
 
 
INTRODUCTION 
Type 1 Diabetes is an autoimmune disease mediated by T cell destruction of the 
insulin-producing beta cells in the pancreatic islets of Langerhans (25). The non-obese 
diabetic (NOD) mouse is a classic model for studying this disease because it shares many 
similarities with human Type 1 Diabetes, including the requirement of CD4
+
 T cells (32, 
36, 58). However, knowledge of how diabetogenic CD4
+
 T cells are regulated and how 
this regulation fails causing diabetes is limited due to a lack of tools to monitor 
endogenous islet-antigen specific CD4
+
 T cells in vivo.  
Common models used to study islet-reactive CD4
+
 T cells in NOD mice include 
adoptive transfer of high numbers of naïve or in vitro activated T cell receptor transgenic 
cells into wild type (WT) or lymphopenic NOD recipients (46, 59, 109, 110, 174, 182). 
While informative, these approaches fail to recapitulate the natural inflammatory 
environment present in NOD mice and the timing associated with diabetes progression. 
Previous work in other systems showed transferring lower numbers of naïve T cells 
allowed greater clonal expansion on a per cell basis and more efficient effector cell 
differentiation (97, 201-203). Since we speculate that endogenous autoantigen in the 
NOD mouse is low, we predicted that limiting the diabetogenic precursor frequency 
would be essential for autoantigen encounter and activation. Therefore, in this study we 
48 
 
developed a new model by transferring a small number of islet-specific BDC2.5 
transgenic CD4
+
 T cells (101, 103) into prediabetic NOD mice to mimic an endogenous 
pre-immune repertoire.  
Following transfer of a low number of naïve BDC2.5 T cells into pre-diabetic 
NOD mice, these cells encountered autoantigen in the pancreatic LN and converted to an 
activated (CD44
high
) phenotype. In this model, the majority of the population encountered 
autoantigen within the first week post-transfer. On the contrary, when a high number of 
naïve BDC2.5 T cells (1x10
6
) was transferred, a large population never encountered 
antigen even at later time points, highlighting the importance of precursor frequency in 
this model. Following activation, a subset of BDC2.5 T cells in the low transfer model 
differentiated into T-bet expressing, IFN-producing Th1 effector cells, up-regulated the 
inhibitory receptor PD-1, infiltrated the pancreas, and localized to the islet infiltrate.  
However, a portion of the population acquired an anergic phenotype and was functionally 
impaired rather than differentiating into effector cells, and these cells were enriched in 
the pancreatic LN. These data suggest that when precursor frequency is reduced to mimic 
an endogenous pre-immune repertoire, islet-reactive CD4
+
 T cells can be restrained by 
peripheral tolerance in the form of anergy induction in the pancreatic LN. However, this 
tolerance is incomplete, allowing IFN-producing Th1 effector cells to infiltrate the 
pancreas and contribute to diabetes.    
 
MATERIALS AND METHODS 
Mice 
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Mice were housed and bred in specific-pathogen free conditions in animal barrier 
facilities at the University of Minnesota. Female NOD mice were purchased from 
Taconic (Germantown, NY) and NOD BDC2.5 T cell receptor transgenic mice were 
purchased from the Jackson Laboratory (Bar Harbor, Maine) and crossed to NOD 
Thy1.1
+
 mice. BDC2.5 mice were used for donors between 4-6 weeks of age. Pre-
diabetic NOD mice (Thy1.2
+
) were used as recipients for Thy1.1
+
 BDC2.5 T cells 
between 7-12 weeks of age. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota.  
 
Adoptive transfer of naïve BDC2.5 T cells 
Naïve Thy1.1
+
 NOD BDC2.5 T cells were enriched from spleen and inguinal, 
axillary, brachial, cervical, and periaortic LNs using negative selection over a magnetic 
column (Miltenyi Biotech, Auburn CA). Cells were resuspended in DMEM containing 
10% fetal bovine serum (Hy-clone), 2 mM L-glutamax, 100 U/ml penicillin-streptomycin, 
0.1 M non-essential amino acids, 10 mM HEPES and 50 M 2-mercaptoethanol (Life 
Technologies, Grand Island, NY) (referred to as complete DMEM) at 1x10
8
 cells/ml. 
Biotinylated antibodies (eBioscience, San Diego, CA) against GR-1, MHC class II, 
CD8, CD117 (c-kit), CD24, and TER119 were added at a final concentration of 0.15 
g/107 cells, CD19 and B220 were added at 0.3 g/107 cells, and CD44 was added at 
0.015 g/107 cells. Cells were incubated for 30 minutes at 4oC, washed with DMEM 
containing 1% fetal bovine serum, and resuspended in 1x10
8
 cells/ml in complete DMEM. 
Anti-biotin microbeads (Miltenyi Biotech) were added and cells were incubated for 30 
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minutes at 4
o
C. Cells were washed with DMEM containing 1% fetal bovine serum and 
subjected to magnetic enrichment per manufacture’s protocol. The unbound fraction was 
collected, washed with HBSS and 7,500 (for low transfer model) or 1x10
6
 (for high 
transfer model) CD4
+
 BDC2.5 T cells were transferred intravenously into pre-diabetic 
Thy1.2
+
 NOD recipients. Diabetes was assessed by urine glucose readings prior to 
transfer. BDC2.5 T cells were distinguished from endogenous CD4
+
 T cells by 
expression of the congenic marker Thy1.1.  
 
Flow cytometry 
BDC2.5 T cells were enriched from single cell suspensions from spleen and/or 
pooled non-antigen draining LN samples due to the low frequency of BDC2.5 T cells in 
these organs compared to the endogenous lymphocyte population (96). Briefly, anti-
Thy1.1 conjugated to APC (eBioscience) was added to single cell suspensions in 100-200 
l medium containing 2.4G2 (Fc receptor blocking antibody) and incubated for 30 
minutes at 4
o
C. Cells were then washed, resuspended in 200 l medium containing 2.4G2 
and anti-APC microbeads (Miltenyi Biotech), and incubated for an additional 30 minutes 
at 4
o
C. Cells were then eluded over a magnetic column (Miltenyi Biotech) and the bound 
fraction containing the enriched BDC2.5 T cell population was collected and stained for 
FACS. Single cell suspensions from the pancreas were generated using a combination of 
collagenase P digestion (Roche, Indianapolis, IN) and discontinuous percoll separation as 
described (204). Briefly, the pancreas was removed, injected with collagenase P, and 
digested at 37
o
C for 15 minutes. The digested tissue was then washed with RPMI 
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containing 0.25% fetal bovine serum, 10 mM HEPES (Life Technologies), and 40 g/ml 
DNase (Sigma, St. Louis, MO), subjected to a 40%/60% discontinuous percoll gradient, 
and the interface between the 40% and 60% percoll layers was collected and stained for 
FACS. Antibodies used to surface stain samples that were purchased from eBioscience 
included: anti-Thy1.1 (H1S51), CD4 (RM4-5), CD3e (145-2C11), B220 (RA3-6B2), 
CD11b (M1/70), CD11c (N418), CD44 (IM7), and PD-1 (J43). CD8a (5H10, Life 
Technologies) and CD44 (IM7, BD Biosciences, San Jose, CA) were also used. 
Antibodies used for intracellular staining from eBioscience included anti-IL-2 (JES6-
5H4) and IFN (XMG1.2). Intracellular stains were conducted following surface staining 
as described below. Cell numbers were assessed by FACS using AccuCheck Counting 
Beads (Life Technologies).  
Samples were collected using BD LSRII and Fortessa FACS instruments with 
FACS DIVA software (BD Bioscience). Data were analyzed using FlowJo software 
(Treestar, Ashland, OR). The gating strategy to define BDC2.5 T cells was singlet
+
, 
CD3
+
 lineage
-
 (B220, CD11b, CD11c), CD4
+
, Thy1.1
+
 cells. Single cells (singlets) were 
gated using side scatter area by side scatter width to exclude doublets.  
 
Stimulation of cells for cytokine production 
Single cell suspensions from the pancreatic LN and pancreas were generated as 
described above and suspended in complete DMEM with 10 g/ml brefeldin A, 100 
ng/ml phorbol 12-myristate 13-acetate (PMA), and 1000 ng/ml ionomycin (Sigma). 
Conditions that received no stimulation were supplemented with brefeldin A but not 
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PMA and ionomycin. Cells were incubated at 37
o
C in a humidified incubator containing 
5% CO2 for four hours. Cells were then washed and surface stained for flow cytometry in 
medium containing Fc receptor block (2.4G2) and brefeldin A. For intracellular cytokine 
staining, cell membranes were permeabilized using the BD cytofix/cytoperm 
fixation/permeabilization kit (BD Biosciences) according to manufacturer’s 
recommendations. For intracellular IL-2 staining, single cell suspensions were incubated 
overnight at 4
o
C in BD cytofix/cytoperm buffer prior to staining with anti-IL-2 antibody. 
Gates drawn for intracellular cytokines were on BDC2.5 T cells from samples that 
received brefeldin A but no PMA and ionomycin. In order to assess cytokine production 
from anergic and effector BDC2.5 T cells, 500 g of acetylated p31 peptide 
(YVRPLWVRME) (Genemed Sythesis, San Antonio, TX) was injected intravenously 
and cells were harvested 4 hours later into medium containing brefeldin A. The following 
enrichment and staining steps were also conducted in media containing brefeldin A and 
azide. 
 
Immunofluorescence Microscopy 
 Pancreata were frozen in O.C.T, cut at seven m, and fixed using acetone. 
Antibodies included guinea pig anti-swine inulin (Dako, Denmark) and donkey anti-
guinea pig AF488 (Jackson ImmunoResearch), Thy1.1-PE (clone OX7, Biolegend, CA), 
and CD3e-APC (clone 145-2C11, eBioscience). Slides were mounted using Prolong Gold 
with DAPI (Life Technologies). Slides were imaged on a Leica epifluorescent DM5500 
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microscope (Germany). Data was compiled using MetaMorph software (Molecular 
Devices, CA).  
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 software. P values 
were calculated using an unpaired two-tailed Student’s t test using a 95% confidence 
interval. Values of 0.05 or less were considered statistically significant. Asterisks used in 
the figure legends to indicate statistical significance were: not significant >0.05 (ns), 
significant 0.01 to 0.05 (*), very significant 0.001 to 0.01 (**), and extremely significant 
<0.001 (***) (GraphPad Prism, La Jolla, CA).  
 
RESULTS 
Transferring a low number of naïve BDC2.5 T cells reduces competition for antigen 
and causes a higher frequency to become activated than transferring a non-
physiologically high number of BDC2.5 T cells 
To investigate the role of PD-1 in regulating islet-reactive CD4
+
 T cells during 
Type 1 Diabetes progression, we first established a model to track these cells in vivo. We 
utilized the BDC2.5 transgenic mouse, which contains CD4
+
 T cells specific for an islet 
peptide-MHC class II complex (101, 103). We did not provide exogenous antigen or 
adjuvant but rather relied on presentation of endogenous levels of autoantigen to activate 
the cells. We speculated that since levels of endogenous islet-peptide/MHCII complexes 
are low, precursor frequency would dictate the ability of T cells to become activated 
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(201). To test this hypothesis, we transferred naïve BDC2.5 cells into NOD mice and 
compared the frequency of cells that increased CD44 expression after a low (7,500 cells) 
or high transfer (1x10
6
) (Figure 2-1). At day 6 post-transfer, a significantly higher 
frequency of BDC2.5 cells had converted to CD44
high
 in the low transfer compared to the 
high transfer in the pancreatic LN (low transfer = 90.67±1.71% versus high transfer 
71.71±3.64%, p=0.0087) and spleen and non-antigen draining LNs (non-dLNs) (low 
transfer = 68.34±3.41% versus high transfer = 25.95±2.81% p=0.0002) (Figure 2-1 A and 
C). Importantly, at a later time point (day 28), many of the BDC2.5 cells remained naïve 
in the high transfer situation while nearly the entire population in the low transfer setting 
had encountered autoantigen (Figure 2-1 B and D) (in the pancreatic LN low transfer = 
87.83±1.75% versus high transfer = 61.11±2.74%, p=0.0002, and spleen+non-dLNs low 
transfer = 83.49±7.18% versus high transfer = 34.47±4.17%, p=0.0011). For this reason, 
the remainder of this thesis utilized the low transfer model when investigating the 
dynamics of BDC2.5 T cells during Type 1 Diabetes progression.  
 
BDC2.5 T cells encounter autoantigen, undergo a moderate clonal expansion 
without a traditional contraction, and infiltrate the pancreas in the low transfer 
model 
To further characterize the low transfer BDC2.5 model, we transferred 7,500 
naïve BDC2.5 cells into NOD mice and examined conversion to a CD44
high
 antigen-
experienced phenotype, clonal expansion, persistence, and infiltration of the pancreas. 
Approximately 10-15% of the BDC2.5 T cells survived the transfer (data not shown), 
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providing a naive pre-immune repertoire of approximately 750 cells. Although this is 
higher than what has recently been reported for endogenous pre-immune CD4
+
 T cells 
using peptide/MHCII tetramers (20-400 cells) (95, 205, 206), it is orders of magnitude 
closer to reality than other transfer models (59, 182). Figure 2-2 A shows representative 
FACS contour plots comparing CD44 expression on the transferred BDC2.5 population 
(Thy1.1
+
) to the endogenous CD4
+
 T cell population. Following low transfer, the 
majority of BDC2.5 T cells (73±6%) in the pancreatic LN increased CD44 expression 
indicating they encountered autoantigen by day 3 post-transfer, while a minority of cells 
in the spleen and non-dLNs expressed CD44 (34.8±6.2) (Figure 2-2 A and B). At time 
points 28 days and later there was no significant difference in CD44 levels between these 
organs (Figure 2-2 A and B). We conclude from these data that the entire population 
converted to the CD44
high
 phenotype by day 28, though the majority were CD44
high
 by 
day 7 (Figure 2-2 A and B).  
We next enumerated BDC2.5 T cells to determine the magnitude of clonal 
expansion and the shape of the clonal expansion curve. Endogenous priming led to a 2.5-
fold increase in BDC2.5 T cells between day 3 and day 7 (Figure 2-3 A), which was low 
compared to a classic acute infection response (205).  Interestingly, we did not measure a 
standard contraction of antigen-specific T cells (Figure 2-3 A-C). The lack of a 
contraction phase had been observed previously during chronic viral infections (207), and 
we hypothesized that we did not observe a contraction due to the persistence of 
autoantigen in this model. Importantly, BDC2.5 T cells trafficked to the pancreas and 
localized to the infiltrate surrounding the islet (peri-insulitis) (Figure 2-4 A and B). 
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BDC2.5 T cells were rarely found deep within the islet core (insulitis) (Figure 2-4 B). 
Due to the ability of the BDC2.5 T cells to become activated and infiltrate the pancreas 
following exposure to endogenous autoantigen, the low transfer system provided a novel 
tool to investigate islet-reactive T cell biology under physiological conditions in vivo.   
 
BDC2.5 T cells differentiate into T-bet
+
 IFN-producing Th1 cells 
We next determined the effector potential of the transferred BDC2.5 T cells. 
Previous work identified a critical role for IFN-producing Th1 cells in the pathogenesis 
of Type 1 Diabetes (44-46). We hypothesized that since BDC2.5 T cells were capable of 
infiltrating the pancreas, these cells would differentiate into the pathogenic Th1 subset. 
We first measured T-bet, a master transcription factor which controls differentiation into 
Th1 cells (208).  Following activation, the majority of BDC2.5 cells in all organs 
expressed T-bet (inguinal LN 51.08±7.36, spleen 72.54±4.68, pancreatic LN 79.11±7.00, 
pancreas 76.71±13.49) (Figure 2-5 A-C), supporting our hypothesis that these cells 
develop a Th1 phenotype.  
We further validated that BDC2.5 T cells differentiated into Th1 cells by testing 
for production of the hallmark Th1 cytokine IFN. BDC2.5 T cells from the pancreatic 
LN and the pancreas were capable of producing IL-2 and IFN following ex vivo 
stimulation with PMA and ionomycin (Figure 2-6 A and B).  Interestingly, there was a 
substantially higher frequency of cells capable of producing IFN (either or alone or co-
producing IL-2) in the pancreas compared to the pancreatic LN (48.45% in the pancreatic 
LN versus 68.245% in the pancreas), suggesting the population in the pancreas is more 
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enriched for pathogenic effector cells than the pancreatic LN. Collectively these data 
showed that when a low number of naïve BDC2.5 T cells were transferred into pre-
diabetic NOD, they became activated, differentiated into IFN and IL-2-producing Th1 
cells, infiltrated the pancreas, and persisted for an extended period of time.    
 
BDC2.5 T cells chronically express the inhibitory receptor PD-1 in the secondary 
lymphoid organs and pancreas, with the highest levels detected in the pancreas 
We were interested in using the low transfer BDC2.5 T cell model to evaluate the 
role for PD-1 during Type 1 Diabetes. Therefore, we next assessed PD-1 expression 
kinetics on BDC2.5 T cells in the secondary lymphoid organs and pancreas. PD-1 is 
expressed following T cell activation (157), and remains elevated during chronic antigen 
stimulation (158). Therefore, we hypothesized that PD-1 expression would be detected at 
time points consistent with recent activation (conversion to CD44
high
) and would remain 
elevated due to the persistence of autoantigen. As expected, BDC2.5 cells in the 
pancreatic LN were PD-1
+
 at day 3, consistent with recent T cell activation (Figure 2-7 
A). PD-1 expression on the BDC2.5 T cells in the spleen and non-dLNs was lower at day 
3 than in the pancreatic LN as expected since a higher frequency of BDC2.5 cells were 
naïve in this location (157). At day 7, there was a decrease in PD-1 expression in the 
pancreatic LN compared to day 3, though the significance of this decline is unclear. By 
day 21 post-transfer PD-1 levels were elevated in the pancreatic LN and spleen and non-
dLNs, and these levels remained elevated (Figure 2-7 A and B). By day 7, PD-1 levels 
were highest in the pancreas and remained highest in this organ (Figure 2-7 A and B). We 
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predict that the elevated levels of PD-1 reflect chronic antigen engagement in the NOD 
mouse, and further speculate that the elevated mean fluorescence intensity (MFI) of PD-1 
in the pancreas compared to the secondary lymphoid organs reflects enhanced antigen 
presentation and negative regulation occurring in the pancreas to suppress these cells.   
 
A population of BDC2.5 T cells is anergic in the pancreatic LN, while effector cells 
are enriched in the spleen and pancreas 
The development of Type 1 Diabetes is dependent on the loss of peripheral 
tolerance that would normally act to restrain autoreactive T cells. However, tolerance 
induction in islet-reactive T cell populations during spontaneous diabetes development 
has never been directly tested due to the inability to track these antigen specific cells in 
vivo under physiological conditions. A variety of peripheral tolerance mechanisms have 
evolved to restrain autoreactive T cells (as discussed in Chapter 1), and it is the loss of 
these mechanisms that ultimately leads to autoimmunity. Therefore, we speculated that 
BDC2.5 T cells would be partially restrained by peripheral tolerance, but that regulation 
would eventually be lost resulting in infiltration of the pancreas. Anergy is a state of 
functional hyporesponseviness, and is typically induced following suboptimal activation 
(134). We hypothesized that anergy induction would occur in the BDC2.5 T cell 
population following priming in pancreatic LN of NOD mice due to low levels of 
autoantigen and a lack of inflammatory cues necessary for optimal T cell priming. 
Martinez et al. recently identified the co-expression of folate receptor 4 (FR4) and CD73 
on antigen-experienced (CD44
high
) Foxp3
-
 cells as a marker of T cell anergy (209). We 
59 
 
identified a population of anergic phenotype FR4
+
 CD73
+
 CD44
high
 Foxp3
-
 cells three 
weeks post-transfer (Figure 2-8 A and B). Interestingly, the majority of the antigen-
specific CD4
+ 
T cells in the pancreatic LN were the anergic phenotype (67.46±4.5%, 
Figure 2-8 A and B). We speculate that the remaining population of effector BDC2.5 T 
cells in the pancreatic LN either failed to become anergic or had broken tolerance, 
resulting in a population of cells capable of migrating to the pancreas to contribute to 
disease pathology. In support of this notion, the anergic phenotype was largely absent 
from the spleen (11.91±2.94% anergic) and pancreas (19.19±6.51% anergic) (Figure 2-8 
A and B), which were dominated by effector phenotype (FR4
-
CD73
-
CD44
high
Foxp3
-
) 
cells (spleen 88.08% and pancreas 80.81% effector phenotype). In order to validate that 
co-expression of FR4 and CD73 correlated with functional anergy in diabetogenic T cells, 
we assessed IFN production in the pancreatic LN by stimulating BDC2.5 T cells in vivo 
with cognate peptide (acetylated p31) intravenously. Following peptide challenge, the 
production of IFN(as measured by geometric MFI) and the frequency of IFN-
producing cells were both lower in the anergic phenotype cells compared to the effector 
phenotype cells (Figure 2-8 C-E), suggesting that co-expression of FR4 and CD73 
correlated with functional anergy in NOD mice despite its susceptibility to Type 1 
Diabetes. The data support a model where, following antigen encounter, the majority of 
islet-reactive CD4
+
 T cells becomes anergic, but a small population of effector cells 
escapes tolerance induction, differentiates into pathogenic Th1 cells, and infiltrates the 
pancreas. 
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DISCUSSION 
Current knowledge of how CD4
+
 T cells are regulated during spontaneous 
diabetes progression is limited due to a lack of tools to track these cells in vivo. Our study 
utilized the transfer of a low number of naïve autoreactive T cells to mimic rare self-
reactive T cells in the pre-immune repertoire (95, 206). Precursor frequency can influence 
the magnitude of an immune response, and previous reports showed transferring non-
physiologically high numbers of T cell receptor transgenic T cells can lead to abnormal T 
cell activation and function (97, 202, 203). We reasoned that precursor frequency would 
be critically important in Type 1 Diabetes because of limited endogenous self-
peptide/MHCII complexes. Indeed, analysis of CD44
high
 frequencies in BDC2.5 cells 
following low or high transfer revealed that a significantly higher frequency of cells 
encountered antigen and became activated in the low transfer system. Importantly, in the 
high transfer a large fraction of the cells failed to encounter antigen even at later time 
points despite the fact that antigen persists, presumably due to competition for limiting 
peptide/MHC class II complexes (201). In addition to antigen being a limiting factor in 
activation, we postulate that tolerance mechanisms in NOD mice are also limiting. 
Overwhelming the system with large numbers of either naïve or previously activated cells 
reduces the likelihood that endogenous regulatory mechanisms (e.g. PD-L1 in the islet) 
could induce or maintain tolerance. In order to study how peripheral tolerance is 
maintained and why it breaks down, we contend that models that more closely mimic 
physiological conditions should be used. Lastly, this low transfer approach allowed us to 
investigate diabetogenic T cell dynamics in the natural inflammatory environment in 
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NOD mice during Type 1 Diabetes pathogenesis, which cannot be recapitulated with in 
vitro systems, priming regimens, and mice that have transgenic expression of model 
antigens in the pancreas (59, 110, 169, 184, 185, 210). By limiting the precursor 
frequency, we were able to define the dynamics of autoreactive T cell activation in 
response to endogenous autoreactive peptide/MHCII complexes.  
Following transfer of a low number of BDC2.5 T cells into prediabetic NOD mice, 
the majority of cells converted to an activated CD44
high
 phenotype, but the clonal 
expansion of the population was incredibly weak compared to those observed during 
infections (205, 211). We speculate that the weak clonal expansion that occurred was due 
to suboptimal priming by low levels of endogenous peptide/MHC complexes as well as 
insufficient levels of costimulatory molecules needed to drive high levels of proliferation. 
The weak clonal expansion that these cells go through likely contributes to the induction 
of peripheral tolerance through T cell anergy, which is often associated with suboptimal 
T cell priming. Our data with FR4 and CD73 co-expression support the notion that 
BDC2.5 T cells become anergic in the pancreatic LN following autoantigen encounter in 
a relatively low inflammatory context, and our data examining IFN production 
following peptide restimulation further supports that these cells are functionally anergic. 
Despite anergy induction, we observed a small population of effector phenotype BDC2.5 
T cells in the pancreatic LN, and we speculate that this population was capable of exiting 
the pancreatic LN and trafficking to the pancreas. Anergic phenotype cells were absent 
from the pancreas, suggesting that effector cells were uniquely capable of infiltrating the 
autoimmune target organ. What factors drive anergy induction in the pancreatic LN and, 
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importantly, which factors are required to maintain tolerance to prevent the development 
of pathogenic effector cells are unclear but an area of interest clinically to induce 
tolerance in patients. In Chapter 4 the role of PD-1 in tolerance in this low transfer 
system will be tested based on work suggesting that PD-1 plays critical roles in both the 
induction and maintenance of anergy in other diabetes models (59, 110, 183, 186).  
One hypothesis for why the anergic phenotype cells are uniquely enriched in the 
pancreatic LN is that the persistence of antigen in this organ prevents T cells from 
egressing from this organ. Memory T cells can become resident in several non-lymphoid 
tissues, providing a front-line defense against invading pathogens (212-214). What 
factors contribute to memory T cell residence, particularly following infection with acute 
pathogens, are not fully understood. However, during chronic infections the presence of 
antigen can lead to long term maintenance of antigen-specific T cell populations (207, 
211, 215). During chronic infections the T cell population does not go through a standard 
contraction phase (207), and we also observed a similar lack of contraction in our model. 
We therefore envision a model where islet-reactive CD4
+
 T cells encounter autoantigen 
in the pancreatic LN, become suboptimally activated by endogenous autoantigen and are 
rendered anergic, and become resident to the pancreatic LN where constant antigen 
encounter not only keeps these cells alive but also keeps them from leaving the pancreatic 
LN to infiltrate the pancreas. Preventing trafficking to the pancreas protects this tissue 
from autoimmune destruction, thereby providing a novel tolerance mechanism. However, 
since tolerance is incomplete in NOD, a small population of BDC2.5 T cells are either 
able to avoid tolerance induction or are capable of breaking tolerance, and this effector 
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population exits that pancreatic LN and infiltrates the pancreas. What factors contribute 
to this loss of tolerance are unclear, but understanding the mechanism that leads to the 
release of this effector population will be critical for targeting pathogenic autoreactive T 
cells in patients. In Chapter 4 the role of PD-1 in the induction and maintenance of this 
anergic population will be described, though other factors involved in regulating this 
form of tolerance should also be explored to determine the efficacy of inducing anergy in 
patients.     
 
FOOTNOTES 
1
Portions of this work have been previously published. Reprinted from Diabetes. Volume 
62. Kristen E. Pauken, Marc K. Jenkins, Miyuki Azuma, and Brian T. Fife. PD-1, but 
not PD-L1, expressed by islet-reactive CD4
+ 
T cells suppresses infiltration of the 
pancreas during Type 1 Diabetes. p. 2859-2869. Copyright 2013, with permission from 
the American Diabetes Association (license number 3196070044473). 
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CHAPTER 3:  
Tracking endogenous insulin-specific CD4
+
 T cells during Type 1 Diabetes with 
peptide/MHC class II tetramers revealed differences in T cell priming and effector 
functions between diabetes-prone and diabetes resistant mice
1
 
 
INTRODUCTION 
The importance of the insulin-specific T cell response during Type 1 Diabetes in 
the non-obese diabetic (NOD) mouse is well established. Insulin-specific CD4
+
 T cells 
can be detected in the pancreas infiltrate by 4 weeks of age, and can continually be 
detected through at least 12 weeks of age (74, 80). The majority of the insulin-specific 
CD4
+
 T cells responds specifically to the amino acid peptide residues 9-23 from the 
insulin B chain (74). Transfer of insB9-23-reactive T cell clones into young NOD mice 
accelerates diabetes, highlighting the pathogenic nature of these cells during disease 
progression (74). Furthermore, 40% of transgenic mice expressing a T cell receptor 
specific for insB9-23 (BDC12.4.1) develop diabetes on a Rag KO background (83). 
Abolishing the T cell response directed against the 9-23 epitope eliminates diabetes in 
NOD (70), and administering tolerogenic immunizations against the insB9-23 peptide or 
variants modified to bind with high affinity to I-A
g7
 slows or prevents diabetes in NOD 
mice (84-86). Despite the well-established role of insulin-specific CD4
+
 T cells during 
diabetes, little is known about how this pathogenic immune response develops due to the 
difficulty of tracking these cells in vivo. Important unanswered questions in the field 
include: what is the frequency and activation status of insulin-specific CD4
+
 cells, does 
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this change over time, do these cells exist in diabetes-resistant strains, what frequency 
participates in clinical diabetes, and how are they regulated? To date there has not been a 
careful analysis and characterization of this critical antigen-specific CD4
+
 T cell 
population during diabetes pathogenesis to understand how peripheral tolerance fails and 
diabetes ultimately develops.  The goal of this chapter was to begin to address these 
issues, which ultimately will aid in the development of better treatments for diabetic 
patients.  
Peptide/MHC class II tetramers are powerful tools to track antigen-specific CD4
+
 
T cells in vivo. When coupled with magnetic enrichment, incredibly rare populations can 
be tracked with high precision (95-97, 206). However, one complication of peptide/MHC 
class II tetramers is determining the binding register for the peptide, since CD4
+
 T cell 
epitopes can bind in a variety of different conformations. For the insulin B9-23 epitope the 
field lacks a consensus on the relevant binding register(s) (87, 98-100). Register 1 
comprised of the core segment 12-20 (VEALYLVCG) and register 2 containing the core 
segment 13-21 (EALYLVCGE) can stably bind I-A
g7
 (98). Register 3 containing the core 
segment 14-22 (ALYLVCGER) poorly binds I-A
g7
 (87). However, modifying the insB10-
23 peptide to enhance binding to I-A
g7
 caused the register 3 peptide to stimulate IL-2 
production from more insulin-specific hydridomas than either register 1 or 2, suggesting 
that this register can recognize a diverse repertoire of insulin-specific CD4
+
 T cells  (87). 
Additionally, sub-immunogenic immunization of both young (4-6 weeks) and old (12-14 
weeks) NOD mice with this modified register 3 peptide prevented diabetes (84), 
highlighting the importance of this epitope for spontaneous disease progression.  
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Based on these data, we constructed a tetramer reagent containing the modified 
register 3 epitope (HLVERLYLVCGEEG) bound to I-A
g7
 to define the dynamics of the 
insulin-specific CD4
+
 T cell response in diabetes-susceptible NOD mice as well as 
diabetes-resistant B6 mice expressing the I-A
g7
 allele (B6.g7) (136). Using this reagent, 
we performed a careful time course analysis and detected a population of insulin-specific 
CD4
+
 T cells in the secondary lymphoid organs of both strains, but the frequency and 
number of antigen-experienced cells was substantially greater in NOD. Additionally, 
these cells produced the inflammatory cytokine IFNand infiltrated the pancreas in NOD 
but not B6.g7 mice. Similarly to the BDC2.5 low transfer model presented in Chapter 2, 
the majority of insulin-specific cells in the pancreatic LN of NOD mice were anergic with 
the surface phenotype of CD73
+
FR4
+
 (209). However, this anergic population decreased 
in frequency as the NOD mice aged. These data suggest that only a small subset of 
endogenous insulin-specific CD4
+
 T cells are pathogenic in NOD mice, and that 
peripheral tolerance acts to restrain those cells but ultimately fails in mice that progress to 
diabetes. Interestingly, this population was missing from B6.g7 mice.  These data suggest 
that B6.g7 mice are not protected due to deletion of this autoreactive repertoire, nor the 
development of T cell anergy, but rather because these cells remain naïve. These data 
provide insight into distinct mechanisms for regulation of insulin-specific CD4
+
 T cells in 
diabetes-resistant and -susceptible mouse strains during disease progression.    
 
MATERIALS AND METHODS 
Mice 
75 
 
Mice were housed at the University of Minnesota under specific pathogen free 
conditions. NOD mice were purchased from Taconic (Germantown, NY). B6 mice 
expressing the NOD I-A
g7
 allele (B6.g7 mice) were generated by Mathis and Benoist 
(136). Mice were used for tetramer experiments between 3-30 weeks of age. Diabetes 
was assessed by blood glucose reading with 250 mg glucose/dL blood indicating clinical 
diabetes (LifeScan, Inc., Milpitas, CA). All animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of Minnesota. 
 
Peptide/MHC class II tetramer reagents 
The insB10-23r3:I-A
g7
 tetramer reagent was constructed as described (95). Briefly, 
the I-A
g7
 monomer containing the peptide sequence HLVERLYLVCGEEG was 
produced and biotinylated in S2 cells (Drosophilia melanogaster). Biotinylated monomer 
was further purified by eluting over a monomeric avidin column (Thermo Scientific, 
Pittsburgh, PA), and the final tetramer product was made by combining with streptavidin-
phycocerythrin (PE) and streptavidin-allophycocyanin (APC) from Prozyme (Hayward, 
CA). The HEL11-25:I-A
g7
 tetramer containing the peptide sequence 
AMKRHGLDNYRGYSL was obtained from the National Institute of Health Tetramer 
Core Facility (Atlanta, GA). 
 
Flow cytometry 
Single cell suspensions were generated from the pancreatic LN, spleen and non-
draining LNs, and pancreas as described previously (216). Tetramer-binding CD4
+
 T 
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cells were enriched from the spleen and non-draining LNs (inguinal, axillary, brachial, 
cervical, mesenteric, and periaortic) pooled using magnetic enrichment (Miltenyi Biotech, 
Auburn, CA). Briefly, single cell suspensions were incubated with 10 nM of insulin 
tetramer conjugated to PE and APC for one hour at room temperature followed by anti-
PE and anti-APC microbeads for 30 minutes at 4
o
C and subsequently eluted over 
magnetic columns. Magnetic enrichment was not conducted on the pancreatic LN and 
pancreas samples since the low number of total cells allowed the entire sample to be 
analyzed by flow cytometry. Lymphocytes were enriched from pancreas samples using 
collagenase P digestion (Roche, Indianapolis, IN) and discontinuous percoll gradient as 
described (216).  
Surface antibodies used included CD3, CD4, B220, CD11b, CD11c, CD44, 
CD45RB, CD8, FR4, and CD73. Intracellular stains included Foxp3, IFN, TNF, and 
IL-17A. Foxp3 staining was conducted using the Foxp3 Fixation/permeabilization kit 
according to manufacturer’s recommendations (eBioscience, San Diego, CA). 
Intracellular cytokine staining for IFN and IL-17A was conducted using the 
cytofix/cytoperm kit according to manufacturer’s instructions (BD Biosciences, San Jose, 
CA). Samples were collected using BD LSRII and Fortessa instruments. Data was 
analyzed using Flow Jo software (Tree Star, Ashland, OR). Cell numbers were assessed 
by FACS using AccuCheck Counting Beads (Life Technologies, Grand Island, NY). 
Insulin-specific CD4
+
 T cells were defined as CD4
+
 lineage
-
 (B220
-
, CD11b
-
, CD11c
-
), 
CD8-, insB10-23:I-Ag7-PE+ and –APC+ cells.  
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Cytokine stimulation 
 To assess cytokine production from insulin-specific CD4
+
 T cells, pancreatic LN, 
spleen, and non-draining LNs were pooled and stimulated in vitro in complete DMEM 
(containing 10% fetal bovine serum (Hy-clone), 2 mM L-glutamax, 100 U/ml penicillin-
streptomycin, 0.1 M non-essential amino acids, 10 mM HEPES and 50 M 2-
mercaptoethanol (Life Technologies, Grand Island, NY)) with 100 ng/ml phorbol 12-
myristate 13-acetate (PMA), 1000 ng/ml ionomycin, and 10 g/ml brefeldin A (Sigma, St. 
Louis, MO) for 4 hours (216). Subsequent tetramer staining and enrichment and surface 
staining was conducted in media containing 2.4G2 (FC receptor block), brefeldin A, and 
azide.  
 
In vivo priming 
 The modified insB10-23 peptide (HLVERLYLVAGEEG) (Genemed Synthesis) 
(87) or whole insulin protein (Novo Nordisk Pharmaceuticals Inc, Princeton, NJ) was 
emulsified in complete Freud’s adjuvant at a concentration of 100 g. Mice were 
immunized subcutaneously in the back and the pancreatic LN, non-draining LNs, and 
spleen were harvested for FACS analysis 7-14 days post-immunization.  
 
Statistics  
Statistical analyses were performed using unpaired two-tailed Student’s t tests 
with a 95% confidence interval using GraphPad Prism 5 software (GraphPad, La Jolla, 
CA). Asterisks used to indicate statistical significance were: not significant >0.05 (ns), 
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significant 0.01 to 0.05 (*), very significant 0.001 to 0.01 (**), and extremely significant 
<0.001 (***).  
 
 
RESULTS 
Development and validation of the insB10-23r3:I-A
g7
 tetramer reagent 
 In order to study the dynamics of insulin-specific CD4
+
 T cells in vivo, we 
developed
2
 a tetramer reagent containing a portion of the insulin B chain (10-23) bound 
to I-A
g7
. Amino acid substitutions at 14 (A to R) and 22 (R to E) were performed to trap 
the insulin peptide in the register 3 binding conformation based on previous work (Figure 
3-1 A) (87). In the previous study, this modified peptide was capable of stimulating IL-2 
production from a wider variety of insulin-specific clones than either registers 1 or 2 (87), 
and further work has shown that sub-immunogenic immunization with this peptide can 
prevent diabetes in NOD mice (84). These results suggest the modified register 3 epitope 
provides an ideal detection reagent because it can bind a diverse repertoire of insulin-
specific CD4
+
 T cells that are involved for disease pathogenesis.  
To validate that our tetramer bound a unique T cell population in unimmunized 
NOD mice we compared insulin tetramer staining to an irrelevant control tetramer HEL11-
25:I-A
g7
 and found distinct staining with no double positive events indicating reagent 
specificity (Figure 3-1 B). We next confirmed the specificity of the tetramer reagent by 
immunizing NOD and B6.g7 mice with the modified insB10-23 peptide in CFA and 
assessing clonal expansion 7-14 days later. The insulin B peptide induced a robust 
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response in both NOD (17,071±2707 cells) and B6.g7 (36,131±6227 cells) (Figure 3-1 C 
and D). Interestingly, the clonal expansion was significantly higher in B6.g7 than NOD 
mice (2.12 fold). These data validate that our reagent is specific for the insB10-23 peptide. 
It should be noted that immunizing with both insB10-23 and HEL11-25 resulted in the 
expansion of mutually exclusive populations (data not shown), consistent with these two 
tetramers binding unique populations in both pre-immune mice as well as immunized 
mice. We next immunized NOD and B6.g7 with whole insulin protein emulsified with 
CFA. We failed to detect substantial clonal expansion in either NOD (1,618±562 cells) or 
B6.g7 (155±64 cells) mice (Figure 3-1 D).
3
 This result was expected for this epitope, 
since previous work by Unanue and colleagues had identified that the pathogenic insB9-
23-reactive CD4
+
 T cells are Type B phenotype, or capable of responding to the 9-23 
peptide but not whole insulin. Therefore, it is possible that the major cell population we 
are detecting with our tetramer reagent is Type B rather than Type A cells. However, we 
cannot completely exclude the possibility that we are also detecting Type A cells using 
clonal expansion as our only assay. Alternatively, it is possible that Type A cells do not 
expand as robustly in vivo as Type B cells or the levels of 9-23 peptide/MHC complexes 
may be far lower because other peptides will be competing for MHC binding in the 
whole insulin immunization. We therefore conclude that our tetramer is capable of 
detecting Type B cells, though additional work will be needed to determine if Type A 
cells are also detected with this tetramer reagent. 
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Insulin-specific CD4
+
 T cells were detected in the secondary lymphoid organs of 
NOD and B6.g7 mice, but only infiltrated the pancreas in NOD mice 
We next compared the insulin-specific CD4
+
 T cell response in unimmunized 
diabetes-susceptible NOD mice to diabetes-resistant B6.g7 mice by enumerating the 
insulin-specific CD4
+
 T cells in the spleen and non-draining LNs, pancreatic LN, and 
pancreas at a variety of ages that are relevant during diabetes development. However, we 
found high background staining with the insulin tetramer based on non-specific binding 
of the tetramer in the CD8
+
 T cell population (Figure 3-2 A-D), particularly in the 
pancreatic LN (Figure 3-2 C and D). In order to increase the sensitivity of our reagent we 
stained with the insulin tetramer conjugated to two different fluorochromes (PE and 
APC) and gated on cells that bound both tetramers (Figure 3-2 B and D).  This approach 
was utilized for the remainder of this thesis to reduce background and enhance reagent 
sensitivity.  
Using staining with both PE and APC tetramers, we detected insulin-specific 
CD4
+
 T cells in the secondary lymphoid organs of both NOD and B6.g7 mice (Figure 3-3 
A and B). However, these cells only infiltrated the pancreas of NOD mice (Figure 3-3 A 
and C). The number of insulin-specific CD4
+
 T cells increased in the secondary lymphoid 
organs of NOD mice with age, peaking at 14 weeks (Figure 3-3 B, Table 3-1). There was 
significantly more insulin-reactive CD4
+
 T cells in NOD mice at all ages examined 
compared to B6.g7 mice (Figure 3-3 B and C).  The number decreased at 20 weeks in 
NOD compared to 14 weeks, but the significance of this decline was unclear. It was 
possible that since disease is not 100% penetrant in NOD mice, the older mice examined 
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could have individual animals that never would have developed clinical diabetes within 
the analyzed group (Figure 3-3 B). Infiltration of the pancreas was detected in a few 
NOD mice at weeks 3 and 5 of life, but substantial and more consistent infiltration of the 
pancreas did not occur until later in life (at weeks 14-20) (Figure 3-3 C). Importantly, all 
diabetic NOD mice examined contained insulin-specific CD4
+
 T cells in the pancreas 
(Figure 3-3 C). In B6.g7 mice there was a slight, but not significant, increase in cell 
number between weeks 3 and 5 of life, which was likely due to the increase in the overall 
number of lymphocytes at this age. The number of insulin-specific CD4
+
 T cells did not 
change in B6.g7 mice between weeks 5 and 20, and these numbers remained low 
compared to age-matched non-diabetic NOD (Figure 3-3 B, Table 3-1 and 3-2). 
Importantly, no insulin-specific CD4
+
 T cells were observed in the pancreas of B6.g7 
mice at any time point (Figure 3-3 C). We conclude from these data that defects in central 
tolerance lead to the accumulation of these insulin-specific CD4
+
 T cells in both NOD 
and B6.g7, but defects in peripheral tolerance in NOD compared to B6.g7 mice lead to 
the expansion of these cells in the secondary lymphoid organs and infiltration of the 
pancreas.    
 
Endogenous antigen results in the up-regulation of CD44 on insulin-specific CD4
+
 T 
cells in NOD but not B6.g7 mice.   
 We next examined the activation phenotype of insulin-specific CD4
+
 T cells in 
NOD and B6.g7 mice. We hypothesized that in NOD mice, a conversion to a CD44 high 
antigen-experienced phenotype would occur early in life on the insulin-specific CD4
+
 T 
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cell population, since this is when the critical events are thought to occur that eventually 
lead to diabetes (31). Conversely, we predicted that majority of insulin-specific CD4
+
 T 
cells that escaped central deletion and persisted in the periphery of B6.g7 mice would 
either be naïve or anergic since the mice are protected from diabetes. To test this 
hypothesis, we measured CD44 expression. In both the spleen and non-draining LNs and 
the pancreatic LN, there was a higher frequency (Figure 3-4) and number (Figure 3-5, 
Table 3-1 and 3-2) of CD44
high
 cells in NOD mice compared to B6.g7 mice. In NOD 
mice, there was a significant conversion from CD44 low to high expression that occurred 
in the pancreatic LN between weeks 3 and 5 of life (p<0.0001) (Figure 3-4 B), consistent 
with the notion that the antigen release that led to activation of this pathogenic cell 
population occurred early in life. 
 
CD44 does not accurately report antigen experience during Type 1 Diabetes  
While the frequency of insulin-specific CD4
+
 T cells that displayed a CD44
high
 
antigen-experienced phenotype was higher in NOD mice than B6.g7 mice as expected, 
we found it striking that the maximal frequency of CD44
high
 cells only reached 40% in 
the spleen and non-draining LNs and 60% in the pancreatic LN in NOD mice (Figure 3-
4) since this population is essential for Type 1 Diabetes pathogenesis. Previous work 
examining antigen-specific CD8
+
 T cells during lymphocytic choriomeningitis virus 
(LCMV) infection showed that during chronic infection (Clone 13), CD44 levels 
decreased compared to levels during acute infection (Armstrong), causing cells that were 
chronically encountering antigen to display a CD44 “intermediate” phenotype (207). We 
83 
 
speculated that down-regulation of CD44 due to chronic exposure to insulin was 
occurring in our tetramer-binding population. In support of this hypothesis, the number of 
CD44
low
 insulin-specific CD4
+
 T cells was abnormally high for a truly “naïve” repertoire 
in older NOD mice (14 weeks, 20 weeks, and diabetic) compared to younger NOD mice 
(3 weeks and 5 weeks) (Figure 3-5, Table 3-1). The number of naïve CD4
+
 T cells in pre-
immune repertoires for foreign antigens typically ranges from 20-400 (95, 206). In 3 and 
5 week old NOD mice, the number of CD44
low
 cells was within this range; however, in 
older NOD mice, the average number was between 500-800 cells (Figure 3-5, Table 3-1). 
Interestingly, this increase in the number of CD44
low
 cells was not observed in B6.g7 
mice, where we predicted the majority of the insulin-specific population would be naïve 
(Figure 3-5, Table 3-2). The only significant change in CD44
 low 
cell frequency occurred 
in older NOD mice, which was consistent with the hypothesis that CD44 was not 
accurately reporting antigen experience in NOD mice similar to chronic antigen during 
viral infections (207).   
To test whether insulin-specific CD4
+
 T cells were chronically stimulated in NOD 
mice, we conducted further phenotypic analysis comparing CD44 with CD45RB, a 
marker that is highly expressed on naïve T cells and is down-regulated upon T cell 
activation (217). In all mice examined, there was a greater frequency of CD45RB
dim
 cells 
than CD44
high
 cells, suggesting that we underestimated the frequency of antigen-
experienced cells using CD44 as our only marker of activation (Figure 3-6 A-C); 
however, there was only a statistically significant difference between CD45RB
dim
 and 
CD44
high
 frequencies in the older group of NOD mice (15-20 weeks, p=0.0122 in the 
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spleen+non-dLNs and p=0.0003 in the pancreatic LN). These data suggest that using 
solely CD44 as an activation marker caused an under-estimation of the frequency of 
antigen-experienced cells, particularly in older NOD mice. Furthermore, we speculate 
that the CD44
dim
 CD45RB
dim
 population is chronically stimulated and perhaps 
functionally exhausted, though additional work is needed to formally test this hypothesis.  
 
Insulin-specific CD4
+
 T cells express the inhibitory receptor PD-1 following 
activation in NOD mice, but do not express PD-1 in B6.g7 mice 
 We next determined the expression of the inhibitory receptor PD-1 on insulin-
reactive CD4
+
 T cells in NOD and B6.g7 mice. PD-1 is expressed following antigen 
encounter (157), and we showed previously that BDC2.5 T cells in the low adoptive 
transfer model expressed PD-1 following antigen encounter in NOD mice (Figure 2-7). In 
the BDC2.5 low transfer model, PD-1 remained elevated in the secondary lymphoid 
organs compared to the endogenous naïve CD4
+
 T cell population long after initial 
antigen encounter; therefore, we hypothesized that a high frequency of insulin-specific 
CD4
+
 T cells would express PD-1 in NOD mice following antigen encounter. 
Furthermore, we hypothesized that the frequency of PD-1
+
 cells would be low in B6.g7 
mice since the majority of the insulin-specific CD4
+
 T cells in these mice are not antigen-
experienced. The frequency of PD-1
+
 cells was similar to what was observed with CD44 
in the spleen and non-draining LNs (PD-1 Figure 3-7 A, CD44 Figure 3-4 A) and 
pancreatic LN (PD-1 Figure 3-7 B, CD44 Figure 3-4 B) for both NOD and B6.g7 mice. 
Consistent with this notion, PD-1 was typically expressed on CD44
high
 cells (Figure 3-7 
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C). There were some CD44 low/intermediate cells that expressed PD-1, but it was likely 
that these cells were also antigen-experienced and perhaps chronically stimulated since 
we previously showed that CD44 alone does not report all antigen experienced-cells in 
NOD mice (Figure 3-6). The frequency of PD-1
+
 cells was significantly higher in the 
spleen and non-draining LNs and pancreatic LN of NOD than B6.g7 at 5 
(spleen+nondLNs p=0.0042, pancLN p=0.0007) and 20 (spleen+nondLNs p =0.0008, 
pancLN p=0.0091) weeks of age as expected since there was a significantly greater 
frequency of CD44 high cells in NOD at these time points (5 weeks spleen+nondLNs 
p<0.0001 and pancLN p<0.0001 and 20 weeks spleen+nondLNs p=0.0001 and pancLN 
p=0.0035 (Figure 3-4 A and B)). There was no statistically significant difference in PD-1 
in the spleen and non-draining LNs (p=0.0614 ns) or the pancreatic LN (p=0.7578) 
between 3 week old NOD and B6.g7 as expected since there was less of a difference in 
CD44 frequencies between these strains at this age (Figure 3-7 A and B). Unexpectedly, 
there was a higher frequency of PD-1
+
 cells in the pancreatic LN of B6.g7 than predicted 
based on the frequency of CD44
high
 cells at these time points (PD-1 versus CD44: 3 
weeks 32.95±9.27% versus 9.83±6.08%; 5 weeks 19.97±8.0% versus 5.02±2.47%; 20 
weeks 21.7±7.6 versus 6.79±3.41%), suggesting that some antigen encounter had 
occurred in this organ in these mice. The frequency of PD-1
+
 insulin-specific CD4
+
 T 
cells was consistently higher in the pancreatic LN compared to the spleen and non-
draining LNs in NOD (spleen+nondLNs versus pancreatic LN, 3 weeks 23.64±4.59% 
versus 30.26±4.0%, 5 weeks 21.91±2.08% versus 55.34±4.7%, 14 weeks 33.03±6.23% 
versus 45.00±4.48, 20 weeks 25.96±3.64% versus 37.8±3.4%, and diabetic 28.78±5.28% 
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versus 40.18±7.9%) (Figure 3-7 A and B), consistent with the notion that antigen is being 
encountered in the pancreatic LN.   
We had previously shown that PD-1 expression levels on BDC2.5 T cells in the 
low transfer system were higher in the pancreas than the secondary lymphoid organs 
(Figure 2-7). Therefore, we hypothesized that PD-1 levels on insulin-specific CD4
+
 T 
cells would be higher in the pancreas of NOD mice than the pancreatic LN and spleen 
and non-draining LNs. While PD-1 levels were consistently high in the pancreas, the 
expression levels compared to the pancreatic LN varied (Figure 3-7 D). In some cases 
PD-1 levels were higher in the pancreas than the pancreatic LN, and in others the 
expression was more similar. However, PD-1 was uniformly expressed on all cells in the 
pancreas, suggesting that the insulin-specific CD4
+
 T cells were encountering antigen in 
this location similarly to the BDC2.5 T cell population.  
 
Insulin-specific CD4
+
 T cells differentiate into IFN- producing Th1 cells in NOD 
mice, but fail to produce this cytokine in B6.g7 mice 
 IFN-producing Th1 cells are the major pathogenic CD4+ T cell subset during 
diabetes (44-46). We hypothesized that insulin-specific CD4
+
 T cells would produce 
IFN in NOD mice, but not B6.g7 because the majority of the insulin-specific CD4+ T 
cells were not activated. We also examined TNF and IL-17A. IL-17A was examined 
because its role in diabetes has been controversial, with some sources arguing it is 
pathogenic and others arguing that it is dispensable (49-51). TNF was included to test if 
the cells were healthy and viable, since this cytokine can be produced by naïve and 
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activated T cells (218). Therefore, if insulin-specific CD4
+
 T cells in B6.g7 were naïve 
rather than tolerant we would expect them to produce TNF. We tested these hypotheses 
by stimulating cells from pancreatic LN, spleen, and non-draining LNs with PMA and 
ionomycin ex vivo. IFN, TNF, and IL-17A were all produced in the bulk polyclonal 
CD4
+
 CD44
high
 population in both NOD and B6.g7 mice, providing positive controls that 
all cytokines could be detected (Figure 3-8 A). Following stimulation, tetramer-binding 
cells in NOD mice produced IFN and TNF but not IL-17A (Figure 3-8 A and B). 
B6.g7 produced little to no IFN or IL-17A as predicted due to the large frequency of 
CD44
low
 “naïve” insulin-specific CD4+ T cells in these mice (Figure 3-8 A and B). 
Importantly, insulin-specific CD4
+
 T cells from B6.g7 produced TNF, suggesting that 
these cells were viable (Figure 3-8 A and B). Interestingly, there was not a significant 
difference in the frequency of IFN- (p=0.5674) or TNF-producing cells (p=0.0551) in 
diabetic compared to non-diabetic NOD mice, though there was a trend towards more 
TNF produced in diabetic NOD (Figure 3-8 B). These data support a model where 
insulin-specific CD4
+
 T cells become activated and differentiate into pathogenic Th1 
cells in NOD, but not B6.g7 mice.     
We next compared the frequency of cytokine-producing cells in the CD44
high
 to 
the CD44
low
 compartment, since we speculated that a fraction of CD44
low
 cells were 
chronically stimulated in NOD (Figure 3-8 C). As expected, the majority of the IFN 
production was from the CD44
high
 compartment in NOD (non-diabetic 30.77±6.1; 
diabetic 37.76±7.8); however, there was a small frequency of cells that produced IFN in 
the CD44
low
 population (non-diabetic 6.9±1.87; diabetic 8.85±2.1) (Figure 3-8 C). This 
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result was consistent with the notion that some of the cells in the CD44
low
 compartment 
were antigen-experienced (CD45RB
dim
). We speculate that a proportion of these cells 
could be functionally impaired or exhausted compared to their CD44
high
 counterparts due 
to chronic antigenic stimulation; however, the CD44
low
 compartment could also contain 
naïve cells.  
 
Insulin-specific regulatory T cells develop in both NOD and B6.g7 mice 
Treg cells are important mediators of peripheral tolerance. Lineage deviation into 
a regulatory phenotype prevents autoreactive T cells from inducing aberrant tissue 
pathology, and these cells play an important role in controlling Type 1 Diabetes 
progression (139). We hypothesized that a subset of insulin-specific CD4
+
 T cells would 
develop a regulatory phenotype since these cells are specific for self antigen. To test this 
hypothesis, we determined whether insulin-specific CD4
+
 T cells express Foxp3, the 
master transcription factor that controls the Treg cell lineage (114, 115). In both NOD 
and B6.g7, between 10-20% of the tetramer positive cells expressed Foxp3 in the spleen 
and non-draining LN and 10-30% expressed Foxp3 in the pancreatic LN (Figure 3-9). 
There was no statistically significant difference in the frequency of Foxp3
+
 insulin-
specific CD4
+
 T cells between NOD and B6.g7, suggesting that insulin-specific Treg 
cells alone were unlikely to contribute to the differences observed in diabetes incidence 
between the two mouse strains. However, the functional relevance of this population in 
either mouse strain remains to be tested.  
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Autoimmune diabetes develops in NOD mice despite robust anergy development in 
the endogenous insulin-specific CD4
+
 T cell compartment in the pancreatic LN.   
 In Chapter 2 we established that a large frequency of BDC2.5 T cells displayed an 
anergic phenotype (FR4
+
 CD73
+
) in the pancreatic LN, but this population was largely 
absent from the spleen and pancreas (Figure 2-8). We next utilized our tetramer reagent 
and stained for this anergic phenotype among the insulin-tetramer positive cells in NOD 
and B6.g7 mice. Since FR4
+
 CD73
+
 BDC2.5 T cells were largely absent from the 
pancreas, we focused on expression of these markers in the secondary lymphoid organs. 
Similarly to the BDC2.5 model, the majority of insB10-23r3-specific CD4
+
 T cells 
displayed the anergic phenotype within the pancreatic LN (Figure 3-10 A and B). 
Additionally, CD73
-
 FR4
-
 effector phenotype cells were the predominant population in 
the spleen and non-draining lymph nodes (Figure 3-10 B and data not shown). We 
speculate it is this population of cells that had escaped peripheral tolerance or broken 
tolerance and would contribute to diabetes pathogenesis. Interestingly, the frequency of 
anergic phenotype insulin-specific T cells was significantly higher in the pancreatic LN 
of young NOD mice (5 weeks) compared to older NOD mice (20-26 weeks) (p=0.0086) 
(Figure 3-10 B), while effector phenotype cells concomitantly increased in older NOD 
mice compared to young NOD mice (data not shown). These data support a model where 
tolerance is induced in a large fraction of insulin-specific CD4
+
 T cells early in life in the 
antigen-containing pancreatic LN, but since insulin-specific cells can be detected in the 
pancreas at this age (Figure 3-3 C), tolerance is notably incomplete and diabetes may 
only require a small fraction of self-reactive T cells escaping or reversing peripheral 
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tolerance. Furthermore, these data suggest that tolerance is not maintained over time, 
which may contribute to enhanced infiltration of the pancreas as NOD mice age. We did 
not find a significant population of anergic CD44
high
 Foxp3
-
 cells in the B6.g7 mice, 
despite the possibility that these mice could have been protected from diabetes due to 
efficient anergy induction. Rather, these cells maintain a naïve phenotype (Figure 3-4 and 
3-6) and subsequently these mice do not develop disease.   
Previous work defined the anergic phenotype as CD44
high
, since antigen encounter 
is a requisite for anergy induction (209). Since the CD44
low
 population in NOD mice 
contained some cells that were chronically stimulated (CD44
dim
 CD45RB
dim
), we 
evaluated FR4 and CD73 expression on Foxp3
-
 CD44
low
 cells. A small frequency of FR4
+
 
CD73
+
 cells were found in the CD44
low
 compartment of a few NOD mice (Figure 3-10 B), 
though it was incredibly modest compared to the CD44
high
 compartment, with the 
majority of mice having no CD44
low
 FR4
+
 CD73
+
 cells. We therefore predict that anergy 
and exhaustion are separate functional states corresponding to unique phenotypes in 
NOD mice. Whether anergic cells can eventually become exhausted is unclear, but would 
be interesting to pursue. Lastly, FR4
+
 CD73
+
 cells were completely absent from the 
CD44
low
 Foxp3
-
 population of insulin-specific CD4
+
 T cells in B6.g7 mice, further 
suggesting that these cells were naïve. Collectively these data suggest that anergy is 
induced following antigen encounter in the pancreatic LN of NOD mice but not B6.g7, 
where the majority of cells remain naïve. 
 
DISCUSSION 
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The importance of the insulin-specific adaptive immune response during Type 1 
Diabetes is well established (59, 70, 74, 80, 84, 85). Although it was known that these 
cells became activated early in life and infiltrated the pancreas, the work presented herein 
was the first to track the endogenous insulin-specific CD4
+
 T cell population in vivo 
during diabetes progression. Our work confirmed that these cells became activated early 
and infiltrated the pancreas, but extended the current knowledge by demonstrating that in 
NOD a large proportion of the population failed to encounter autoantigen, and of the 
population that did encounter autoantigen a large fraction did not infiltrate the pancreas. 
We speculate that anergy induction in the pancreatic LN contributes to holding the 
insulin-specific CD4
+
 T cell population in the secondary lymphoid organs, and that 
inhibiting trafficking to the pancreas acts as an important mechanism of peripheral 
tolerance. Lastly, our data comparing CD45RB and CD44 expression in NOD mice over 
time suggested that insulin-specific CD4
+
 T cells chronically engaged autoantigen, which 
could lead to exhaustion in older mice. The notion of exhaustion contributing to loss of 
function during autoimmunity provides a novel regulatory mechanism that remains to be 
explored.  
Use of the insulin tetramer reagent allowed a direct comparison of an endogenous 
diabetogenic T cell response in diabetes-susceptible (NOD) and diabetes-resistant 
(B6.g7) mice for the first time. While the mechanisms that limit autoimmunity in B6.g7 
mice that ultimately fail in NOD mice remain to be fully elucidated, our data support a 
model where there is a substantial difference in presentation of insB10-23/MHC II 
complexes between the two mouse strains. In NOD, insulin-specific CD4
+
 T cells 
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encountered autoantigen in the pancreatic LN between weeks 3-5 of life, and a subset 
became activated, differentiated into IFN-producing effector cells, and began infiltrating 
the pancreas, while another subset became anergic. Despite the induction of anergy in a 
large fraction of the insulin-specific population in the pancreatic LN, insulin-specific 
CD4
+
 T cells in young NOD mice are capable of driving disease pathology. Therefore, 
we speculate that only a small number of activated effector cells are required for diabetes 
progression in NOD mice. On the contrary, these cells fail to encounter autoantigen in 
B6.g7 mice and remain naïve, allowing ignorance to pancreatic antigen to be the main 
mechanism of peripheral tolerance in these mice rather than a more active process such as 
anergy. 
Our work utilizing the modified insB10-23r3 peptide bound to I-A
g7
 has revealed 
important differences between the insulin-specific CD4
+
 T cell response in diabetes-
susceptible and –resistant mice. However, we were limited in this study by the diversity 
of insulin-specific CD4
+
 T cells that our tetramer could detect. While there is growing 
evidence that this modified register 3 epitope binds a critical population of insulin-
specific CD4
+
 T cells both in vitro and in vivo (84, 86, 87, 99), there is new evidence that 
the glutamic acid at B21 (position 8) is inhibitory to tetramer binding for a subset of 
insulin-specific clones (99).  Therefore, a subpopulation of cells was likely excluded from 
this analysis. Future studies incorporating tetramers containing other insB9-23 registers 
may allow us to gain a deeper perspective on the dynamics of the insulin-specific CD4
+
 T 
cell population in vivo. It would be interesting to determine if other insB9-23 registers 
have the same bias towards anergy induction as the register 3 epitope used in this study, 
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or if these cells are more pathogenic. Understanding how peptide/MHC binding impacts 
the effector potential of diabetogenic CD4
+
 T cells may shed important insight into how 
these cells become activated during diabetes and how they can be targeted therapeutically 
to restore tolerance in patients.  
In conclusion, we have developed a peptide/MHC class II tetramer reagent that 
allows tracking of insB10-23r3-specific CD4
+
 T cells in vivo. This reagent can be used not 
only to track CD4
+
 T cell responses in NOD mice, but is also useful for studying 
diabetes-resistant strains including B6.g7. The critical differences between the diabetes-
prone and -susceptible mice were activation of the cells, differentiation into either 
functionally non-responsive anergic cells or pathogenic IFN--producing Th1 cells, and 
effector cell infiltration of the pancreas. Despite the presence of pathogenic CD4
+
 T cells 
in NOD mice, an anergic population emerged specifically in the pancreatic LN. In B6.g7 
mice, an anergic phenotype did not develop: Tolerance was more likely maintained by 
the absence of antigen encounter. These studies provide important insight into the 
differences in the regulation of a known autoreactive CD4
+
 T cell specificity in 
autoimmune-prone versus –susceptible hosts. Future work aimed at identifying factors 
that contribute to the breakdown of tolerance in NOD will be informative to developing 
better therapeutic approaches for diabetic patients. Additionally, work using B6.g7 mice 
could be informative to determine if therapies designed to enhance immunity will 
promote autoimmunity in a host with limited risk of developing the disease.  
 
FOOTNOTES 
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1
Portions of this work will be submitted for publication in 2013.  
2
J. Linehan constructed the insB10-23r3:I-Ag7 tetramer reagent. 
3
J. Linehan and J. Spanier contributed to Figure 3-1 C and D priming of NOD and B6.g7 
mice with insB10-23 or whole insulin protein. 
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CHAPTER 4:  
The PD-1 pathway is critical for suppressing islet-specific effector CD4
+
 T cell 
functions, but is not required for the induction of peripheral tolerance following 
exposure to endogenous autoantigen.
1
 
 
INTRODUCTION 
The inhibitory receptor Programmed Death-1 (PD-1) interacting with PD-L1 is 
critical for suppressing diabetes since disrupting PD-1/PD-L1 interactions accelerates 
diabetes in NOD mice (137, 138, 174). Polymorphisms in PD-1 have also been associated 
with human Type 1 Diabetes (181). Previous studies demonstrated roles for the PD-1 
pathway in inhibiting CD4
+
 T cell survival, proliferation, and cytokine production using 
in vitro and in vivo systems (59, 169, 174, 176, 177). Additionally, PD-1 interacting with 
PD-L1 has been shown to be critical for both the induction and maintenance of T cell 
anergy in islet-reactive CD4
+
 T cells (59, 110). The ability of PD-1 to maintain tolerance 
in this model was at least partially due to its ability to prevent the T cell stop signal 
required for CD4
+
 T cells to execute their effector functions (110). Importantly, PD-1 
acted on tolerant islet-reactive T cells in the pancreatic LN as well as pancreatic islets, 
highlighting the role for this pathway in mediating tolerance in the autoimmune target 
organ (110). However, since many of the in vivo studies relied on adoptive transfer of 
non-physiologically high numbers of T cell receptor transgenic T cells, the cellular 
mechanisms by which PD-1 constrains diabetogenic CD4
+
 T cells in hosts with a normal 
T cell repertoire remain unclear.  
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We re-examined the role of PD-1 in regulating CD4
+
 T cells in vivo using the 
new adoptive transfer model described in Chapter 2 that more closely mimics the normal 
naïve pre-immune repertoire, as well as the endogenous insulin-specific CD4
+
 T cell 
population described in Chapter 3 using the insB10-23r3:I-A
g7
 tetramer reagent. In NOD 
mice, anti-PD-L1 resulted in an increase in the number of islet-reactive CD4
+
 T cells in 
the spleen, pancreatic LN, and pancreas. This increase in cell number was at least 
partially due to the ability of PD-1 to regulate cell cycle progression in the secondary 
lymphoid organs both early during initial priming (Day 7) as well as late after the cells 
became quiescent (Day 42). Loss of PD-1 also resulted in increased expression of the 
chemokine receptor CXCR3, which is involved in Th1 cell homing to the pancreas during 
Type 1 Diabetes (219, 220) and aids in optimizing Th1 cell differentiation in antigen-
containing LNs (221). Additionally, loss of PD-1 altered localization of islet-reactive T 
cells within the pancreas, causing them to move from a more benign portion of the islet 
infiltrate into the islet core. These results confirm and extend results from previous 
studies showing that loss of PD-1 enhances T cell effector functions (174, 182). 
Interestingly, our results showed that while the PD-1/PD-L1 pathway is important 
for controlling a variety of effector functions performed by CD4
+
 T cells, only a specific 
subpopulation of islet-reactive cells was susceptible to anti-PD-L1 treatment. Contrary to 
our prediction based on our previous work (59, 110), PD-1 was not required for the 
induction or maintenance of T cell anergy, and blocking PD-1 did not restore 
functionality to anergic T cells. Rather, PD-1 was more important for regulating effector 
phenotype cells. These data suggest that PD-1 is required to suppress effector CD4
+
 T 
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cell proliferation and infiltration of the pancreas, but is largely dispensable for tolerance 
when T cells are primed under physiological conditions. These findings have important 
clinical implications for exploiting the PD-1 pathway to modulate T cell effector 
functions.  
 
MATERIALS AND METHODS 
Mice 
Mice were housed and bred in specific-pathogen free conditions in animal barrier 
facilities at the University of Minnesota. Female NOD mice were purchased from 
Taconic (Germantown, NY). NOD BDC2.5 TCR transgenic mice were purchased from 
the Jackson Laboratory (Bar Harbor, Maine) and crossed to NOD Thy1.1
+
 mice. 
C57BL/6 PD-1-deficient mice (222) were backcrossed thirteen generations to the NOD 
background and PD-L1-deficient mice (174) were backcrossed fifteen generations to the 
NOD background. The mice were bred with BDC2.5 mice, and the resulting offspring 
that were heterozygous for PD-1 or PD-L1 expression were subsequently intercrossed to 
produce NOD.BDC2.5 PD-1 KO or PD-L1 KO mice. Wild type, PD-1- and PD-L1-
deficient BDC2.5 mice were used for donors between 4-6 weeks of age. Pre-diabetic 
NOD mice (Thy1.2
+
) were used as recipients for Thy1.1
+
 BDC2.5 T cells between 7-12 
weeks of age. All animal experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Minnesota.  
 
Detection of islet antigen-specific CD4
+
 T cells 
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 Naïve CD4
+
 T cells from NOD.BDC2.5.Thy1.1
+
 mice were isolated as described 
in Chapter 2 (216). Briefly, naïve CD4
+
 T cells were enriched from single cell 
suspensions from spleen and non-antigen draining LNs (inguinal, axillary, brachial, 
cervical, periaortic) by depleting cells based on CD8, MHC class II, CD117, CD24, 
CD25, B220, CD19, Ter119, Gr-1 and CD44 (eBioscience). Seventy-five hundred naïve 
BDC2.5 T cells were transferred intravenously into prediabetic NOD mice. Mice were 
harvested 3-6 weeks post-transfer and analyzed by flow cytometry as described in 
Chapter 2 (216). Briefly, BDC2.5 T cells from spleen and/or non-draining LNs were 
enriched using positive selection over magnetic columns (Miltenyi Biotech) by 
incubating cells with APC conjugated anti-Thy1.1 (eBioscience) followed by anti-APC 
microbreads. Pancreatic LN and pancreas samples were not subjected to magnetic 
enrichment due to the low number of total cells in these samples. Leukocytes were 
enriched from the pancreas using collagenase P digestion (Roche) and discontinuous 
percoll gradients as described (Pauken et at. 2013).    
 Insulin-specific CD4
+
 T cells were detected using the insB10-23r3:I-A
g7
 tetramer 
reagent described in Chapter 3. Briefly, single cell suspensions were incubated for one 
hour at room temperature with 10 nM of tetramer conjugated to PE and APC in medium 
containing Fc receptor block (2.4G2) and azide. Pancreatic LN and pancreas samples 
were then subjected to surface staining for FACS without subsequent enrichment. Spleen 
and/or non-draining LN samples were subjected to magnetic enrichment by incubating 
with both anti-PE and anti-APC microbeads at 4
o
C for 30 minutes followed by elution 
over magnetic columns (Miltenyi Biotech).  
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Flow cytometry 
 Surface staining was performed for 30 minutes at 4
o
C following enrichment 
protocols described above (magnetic enrichment or percoll). Surface staining was 
performed post-tetramer staining. Antibodies used from eBioscience included anti-
Thy1.1 (HIS51 clone for FACS), CXCR3, PD-1 (clone J43), CD4, CD3, B220, CD11b, 
CD11c, CD44, CD45RB, IL-2, IFN, and TNF. Antibodies from other companies 
included CD44 (V500 conjugate) and Ki67 from BD Bioscience and anti-CD8 (BV650 
conjugate) from Biolegend. Samples were acquired using BD LSRII and Fortessa 
instruments (BD) and analyzed using Flow Jo software (Treestar). The gating strategy for 
BDC2.5 T cells was singlet
+
, CD3
+
 lineage
-
 (B220
-
, CD11b
-
, CD11c
-
) CD4
+
 Thy1.1
+
. The 
gating strategy for insulin-specific CD4
+
 T cells was singlet
+
, CD3
+
 lineage
-
 (B220
-
, 
CD11b
-
, CD11c
-
) CD4
+
 CD8-, insB10-23r3: I-A
g7
-PE and -APC tetramer double positive.   
 
Immunofluorescence Microscopy 
 Pancreata were harvested for immunofluorescence and prepared as described in 
Chapter 2 (Pauken 2013 Diabetes). Briefly, O.C.T. embedded pancreata were cut at seven 
m and fixed using acetone. Antibodies used to stain the tissue sections included guinea 
pig anti-swine inulin (Dako, Denmark) and donkey anti-guinea pig AF488 (Jackson 
ImmunoResearch), Thy1.1-PE (clone OX7, Biolegend, CA), and CD3e-APC (clone 145-
2C11, eBioscience). Slides were mounted using Prolong Gold with DAPI (Life 
Technologies). Slides were imaged on a Leica epifluorescent DM5500 microscope 
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(Germany) and MetaMorph software was used to compile the data (Molecular Devices, 
CA).  
 
Administration of Anti-PD-L1 antibody 
Anti-PD-L1 antibody (clone M1H6) was generated and produced as described 
(164). Rat immunoglobulin G (IgG) was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). Mice were injected intraperitoneally with 200-250 
g/mouse anti-PD-L1 or Rat IgG antibody every other day prior to harvest for 2-3 
injections or diabetes onset. Glucose levels were assessed by urine readings during the 
treatment period and blood glucose was measured at the time of harvest (LifeScan, Inc., 
Milpitas, CA). A reading above 250 mg glucose/dL of blood was considered diabetic.   
 
Proliferation assays 
To investigate proliferation at early time points post-transfer (day 7), purified 
BDC2.5 T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) prior to 
transfer. Following purification as described above, cells were resuspended in PBS with 5 
M CFSE (Life Technologies) for 5 minutes at room temperature. The labeling was 
quenched by adding an equal volume of fetal bovine serum and the cells were washed 
prior to transfer. To investigate proliferation at late time points (day 42), intracellular 
staining for the proliferative marker Ki67 was used instead of CFSE. Cells were 
permeabilized by resuspending in Foxp3 fixation/permeablization buffer according to 
manufacturer’s recommendations (eBioscience). FITC-conjugated anti-Ki67 (B56, BD 
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Biosciences) was added following permeabilization of cells at doses recommended by the 
manufacturer (20 l/sample). 
 
Assessment of cytokine production  
To compare cytokine production following anti-PD-L1 treatment on the bulk 
BDC2.5 T cell population, single cell suspensions from the pancreatic LN and pancreas 
were stimulated in DMEM containing 10% fetal bovine serum (Hy-clone), 2 mM L-
glutamax, 100 U/ml penicillin-streptomycin, 0.1 M non-essential amino acids, 10 mM 
HEPES and 50 M 2-mercaptoethanol (Life Technologies, Grand Island, NY) with 10 
g/ml brefeldin A, 100 ng/ml phorbol 12-myristate 13-acetate (PMA), and 1000 ng/ml 
ionomycin (Sigma, MO) for four hours at 37
o
C and 5% CO2. The BD cytofix/cytoperm 
fixation/permeabilization kit was used for intracellular cytokine staining. Cells were fixed 
overnight at 4
o
C in the cytofix/cytoperm buffer to enhance detection of IL-2. To assess 
cytokine production from anergic and effector BDC2.5 T cells, 500 g of acetylated p31 
peptide (YVRPLWVRME) (Genemed Sythesis, San Antonio, TX) was injected 
intravenously and cells were harvested directly into medium containing brefeldin A 4 
hours later. Subsequent enrichment and staining steps were also conducted in medium 
containing brefeldin A and azide. 
 
Statistics  
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad, 
La Jolla, CA). We performed either unpaired two-tailed Student’s t tests with a 95% 
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confidence interval or Mann-Whitney tests. Asterisks indicating statistical significance 
correspond with: not significant >0.05 (ns), significant 0.01 to 0.05 (*), very significant 
0.001 to 0.01 (**), and extremely significant <0.001 (***).  
 
 
RESULTS 
Anti-PD-L1 accelerates Type 1 Diabetes onset and causes an increase in the number 
of islet-reactive CD4
+
 T cells in NOD mice 
We first determined whether blocking PD-1 signaling impacted the BDC2.5 T 
cells in the low adoptive transfer model described in Chapter 2. This model was utilized 
because the majority of the BDC2.5 T cells encountered autoantigen in a narrow time 
frame, providing a more synchronous population to identify the effect of PD-1 blockade 
than the insulin-specific population detected with the insB10-23r3: I-A
g7
 tetramer. Three 
weeks post-transfer anti-PD-L1 antibody was administered to block the interaction 
between PD-1 and PD-L1. An isotype antibody was administered as a control. Anti-PD-
L1 injection resulted in a substantial increase in diabetes incidence (Figure 4-1 A, 0% 
diabetic in isotype-treated vs. 63.6% diabetic in anti-PD-L1 treated) consistent with 
previous work (137). This accelerated disease onset correlated with an increase in 
BDC2.5 T cell numbers that was statistically significant in the spleen (4.66-fold increase 
with anti-PD-L1, p=0.0009), pancreatic LN (2.46-fold increase with anti-PD-L1, 
p<0.0001), and pancreas (8-fold increase with anti-PD-L1, p=0.0118) (Figure 4-1 B). 
There was not a statistically significant increase in BDC2.5 T cell numbers in the 
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inguinal LN following PD-1 blockade (p=0.4166) (Figure 4-1 B), which was consistent 
with PD-1 regulating T cells in an antigen-dependent manner (166). We were surprised to 
observe an increase in BDC2.5 T cells numbers in the spleen, since the presence of 
pancreatic antigen in this organ has not been documented to our knowledge. We 
speculate that the increase in BDC2.5 T cells in the spleen reflected increased trafficking 
from the pancreatic LNs through blood circulation en route to the pancreas.  
 Loss of PD-1 signaling accelerates autoimmunity in a variety of mouse strains; 
however, the nature of the autoimmune disease induced is dependent on genetic 
background (138, 155, 156). PD-1 KO mice on the NOD genetic background develop 
accelerated Type 1 Diabetes (138), while PD-1 KO B6 develop a lupus-like nephritis 
(155). Based on these data, we hypothesized that blocking PD-1 through administration 
of anti-PD-L1 would not induce diabetes in B6.g7 mice, which do not develop Type 1 
Diabetes spontaneously (223). An alternative possibility would be that since NOD MHC 
class II (H-2
g7
) is the highest genetic risk factor for developing Type 1 Diabetes, B6.g7 
would be susceptible to developing diabetes following PD-1 blockade. We determined 
that administering anti-PD-L1 dramatically accelerated Type 1 Diabetes onset in NOD 
mice, consistent with previous reports (137); however; anti-PD-L1 did not induce 
diabetes in B6.g7 mice (Figure 4-2). This result demonstrated that the presence of the H-
2
g7
 allele alone was not sufficient to induce diabetes even when a key inhibitory pathway 
was blocked. 
  We next investigated the impact of anti-PD-L1 treatment on insulin-specific 
CD4
+
 T cells in 15 week old NOD and B6.g7 mice. Since we observed an increase in the 
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number of BDC2.5 T cells in the spleen, pancreatic LN and pancreas in our low adoptive 
transfer model (Figure 4-1 B) (216), we hypothesized that anti-PD-L1 would cause an 
increase in the number of insulin-specific CD4
+
 T cells in these organs in NOD mice. In 
NOD mice, we did not observe a substantial increase in the number of insulin-specific 
CD4
+
 T cells on a population level in the secondary lymphoid organs (Figure 4-3 A). 
There was a trend towards more of these cells in the pancreas following anti-PD-L1 
treatment, and substantially more of the pancreata analyzed with anti-PD-L1 contained 
insulin-specific cells compared to isotype control-antibody treated mice. However, this 
increase was not statistically significant. One critical difference between the population 
detected in the BDC2.5 T cell transfer model and with the insB10-23r3: I-A
g7
 reagent was 
the frequency of CD44
high
 cells: Nearly 100% of BDC2.5 T cells encountered autoantigen 
in the pancreatic LN within 28 days post-transfer (Figure 2-2), whereas a large fraction of 
insulin-specific CD4
+
 T cells remained CD44
low
 in NOD mice (Figure 3-4). Since PD-1 
expression correlated with CD44 expression (Figure 3-7), we predicted that anti-PD-L1 
would specifically impact the CD44
high
 population. Indeed, when the number of CD44
high
 
cells was compared, anti-PD-L1 treatment resulted in significantly increased numbers of 
insulin-specific CD4
+
 T cells in both the spleen (p=0.0069) (Figure 4-3 B) and pancreatic 
LN (p=0.0216) (Figure 4-3 C). There was not a statistically significant difference in the 
number of CD44
low
 insulin-specific CD4
+
 T cells in the spleen (p=0.7865) or pancreatic 
LN (p=0.6483) (Figure 4-3 B and C). This result was expected since the majority of 
CD44 low cells do not express PD-1 (Figure 3-7 and data not shown). However, since the 
CD44
low
 population contains a mixture of naïve cells (CD45RB
high
) and potentially 
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chronically stimulated cells (CD45RB
dim
), we speculate that PD-1 blockade was only 
capable of reversing a subset of antigen-experienced cells. Which insulin-specific T cell 
populations are susceptible to PD-1 blockade enhancing functions is not addressed in this 
study, but would be interesting to pursue considering the heterogeneity in this population.   
 Lastly, we determined how PD-1 blockade impacted insulin-specific CD4
+
 T cells 
in B6.g7 mice. We hypothesized that anti-PD-L1 would have less of an effect on insulin-
specific CD4
+
 T cells in B6.g7 mice than NOD mice because the frequency of these cells 
that expressed PD-1 was lower in B6.g7 mice compared to NOD mice (Figure 3-7), and 
therefore a smaller fraction of the population was likely susceptible to PD-1 blockade. 
Additionally, anti-PD-L1 accelerated diabetes in NOD but not B6.g7 (Figure 4-2). When 
the insulin-specific CD4
+
 T cell population was analyzed in the secondary lymphoid 
organs, there was not a statistically significant increase in the number of these cells 
following anti-PD-L1 treatment (Figure 4-4 A). Most importantly, there was no 
infiltration of the pancreas with anti-PD-L1 (Figure 4-4 A). Unexpectedly, there was a 
significant increase in the number of cells in the pancreatic LN in the CD44
high
 
population of insulin-specific CD4
+
 T cells (Figure 4-C). As described earlier, a higher 
frequency of insulin-specific cells expressed PD-1 in the pancreatic LN than CD44 in 
B6.g7 mice (Figure 3-7). Therefore, expression of PD-1 in this organ could render these 
cells susceptible to PD-1 blockade. Nonetheless, PD-1 blockade does not result in an 
increase in these cells in the CD44
high
 population in the spleen or increase infiltration of 
the pancreas. Therefore, the significance of this increase was likely minor in terms of 
Type 1 Diabetes pathogenesis.     
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Anti-PD-L1 causes sustained proliferation early during the priming phase of the 
response and causes cells to re-enter cell cycle late during the persistent phase of the 
response 
We next focused on mechanisms by which PD-1 regulated islet-reactive CD4
+
 T 
cells to slow Type 1 Diabetes progression. Due to the advantage of the BDC2.5 transfer 
model providing a synchronous population of cells in terms of antigen encounter and 
activation, the remainder of these studies were performed using this model instead of 
tracking insulin-specific CD4
+
 T cells using tetramer. Previous work had identified a role 
for PD-1 in regulating T cell proliferation, survival, and cytokine production (169, 174, 
184, 185, 224). We first focused on cell proliferation as a potential mechanism regulating 
the BDC2.5 T cell population considering the profound cellular increase following PD-1 
blockade. We hypothesized that the cell number increase was due to increased 
proliferation rather than enhanced survival due to the stability of the BDC2.5 T cell 
population observed in the clonal expansion curve (Figure 2-3). To test this hypothesis 
we transferred naïve CFSE-labeled BDC2.5 T cells, treated with anti-PD-L1 at days 4 
and 6 post-transfer and measured proliferation at day 7. Anti-PD-L1 treatment resulted in 
a statistically significant increase in the frequency of BDC2.5 T cells that had fully 
diluted CFSE in the spleen (47.83±4.41% with isotype vs. 61.18±2.62% with anti-PD-L1, 
p=0.0405) and pancreatic LN (24.00±4.86% with isotype vs. 38.68±2.60% with anti-PD-
L1, p=0.037) at day 7 post-transfer (Figure 4-5 A and B). There was not a statistically 
significant difference in the frequency of CFSE-diluted BDC2.5 T cells in the inguinal 
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LN or the pancreas between isotype- and anti-PD-L1-treated mice (Figure 4-5 A and B). 
In the inguinal LN the majority of the BDC2.5 T cells in both conditions were undiluted 
(6.28±2.36% CFSE
-
 with isotype vs. 17.21±4.64% CFSE
-
 with anti-PD-L1, p=0.081), 
which was consistent with most cells being naïve at this early time point. Conversely, the 
majority of the BDC2.5 T cells in the pancreas at day 7 had completely diluted the CFSE 
dye with or without anti-PD-L1 treatment (84.25±2.45% with isotype vs. 87.67±6.51% 
with anti-PD-L1, p=0.7177). This result was consistent with the notion that rapidly 
proliferating BDC2.5 T cells were the predominant population entering the pancreas at 
early time points following activation.  
We next tested whether PD-1 regulated cell cycle entry late post-transfer at a time 
point when the BDC2.5 T cell population had reached a plateau in the clonal expansion 
curve. We transferred naïve BDC2.5 T cells, waited 6 weeks, and treated with anti-PD-
L1 or isotype control antibody and measured expression of Ki67, a molecule associated 
with cell cycle entry. The majority of the BDC2.5 T cells from isotype control antibody-
treated animals were quiescent (Ki67
neg
) from the inguinal LN (90.67±5.21%), spleen 
(68.57±5.01%), pancreatic LN (75.13±4.77%), and pancreas (70.17±5.66%) 6 weeks 
post-transfer (Figure 4-6 A and B).  However, PD-1 blockade resulted in a substantial and 
significant increase in the frequency of the BDC2.5 population that had recently entered 
cell cycle (Ki67
+
) in the spleen (31.43±5.01% with isotype vs. 70.83±4.61% with anti-
PD-L1, p=0.0044), pancreatic LN (24.87±4.77% with isotype vs. 57.60±9.04% with anti-
PD-L1, p=0.0328), and pancreas (29.83±5.66% with isotype vs. 61.37±6.84% with anti-
PD-L1, p=0.0238) (Figure 4-6 A and B). PD-1 blockade did not result in a significant 
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increase in Ki67
+
 BDC2.5 T cells in the inguinal LN as expected since this organ lacks 
pancreatic antigen (9.33±5.21% with isotype vs. 23.86±13.51% with anti-PD-L1, 
p=0.3724) (Figure 4-6 A and B). Collectively these data suggest that PD-1 regulates 
CD4
+
 T cell proliferation both early during the initial priming and expansion phase 
(Figure 4-5) as well as late during the persistent phase of the response (Figure 4-6).  
 
PD-1 blockade causes increased expression of the chemokine receptor CXCR3 
Our results indicated that PD-1 blockade resulted in a substantial increase in 
BDC2.5 T cells in the pancreas (Figure 4-1 B). Therefore, we next determined whether 
PD-1 regulated expression of chemokine receptors associated with T cell trafficking to 
the pancreas. We hypothesized that PD-1 blockade would result in increased expression 
of CXCR3, a chemokine receptor known to promote effector Th1 cell trafficking to 
pancreatic islets during Type 1 Diabetes progression (219). CXCL10, a ligand for 
CXCR3, is highly expressed within pancreatic islets and is involved in the recruitment of 
pathogenic CXCR3-expressing T cells to the pancreas during disease progression (219, 
220). Additionally, recent work showed that CXCR3 expression is important for 
optimizing Th1 cell differentiation in antigen-containing LNs due to the ability to 
promote homing of cells to locations in the LN with optimal antigen presentation (221). 
We examined CXCR3 expression on BDC2.5 T cells three weeks post-transfer because 
we consistently observed BDC2.5 T cell accumulation in the pancreas at this time point. 
As predicted, PD-1 blockade resulted in the up-regulation of CXCR3 (based on MFI) on 
BDC2.5 T cells in the spleen and pancreatic LN that was highly significant (2.49-fold 
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increase with anti-PD-L1 in the spleen, p<0.0001 and 3.15-fold increase with anti-PD-L1 
in the pancreatic LN, p<0.0001). There was also an increase in CXCR3 in the inguinal 
LN (3.66-fold increase with anti-PD-L1, p=0.0288), but the biological significance of this 
increase was unclear (Figure 4-7 A and B). The levels of CXCR3 were low in the 
pancreas in both isotype- and anti-PD-L1-treated animals, and we speculate this was due 
to receptor down-regulation following exposure to CXCR3 ligands (Figure 4-7 A and B). 
PD-1 blockade also resulted in a significant increase in the frequency of CXCR3-
expressing BDC2.5 T cells in the inguinal LN (7.92±4.3% with isotype vs. 33.44±9.13% 
with anti-PD-L1, p=0.0249), spleen (40.25±2.73% with isotype vs. 66.93±4.42% with 
anti-PD-L1, p<0.0001), and pancreatic LN (18.75±3.72% with isotype vs. 48.86±5.46% 
with anti-PD-L1, p=0.0002) (Figure 4-7 C). This up-regulation of CXCR3 may account 
for enhanced Th1 differentiation in the pancreatic LN and increased trafficking of islet-
reactive CD4
+
 T cells to the pancreas during Type 1 Diabetes progression.   
 
Anti-PD-L1 does not increase the per cell capacity to produce effector cytokines, but 
causes an increase in the number of cytokine-producing cells in the pancreatic LN 
and pancreas 
We previously determined that the BDC2.5 T cells were programmed to become 
IFN- and IL-2-producing Th1 effector cells following exposure to autoantigen (Figure 2-
6). We hypothesized that anti-PD-L1 treatment would enhance the capacity for BDC2.5 T 
cells to produce effector cytokines to accelerate diabetes progression. To test this, we 
examined the effect of PD-1 blockade on the effector cytokine potential of BDC2.5 T 
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cells in the pancreatic LN and pancreas. Mice were treated mice with anti-PD-L1 or an 
isotype control antibody approximately one month post-transfer of naïve BDC2.5 T cells 
and IFN, TNF, and IL-2 were measured following ex vivo stimulation with PMA and 
ionomycin. Figure 4-8 panels B and C and Table 4-1 show the frequencies of BDC2.5 T 
cells capable of producing one, two, or three effector cytokines. Contrary to our 
prediction, PD-1 blockade did not significantly alter the frequency of the BDC2.5 T cell 
population programmed to produce IFNTNF and IL-2 (Figure 4-8 A-C and Table 4-
1). However, PD-1 blockade resulted in a significant increase in the number of single, 
double, and triple cytokine-producing BDC2.5 T cells in both the pancreatic LN (Figure 
4-8 D) (with anti-PD-L1 single
+
 3.9-fold increase, p=0.0008; double
+
 4.1-fold increase, 
p=0.0013; and triple
+
 3.7-fold increase, p=0.0011) and pancreas (Figure 4-8 E) (with anti-
PD-L1 single
+
 13-fold increase, p=0.0004; double
+
 8.3-fold increase, p=0.0004; triple
+
 
5.9-fold increase, p=0.004). These data suggest that PD-1 blockade does not alter the 
capacity for BDC2.5 T cells to produce effector cytokines on a per cell basis, but has a 
significant effect on the quantity of cytokine-producing effector BDC2.5 T cells due to 
increased proliferation.  
 
Neutralizing PD-L1 results in more destructive insulitis and causes BDC2.5 T cells 
to re-localize from the more benign portion of the islet infiltrate into the islet core 
Our data demonstrated the importance of PD-1/PD-L1-mediated regulation of 
islet-reactive CD4
+
 T cells temporally, both early during priming and late when the cells 
were mostly quiescent as well as spatially, resulting in enhanced migration from the 
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secondary lymphoid organs to the pancreas. We next determined whether PD-1 was 
regulating the spatial organization of BDC2.5 cells within the pancreatic infiltrate. At 
three weeks post-transfer, the majority of pancreas infiltrate was peri-insulitis (Figure 4-9 
A and C). However, anti-PD-L1 treatment caused a substantial conversion from peri-
insulitis to destructive insulitis (Figure 4-9 B and C), consistent with previous work (137). 
Importantly, BDC2.5 cells were present within the islet core following PD-1 blockade 
(Figure 4-9 B). These data suggest that PD-1 is actively regulating BDC2.5 T cells within 
the pancreas itself, and that blocking PD-1 has a direct effect on cells within the tissue 
rather than simply enhancing migration from the secondary lymphoid organs. These data 
extend our understanding of the spatial regulation PD-1 implements on islet-reactive 
CD4
+
 T cells. 
 
PD-1 expressed by the BDC2.5 T cell is required to regulate the early expansion in 
the secondary lymphoid organs and infiltration of the pancreas, while PD-L1 
expressed by the BDC2.5 T cell is dispensable 
Our results demonstrated that PD-1/PD-L1 blockade enhanced islet-reactive CD4
+
 
T cell proliferation and infiltration of the pancreas. Previous work had demonstrated roles 
for both PD-1 and PD-L1 expressed by effector CD8
+
 T cells in regulating function (184, 
225); however, the specific requirement for PD-1 or PD-L1 on antigen-specific CD4
+
 T 
cells during Type 1 Diabetes has not been studied. Therefore, we generated BDC2.5 mice 
deficient for PD-1 or PD-L1. We first confirmed that PD-1 was absent from the cell 
surface of BDC2.5 T cells from NOD.BDC2.5.PD-1
-/-
 mice, and PD-L1 was absent from 
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the cell surface of BDC2.5 T cells from NOD.BDC2.5.PD-L1
-/-
 mice (Figure 4-10 A). 
NOD.BDC2.5.PD-1
-/-
 and NOD.BDC2.5.PD-L1
-/-
 mice developed normally (data not 
shown), but both strains displayed accelerated Type 1 Diabetes compared to WT BDC2.5 
mice (Figure 4-10 B).  However, disease onset was delayed when compared to reports of 
non-T cell receptor transgenic NOD.PD-1
-/- 
and NOD.PD-L1
-/- 
mice (138, 174). 
Importantly, all donor mice used for these experiments were euglycemic at the time of 
BDC2.5 cell transfer. 
We next tested the role of PD-1 and PD-L1 on BDC2.5 cells in the low cell 
transfer model in NOD recipients. This approach allowed us to determine the requirement 
for PD-1 and PD-L1 on the T cell in a wild type environment. We transferred 7500 naïve 
T cells from either WT or KO BDC2.5 mice into pre-diabetic NOD mice. The park rates 
between WT and KO BDC2.5 cells were comparable (data not shown). At day 7 post-
transfer we observed a statistically significant increase in PD-1-deficient BDC2.5 cells in 
the spleen, pancreatic LN, and pancreas compared to PD-1-sufficient controls (Figure 4-
11 A).  There was not a significant increase in PD-1-deficient BDC2.5 cells in the 
inguinal LN. Conversely, there was no difference in the number of PD-L1-deficient 
BDC2.5 cells compared to PD-L1-sufficient controls in any organ (Figure 4-11 B). These 
data suggested that PD-1, not PD-L1, expressed by the BDC2.5 cell was required to 
suppress proliferation and infiltration of the pancreas. 
Anti-PD-L1 treatment caused an increase in CXCR3 expression and altered the 
organization of BDC2.5 T cells in the pancreatic infiltrate. We hypothesized that PD-1 on 
the BDC2.5 T cell was mediating these effects rather than a bystander effect of anti-PD-
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L1 altering the inflammatory environment. To begin to test this hypothesis, we next 
examined CXCR3 expression on PD-1 KO BDC2.5 cells after low transfer. We found 
significantly higher levels of CXCR3 in the spleen and pancreatic LN compared to WT 
(Figure 4-12 A and B). We observed slightly elevated levels of CXCR3 in the inguinal 
LN (Figure 4-12 A and B) similarly to what was observed with neutralizing antibody 
(Figure 4-7 A and B), but the significance of this expression was unclear. We observed 
the same trend in terms of frequency of CXCR3
+
 cells, with elevated frequencies in the 
inguinal LN, spleen, and pancreatic LN (Figure 4-12 C). Importantly, CXCR3 was not 
elevated in the intact PD-1 KO BDC2.5 mouse compared to WT BDC2.5 mice (data not 
shown). Additionally, since naïve cells were transferred, all BDC2.5 cells were CXCR3
-
 
at the time of transfer.  
Lastly, we determined how the loss of PD-1 selectively on the BDC2.5 cells 
impacted localization within the pancreas. Interestingly, PD-1 KO BDC2.5 cells could be 
detected both around and deep within the islet core (Figure 4-13 A). Mice that received 
PD-1 KO BDC2.5 cells also displayed more severe insulitis compared to mice that 
received WT BDC2.5 (Figure 4-13 B). This result suggested that loss of PD-1 on the 
BDC2.5 cells promoted the ability to penetrate into the core of the islet. Collectively 
these data support a model where PD-1 expressed by islet-reactive CD4
+
 T cells regulates 
proliferation, CXCR3 expression, and pancreas infiltration. 
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PD-1 is required to suppress functions of effector phenotype BDC2.5 T cells, but is 
not required for the induction or maintenance of anergy induced following exposure 
to endogenous autoantigen  
 Our data support a model where PD-1 expressed by the islet-reactive CD4
+
 T cell 
regulates proliferation and infiltration of the pancreas. However, these studies focused on 
a population level. We described two unique subsets of islet-reactive CD4
+
 T cells in 
Chapter 2 (BDC2.5) and 3 (insB10-23r3-specific): anergic cells defined as FR4
+
 CD73
+
 
CD44
high
 Foxp3
-
, and effector cells defined as FR4
-
 CD73
-
 CD44
high
 Foxp3
-
. We were 
interested in determining whether anti-PD-L1 treatment differentially impacted these 
distinct subsets of islet-reactive CD4
+
 T cells. Since previous work identified a critical 
role for PD-1 signaling in both inducing and maintaining T cell tolerance (59, 110), we 
hypothesized that loss of PD-1 would restore functionality to the anergic BDC2.5 T cell 
population. To test this hypothesis, we treated mice with anti-PD-L1 antibody three 
weeks post-transfer of 7500 naïve BDC2.5 T cells and quantified FR4 and CD73 
expression. Loss of PD-1 signaling resulted in a reduction in the frequency of anergic 
phenotype BDC2.5 T cells in the pancreatic LN (Figure 4-14 A and B) as expected based 
on our previous findings (59, 110). Interestingly, loss of FR4 and CD73 only occurred in 
the pancreatic LN and not inguinal LN, suggesting that antigen is involved in the 
maintenance of tolerance (Figure 4-14 B). Unexpectedly, when the absolute cell number 
was quantified, it became evident that the decrease in the frequency of anergic BDC2.5 T 
cells in the pancreatic LN was not due to a loss of the anergic population, but rather a 
substantial and significant (p=0.0053) expansion of the effector BDC2.5 population 
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(Figure 4-14 C). This result suggested that PD-1 blockade did not cause anergy reversal, 
but rather had selectively targeted the effector population that arose due to other defects 
in peripheral tolerance in NOD mice. 
 The conclusion thus far that anti-PD-L1 did not reverse the anergic state was 
based on co-expression of FR4 and CD73. However, it was possible that during the 
antibody treatment period, FR4 and CD73 may not have been down-modulated from the 
cell surface; therefore, these cells may have acquired effector functions without loss of 
the anergy markers. For this reason we analyzed cytokine production by anergic and 
effector phenotype BDC2.5 T cells following anti-PD-L1 treatment. Anti-PD-L1 was 
capable of restoring some cytokine production by anergic phenotype BDC2.5 T cells that 
was statistically greater than isotype control-antibody treated animals (isotype vs anti-
PD-L1: geometric MFI of IFN 118.8±2.46 versus 202.6±13.88, p=0.0012 and frequency 
of IFN-producing cells 16.83±1.40% versus 27.23±2.77%, p=0.0177) (Figure 4-15 A 
and B). However, the cytokine production from anergic cells remained blunted compared 
to the effector population in the isotype-control treated animals (anergic+aPD-L1 
geometric MFI=202.6±13.88 and frequency=27.23±2.77% versus effector+isotype 
geometric MFI=460±48.73 and frequency=46.48±4.58%), and incredibly blunted 
compared to the effector population in the anti-PD-L1 treated animals (effector+aPD-L1 
geometric MFI=729.8±33.24 and frequency=59.84±2.74%) (Figure 4-15 A and B). These 
data suggest while PD-1 blockade had a small effect on anergic BDC2.5 T cells, it was 
not capable of fully restoring function and had a much more substantial effect on 
enhancing functions of effector phenotype CD4
+
 T cells.  
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 Our previous work had identified a role for PD-1 in both the induction and 
maintenance of CD4
+
 T cell anergy (59, 110). However, considering that in the low 
transfer model PD-1 was not required for the maintenance of tolerance (Figure 4-14 and 
4-15), we re-evaluated the role for PD-1 during the induction phase of tolerance. We 
transferred 7500 naïve WT or PD-1 KO BDC2.5 T cells into pre-diabetic NOD mice and 
quantified FR4 and CD73 expression three weeks post-transfer. We found that PD-1 was 
not required for the induction of the anergic phenotype since the frequency of FR4
+
 
CD73
+
 BDC2.5 T cells was not significantly different between WT and PD-1 KO in the 
pancreatic LN (anergic frequency for WT=74.45±4.29% and PD-1 KO=67.52±2.65%) 
(Figure 4-16 A and B). PD-1 KO BDC2.5 T cells also did not accelerate Type 1 Diabetes 
in this low transfer system (data not shown), suggesting that the host was capable of 
controlling this population when provided at a physiologically relevant precursor 
frequency. These data support a model where PD-1 is important for regulating islet-
reactive CD4
+
 T cells during Type 1 Diabetes by suppressing effector cells, not anergic 
cells. Rather, loss of tolerance and progression to clinical disease likely correlates with 
loss of PD-1 signaling by the pathogenic effector population, not the reversal of the 
anergic population (Figure 4-17). The difference between this finding and our previous 
findings (59, 110) highlights the importance of studying islet-reactive CD4
+
 T cells under 
conditions that accurately recapitulate the natural course of Type 1 Diabetes in NOD 
mice. 
 
DISCUSSION 
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The critical link between the PD-1/PD-L1 signaling pathway and Type 1 Diabetes 
is well established (137, 138, 174). However, the mechanism of how this pathway 
regulates autoreactive CD4
+
 T cells during diabetes is not fully understood. In this thesis 
we developed model systems to investigate the effect of PD-1/PD-L1 interactions on 
antigen-specific CD4
+
 T cells. Using these models, we determined that PD-1 
predominantly regulated proliferation; however PD-1 blockade also resulted in enhanced 
infiltration of the pancreas, which may be due to increased CXCR3 expression following 
PD-1/PD-L1 blockade (Figure 4-17). PD-1 expressed by islet-reactive CD4
+
 T cells was 
required to suppress effector functions in a cell-intrinsic manner, while PD-L1 expressed 
by the effector CD4
+
 T cell was dispensable. Contrary to previous findings, the 
enhancement of effector functions associated with PD-1 blockade was primarily due to 
the impact on effector phenotype cells rather than reversing T cell anergy. These data 
suggest that under normal conditions PD-1 acts to limit Type 1 Diabetes progression by 
regulating effector islet-reactive CD4
+
 T cell proliferation and infiltration of the pancreas, 
not by controlling anergic cells (Figure 4-17).  
The role for PD-1/PD-L1 interactions in regulating T cells has been investigated 
previously in vitro and in vivo (59, 166, 169, 174-177, 184, 224). Current knowledge of 
how PD-1 regulates CD4
+
 T cells during Type 1 Diabetes in vivo is largely limited to the 
secondary lymphoid organs, while less is known about the pancreas. Work from Guleria 
and colleagues investigated mechanisms of PD-1-mediated regulation of antigen-specific 
CD4
+
 T cells in NOD mice (182), including BDC2.5 cells. However, a high number of 
BDC2.5 cells were transferred into recipient mice and a large fraction of these cells failed 
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to proliferate in the pancreatic LN even following anti-PD-L1 treatment. In our low 
transfer model, the majority of the BDC2.5 cells in the pancreatic LN diluted CFSE 
following anti-PD-L1 administration, highlighting an important difference between low 
and high T cell transfer numbers during diabetes pathogenesis. We extended the results 
from the previous study and demonstrated that PD-1 blockade caused quiescent cells to 
re-enter cycle during a later and chronic stage of disease. During this time, Ki67
+
 
BDC2.5 cells increased in the pancreas; however, it is unclear whether this increase 
correlated with trafficking or proliferation within the pancreas. It is interesting to 
speculate that islet-reactive CD4
+
 T cells could enter cell cycle in the pancreas since T 
cells persist in this organ in NOD mice for weeks to months prior to diabetes onset. 
Additionally, we showed that loss of PD-1 signaling correlated with increased expression 
of CXCR3. Not only is CXCR3 involved in diabetogenic T cell homing to the pancreas, 
but also optimizes Th1 differentiation in antigen-containing LNs (221). These data 
support a model where PD-1 expressed by the islet-reactive CD4
+
 T cell suppresses 
proliferation and limits CXCR3 expression, thereby inhibiting optimal Th1 differentiation 
and infiltration of the pancreas (Figure 4-17). 
Utilizing a genetic approach, we determined that the effects measured with anti-
PD-L1 were due to a direct effect of PD-1 on CD4
+
 T cells, not PD-L1 on the T cell or 
indirect effects such as alternative ligand binding (e.g. PD-1/PD-L2 or B7-1/PD-L1). 
While the PD-1-KO result underscores the importance of PD-1 on the CD4
+
 T cell in 
regulating diabetes, there are important differences between anti-PD-L1 treatment and the 
selective loss of PD-1 on BDC2.5 cells. Anti-PD-L1 induced rapid onset of diabetes 
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consistent with reports in intact NOD mice (137). Paradoxically, PD-1 KO BDC2.5 cells 
did not accelerate Type 1 Diabetes in NOD mice (data not shown) despite the 
overwhelming number of cells in the pancreas and direct invasion of the islet early post-
transfer. The lack of diabetes observed with PD-1 KO BDC2.5 cell transfers differs from 
previous work using PD-1 KO OT-I T cell transfers into RIP-mOVA mice (184). We 
speculate that this discordance reflects differences in CD4
+
 and CD8
+
 T cells during Type 
1 Diabetes. Since CD8
+
 T cells are responsible for direct killing of beta cells, it stands to 
reason that PD-1 KO diabetogenic CD8
+
 T cells could have a more substantial 
pathogenic effect on disease than PD-1 KO diabetogenic CD4
+
 T cells. Our histological 
data suggest that anti-PD-L1 is impacting other cells within islets in addition to BDC2.5 
cells (Figure 4-9). Additional work is needed to define the role of anti-PD-L1 on the 
dynamic interplay between diabetogenic CD4
+
 and CD8
+
 T cells, dendritic cells and Treg 
cells in the pancreas.  
Our initial studies focused on the role of PD-1 in regulating islet-reactive CD4
+
 T 
cells on a population level. While the data presented herein showed a general increase in 
proliferation (Figure 4-5 and 4-6) and CXCR3 expression (Figure 4-7), there was always 
a population of cells in the anti-PD-L1 treated mice that did not follow that trend but 
rather appeared unaffected by PD-1 blockade. This was particularly evident at late time 
points (Day 42) when cell cycle entry is assessed (Figure 4-6). Previous work in chronic 
LCMV infection had demonstrated that while PD-1 blockade could restore functionality 
to virus-specific CD8
+
 T cells, there was a subset of cells that were resistant to the effects 
of anti-PD-L1 (180). It was speculated that this subset was the most functionally 
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exhausted or terminally differentiated (180, 226). Since we observed a subset of cells that 
did not appear to be responding to anti-PD-L1 treatment, we were interested in 
determining whether PD-1 blockade differentially impacted the two main subsets of 
BDC2.5 T cells we had identified in Chapter 2 (anergic versus effector). The most 
surprising and controversial finding of this work was that loss of PD-1 signaling had a 
more substantial impact on enhancing effector cell functions than reversing T cell anergy 
(Figure 4-17). Work from our own lab had suggested that PD-1 was important for both 
the induction and maintenance of T cell anergy when antigen-coupled ECDI fixed cells 
were used to induce tolerance. However, in this model, a high number (approximately 
5x10
6
) of BDC2.5 T cells that have been activated in vitro using the high affinity 
mimetope p31 were used to induce diabetes in NOD mice. Since these cells were 
activated in vitro, they expressed high levels of PD-1 upon entering the mouse, and 
therefore were more likely to require PD-1 to induce tolerance than naïve cells becoming 
anergic following endogenous autoantigen encounter. Additionally, work from Keir and 
colleagues showed using OT-1 transfers into mice expressing incredibly low levels of 
OVA from the rat insulin promoter (RIP-mOVA
low
 mice) that these cells did not 
proliferate, and PD-1-deficiency was not sufficient to induce proliferation in this context 
(184). If sufficient antigen was provided (by activating the cells in vitro), PD-1 KO OT-1 
could induce diabetes in RIP-mOVA
low
 mice, showing that these cells were not 
intrinsically impaired. Rather, these data suggest that loss of PD-1 was not capable of 
enhancing function when antigen presentation was suboptimal, which was also likely 
occurring in the low transfer BDC2.5 system. Additionally, the inflammatory contexts 
133 
 
were completely different between the high transfer of in vitro activated BDC2.5 and the 
low transfer of naïve BDC2.5. In the high transfer setting, the BDC2.5 T cells were 
sufficient to induce diabetes and destroy the pancreas within one week post-transfer (59). 
On the contrary, in the low transfer setting, the BDC2.5 T cells were not sufficient to 
induce diabetes (data not shown) and infiltration of the pancreas occurred gradually 
(Figure 2-4). Therefore, it is reasonable to predict that tolerance induction in the low 
transfer setting would be less dependent on PD-1 than the high transfer setting. 
Additionally, anergy induction by antigen-coupled ECDI-fixed cells is atypical compared 
to how classical anergy is induced in other models, particularly in vivo (134). 
Traditionally anergy induction is associated with naïve T cells becoming primed in the 
context of low levels or low affinity antigen in the absence of costimulatory molecules or 
other inflammatory molecules needed for optimal T cell activation (134). In the high 
transfer model with p31-coupled cells, the BDC2.5 T cells were characterized as anergic 
based on their impaired proliferative capacity and cytokine production following antigen 
challenge. However, these cells differ from classical anergy in the sense that they are 
encountering antigen for a second time after being optimally activated by a high affinity 
ligand in vitro (59) (Figure 4-18). Additional studies investigating the differences in the 
requirements for the induction and maintenance of tolerance between these two forms of 
anergic cells will be important to determine the efficacy of using antigen-coupled cells to 
induce tolerance clinically. Antigen-fixed ECDI-coupled cells do not induce FR4 and 
CD73 expression (data not shown), so these markers clearly are not requisite for defining 
anergy and do not demarcate all anergic cells.   
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The idea that PD-1 alone is not sufficient to induce or maintain tolerance when 
autoreactive T cells encounter autoantigen under the natural inflammatory conditions 
present during spontaneous diabetes development provides hope for patients receiving 
anti-PD-1 therapy to enhance immunity during chronic viral infections or malignancy, 
suggesting that unless an activated effector population of autoreactive T cells is pre-
existing in the patient, the likelihood of developing autoimmunity is minimal. The risk of 
developing autoimmunity following PD-1 blockade due to either the breakdown of 
peripheral tolerance or the amplification of a pre-existing autoimmune response that had 
already broken tolerance by a different mechanism remains a critical question in the field. 
There are currently over thirty clinical trials blocking PD-1 in humans to enhance 
immunity (clinicaltrials.gov), and the data generated from these trials will help to inform 
the answer that the aforementioned question. By understanding how the PD-1 pathway 
functions during normal Type 1 Diabetes development we will strengthen our ability to 
target this pathway in humans.  
 
FOOTNOTES 
1
Portions of this work have been previously published. Reprinted from Diabetes. Volume 
62. Kristen E. Pauken, Marc K. Jenkins, Miyuki Azuma, and Brian T. Fife. PD-1, but 
not PD-L1, expressed by islet-reactive CD4
+ 
T cells suppresses infiltration of the 
pancreas during Type 1 Diabetes. p. 2859-2869. Copyright 2013, with permission from 
the American Diabetes Association (license number 3196070044473). 
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CHAPTER 5: 
Clinical opportunities and the prospective of targeting the PD-1/PD-L1 pathway to 
modulate T cell responses in patients
1
 
 
INTRODUCTION 
 The role of the PD-1/PD-L1 pathway in limiting autoimmunity by suppressing the 
effector functions of pathogenic autoreactive T cells is well established. The focus of this 
work has been further delineating how this pathway regulates islet-reactive CD4
+
 T cells 
during Type 1 Diabetes development with the ultimate goal of determining whether this 
pathway can be targeted therapeutically to restore peripheral tolerance in patients. There 
were two main themes throughout the thesis: (1) Understanding the dynamics of islet-
reactive CD4
+
 T cells during the physiological progression of Type 1 Diabetes in NOD 
mice, including the development of pathogenic effector populations and well as tolerant 
populations, and (2) which populations of islet-reactive CD4
+
 T cells were susceptible to 
PD-1-mediated regulation. This last chapter will discuss these findings in the context of 
clinical opportunities and potential therapeutic applications in terms of inducing tolerance 
to inhibit autoreactive T cells in an antigen-specific manner as well as targeting the PD-1 
pathway to modulate host immunity. For inducing tolerance, the current clinical trials 
involving anti-CD3 (teplizumab) will be discussed, as well as preclinical models 
involving the adoptive transfer of Treg cells and antigen-coupled ECDI-fixed cells. For 
targeting the PD-1/PD-L1 pathway to modulate host immunity, I will discuss both the 
possibility of engaging PD-1 on autoreactive T cells to induce an inhibitory signal to 
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suppress effector functions, as well as issues regarding administering neutralizing 
antibodies against PD-1 to enhance immunity during chronic antigen settings such as 
persistent viral infections and malignancies. The overall goal of this section is to provide 
an assessment of the potential efficacy of inducing tolerance in Type 1 Diabetic patients, 
whether engaging PD-1 could be useful in tolerance induction, and the risk of eliciting 
autoimmunity as an unwanted side effect of anti-PD-1 therapy to enhance immunity. 
Ultimately, with a better understanding of the basic biology of tolerance and the PD-1 
pathway we will be able to help patients make more informed decisions about treatments 
and develop a cure for Type 1 Diabetes.  
 
THERAPEUTIC APPROACHES TO INHIBIT ANTI-ISLET IMMUNITY IN 
PATIENTS WITH TYPE 1 DIABETES 
Addressing the anti-islet immune response is required to cure patients with Type 1 
Diabetes 
Developing a cure for Type 1 Diabetes in patients involves two critical events. 
First, the insulin-producing beta cells that have been destroyed by the immune system 
must be replaced in order for patients to regulate their own glucose metabolism 
independently of exogenous insulin therapy. There are methods that are currently being 
used successfully in the clinic to restore beta cell mass, including whole pancreas or islet 
transplantation (227). There are also approaches that are still in the development stage but 
hold great promise for the diabetes field, including production of insulin-producing cells 
derived from induced pluripotent stem cells (228). However, it was appreciated early 
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after pancreas transplantation entered the clinic that restoring beta cells was not sufficient 
to cure diabetes. In a patient that received a pancreas transplant from an identical twin, 
and subsequently had no allograft rejection issues, the recurrent autoimmune response 
destroyed the graft (229). These data have been replicated in murine models of Type 1 
Diabetes, supporting a model where diabetogenic T cells persist long term following 
destruction of the pancreas. Following islet transplantation, these cells become re-
activated and subsequently destroy the graft (230). The requirement for high doses of 
broad spectrum immunosuppressive drugs to suppress the autoimmune response 
following islet transplantation has greatly hindered use of islet transplant therapy in 
humans to cure Type 1 Diabetes. Therefore, in order to develop a more viable cure for 
Type 1 Diabetes, a second critical event must occur involving the specific suppression of 
the anti-islet autoimmune response. Our lab and others are currently focused on 
developing antigen-specific therapies to inhibit the diabetogenic T cell response during 
Type 1 Diabetes. The goal of antigen-specific therapies is to avoid broad spectrum 
immunosuppressive drugs which will render the patient highly susceptible to infections 
and malignancies. The following sections will discuss both antigen-specific therapies that 
are in clinical trials as well as prospective therapies that are still in preclinical models.  
 
Clinical trials using anti-CD3 (teplizumab) to induce tolerance in patients with Type 1 
Diabetes have shown mixed results 
The most promising antigen-specific therapy currently in clinical trials is 
teplizumab, a humanized FcR-non-binding antibody specific for human CD3 (231, 232). 
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Anti-CD3 treatment in NOD mice can reverse new onset diabetes following a short 5 day 
treatment regiment (230). Anti-CD3 has a variety of effects on the host immune system, 
ultimately resetting the balance between effector and regulatory T cells in favor of 
regulation. Anti-CD3 preferentially induces apoptosis in activated T cells, which in a 
diabetic patient lacking concurrent infections will predominantly be the autoreactive T 
cell population. This treatment can also induce anergy, resulting in induction of a 
hyporesponsive state, or antigenic modulation, which prevents the T cells from 
encountering antigen based on physical blocking of the T cell receptor or internalization 
or shedding of the T cell receptor (233). The most dramatic effect of anti-CD3 is a 
clearing of islet-reactive T cells from the pancreas within the first two days after 
treatment. However, the effect of anti-CD3 on the effector population is transient, and 
these cells eventually repopulate the pancreas. Therefore, the most significant effect of 
anti-CD3 in terms of long lasting therapeutic potential is its ability to restore regulation in 
the immune system. Treatment with anti-CD3 causes a loss of both effector T cells and 
Treg cells, but Treg cells recover much more quickly, shifting the balance of the immune 
system from deregulated autoimmunity to a state of immune homeostasis. Anti-CD3 is 
considered an antigen-specific therapy because the majority of T cells that are activated 
in a diabetic mouse or patient and subsequently would be depleted are islet-antigen 
specific (233). However, the benefit of this therapy is that knowledge of the antigens to 
be targeted is not required, making treatment easily generalizable between patients. 
Unfortunately, while preclinical data in NOD mice and phase I and II clinical trials were 
promising, preliminary data from the first year of the phase III clinical trial have been 
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disappointing (234). The initial interpretation of the data from the phase III clinical trial 
suggested that anti-CD3 did not improve on the standard insulin therapy after one year 
(234). However, these interpretations have been heavily challenged, with many claiming 
that the parameters used to assess efficacy were misleading and not validated in the 
earlier clinical trials (235). Many are still hopeful that anti-CD3 will be an effective 
immunotherapeutic agent since in this trial it had a positive impact on C-peptide 
production and reduced patients’ exogenous insulin needs (235). An active area of 
research is directed at identifying the mechanism of anti-CD3-mediated tolerance in 
humans and determining ways to increase efficacy by promoting more stable tolerance 
induction. 
 
Preclinical models aimed at inducing tolerance in Type 1 Diabetic patients 
Considering the mixed results obtained with anti-CD3 in the clinic, several groups 
have begun focusing on alternative approaches to induce antigen-specific tolerance to 
cure Type 1 Diabetes. Two of these approaches involve the adoptive transfer of Treg 
cells to induce better extrinsic control over effector autoreactive T cell populations and 
antigen-coupled ECDI-fixed cells as a mechanism to directly target the pathogenic T cell 
population to induce cell intrinsic tolerance. While both approaches aim to induce 
tolerance and suppress pathogenic diabetogenic T cell responses, they both have 
complicating factors that have slowed their entry into the clinic. Both require 
manipulating human cells ex vivo, which makes these protocols expensive, labor 
intensive, and have to be individualized for each patient rather than being mass produced 
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like anti-CD3. Additionally, the notion of antigen specificity complicates both 
approaches. These issues continue to be heavily considered as these therapies move 
closer to the clinic. 
Adoptive transfer of Treg cells to suppress autoimmunity is an attractive 
therapeutic approach to treat Type 1 Diabetic patients because preclinical data using 
NOD mice suggested that adoptive transfer of either polyclonal or islet-antigen specific 
Treg cells could prevent disease (133, 140, 236). Several groups, including those led by 
Bluestone, June, and Blazar, have developed ways to expand Treg cells ex vivo to 
generate large numbers of cells for infusion back into the host (133, 237, 238). This 
approach, which utilizes exposure of highly purified Treg cells to anti-CD3 and anti-
CD28 coated beads in conjugation with high levels of IL-2, generates cells which are 
capable of suppressing autoimmunity when transferred into Treg cell-deficient mice 
(133). However, incredibly high numbers of polyclonal Treg cells were needed for 
protection, reducing the feasibility of this approach in humans. Substantially fewer Treg 
cells were needed if the expanded population was specific for an islet-antigen (BDC2.5) 
(133); however, the requirement for antigen-specific Treg cells inevitably complicates 
translation into the clinic. Antigen-specificity requires more specialized therapy because 
the antigens may be different between patients, increasing the risk of Treg cells failing to 
protect. Additionally, the less generalizable the therapy, the more expensive it becomes. 
Furthermore, there is no evidence to suggest that islet-antigen specific Treg cells will not 
have a more general suppressive effect on host immunity, rendering the patient 
immunocompromised. An added layer of complexity is that new evidence suggests that 
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there are different varieties of Treg cells similarly to how there are different subsets of 
conventional CD4
+
 T cells, and expression of the same master transcription factors 
between Treg cells and effector T cells makes these Treg cells more effective at 
suppressing than non-polarized Treg cells (239). Lastly, one of the greatest concerns with 
Treg cell therapy is the stability of the regulatory functions of the cells being transferred. 
Zhou and colleagues recently showed that there is a subpopulation of Treg cells that can 
lose Foxp3 expression in vivo and convert to pathogenic effector cells capable of 
inducing autoimmunity (204). This issue is particularly concerning for transferring islet-
antigen specific Treg cells into patients, since the loss of regulatory functions and 
acquisition of effector functions could severely exacerbate the pre-existing autoimmune 
disease. The stability of ex vivo expanded human Treg cells and the conditions that could 
promote loss of regulatory properties should be thoroughly explored before adopting this 
therapy to attempt to treat Type 1 Diabetic patients. These issues have slowed translation 
of Treg therapy to the clinic. Additionally, issues of feasibility in humans have impeded 
the progress of moving this therapy forward, including: a lack of unique surface markers 
defining human Treg cells makes this population difficult to efficiently expand, the 
frequency of Treg cells in human peripheral blood is very low, and the number of Treg 
cells that would likely be needed to suppress autoimmunity is too high to easily be 
achieved by current methods. Despite these draw backs, Phase I clinical trials have been 
initiated transferring allogeneic Treg cells into patients with hematopoietic stem cell 
transplants using methods to expand human Treg cells (142, 240, 241), and the data 
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generated during these trials will likely be used to determine whether this approach could 
be useful for Type 1 Diabetic patients. 
Antigen-coupled ECDI-fixed cells are an attractive therapeutic platform because 
they are one of very few therapies that can reverse Type 1 Diabetes in NOD mice (59). 
As discussed in Chapter 1, antigen-coupled ECDI-fixed cells have been used extensively 
in NOD mice to delineate the epitopes involved early in disease initiation as well as late 
during pre-clinical disease and at diabetes onset (59, 85). In NOD, insB9-23 is a critical 
initiating epitope, since treating 4 week old mice with this peptide coupled to splenocytes 
prevents diabetes. Treating older NOD mice with insB9-23-coupled cells failed to prevent 
diabetes, but whole insulin- coupled cells could prevent disease (85). Additionally, whole 
insulin-coupled cells also reversed diabetes in NOD mice (59), though the individual 
insulin peptides have not been tested in this context. The use of whole proteins rather 
than peptides may be advantageous therapeutically, since multiple epitopes can be 
targeted at once. However, priming NOD mice with whole insulin is not capable of 
generating an immune response, which is likely because the major pathogenic T cell 
population selectively recognizes peptides that are not natural cleavage products of 
insulin produced through the MHC class II processing pathway (57). Therefore, 
immunizing with different peptides versus proteins could be problematic in terms of 
antigen recognition. Additionally, Type 1 Diabetes is a complex autoimmune disease that 
involves a variety of antigens at different stages of the disease. The heterogeneity in 
antigens recognized in patients and how these antigens change as disease develops is not 
well understood, and could make it so that coupled cell therapy has to be highly 
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personalized if it is going to be efficacious. Additionally, providing a source of cells to be 
coupled to antigen may be difficult and expensive. Miller and colleagues have developed 
biodegradable microparticles that can be used as platforms for coupled cells antigens to 
circumvent this problem (242), though whether these particles will be nearly as 
tolerogenic as apoptotic cells in humans with high levels of autoimmune-mediated 
inflammation remains to be tested. 
Lastly, additional studies are needed to determine the stability of the tolerance 
induced by Treg cells and antigen-fixed ECDI-coupled cells. Work from our lab has 
shown that PD-1 is required for both the induction and maintenance of tolerance 
following coupled cell therapy (59, 110). This could be problematic, since over 30 SNPs 
have been identified in the human PD-1 gene that are associated with enhanced 
susceptibility to several autoimmunity diseases (discussed in Chapter 1), and it is possible 
that these SNPs render the PD-1 pathway less effective in these patients. However, the 
data presented in this thesis argue that PD-1 is not required for the induction or 
maintenance of tolerance marked by FR4 and CD73 co-expression, but rather is 
selectively important for suppressing the functionality of the pre-existing effector 
population. It could therefore be reasoned that coupled cells induce a less stable form of 
tolerance than whatever is inducing tolerance following encounter with endogenous 
autoantigen. Indeed, coupled cells do not induce FR4 and CD73 (data not shown) even 
though they induce anergy based on functional impairment following antigen rechallenge. 
Whether there are differences in the stability of the tolerance phenotype between the 
FR4
+
 CD73
+
 population in the low transfer (defined in Chapter 2) and the ECDI-fixed 
163 
 
antigen-coupled cell model remains to be tested. However, since PD-1 is important for 
regulating the anergic population following antigen coupled cell therapy, combination 
therapies designed to engage PD-1 on T cells following coupled cell therapy may be 
possible to promote more stable tolerance in patients. Understanding the lineage 
relationships between effector, anergic, and exhausted cells, what factors drive the 
development of each population, and the stability of each population will be critical for 
determining whether durable tolerance can be induced in patients to cure Type 1 Diabetes 
(Figure 4-18).  
 
POTENTIAL OBSTACLES INVOLVED IN EXPLOITING THE PD-1 
PATHWAY TO INDUCE TOLERANCE IN TYPE 1 DIABTES 
Identifying which cell type(s) to target to engage the PD-1/PD-L1 pathway in patients 
The broad expression of PD-L1 on hematopoietic and non-hematopoietic cells 
suggests that PD-1/PD-L1 interactions are involved in regulating T cell functions in non-
lymphoid tissues. This aspect of the PD-1 pathway makes it an attractive therapeutic 
target, since T cell functions can be regulated in the autoimmune target organ where the 
damage is occurring. However, addressing which cell type, whether hematopoietic or 
non-hematopoietic, must express PD-L1 in order to suppress T cell functions is 
particularly important since recent work using chronic viral infections showed that PD-
L1 on both of these lineages was required for protective immunity, but that it played 
distinct roles on hematopoietic versus non-hematopoietic cells (243). Additionally, PD-
L1 expressed by hematopoietic versus non-hematopoietic cells may drastically alter 
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which T cell subsets can be targeted for PD-1-mediated inhibition, which will be 
discussed in a later section. 
Work by Keir and colleagues demonstrated that PD-L expressed by non-
hematopoietic cells played an essential role in islet-specific tolerance (174), supporting 
the notion that inhibitory pathways can be engaged in the autoimmune target organ to 
inhibit T cell functions. In further support of this concept, work from our lab showed that 
PD-1 actively regulated tolerant T cells in pancreatic islets, since blocking PD-1 using 
neutralizing antibody to PD-L1 induced the T cell stop signal required to acquire effector 
functions at this site (110). Therefore, selective targeting of PD-L1 to beta cells is an 
attractive approach to treat Type 1 diabetes; however, two separate studies have yielded 
conflicting results. In one study, expression of PD-L1 from the human insulin promoter 
in NOD mice dramatically reduced spontaneous diabetes incidence (244), while 
expressing PD-L1 from the rat insulin promoter in C57BL/6 mice accelerated Type 1 
Diabetes and islet allograft rejection (245). The differences between these two reports 
have not yet been reconciled. Genetic background, transgene promoter source, integration 
site, copy number, and protein expression levels and stability could account for the 
dramatic differences in the therapeutic efficacy observed in these two models. In addition 
to these possibilities, PD-L1 can also bind to B7-1, and the consequences of these 
interactions in pancreatic islets are unclear (149, 246). Data obtained using PD-L1 
expression from the human insulin promoter in NOD is encouraging and warrants further 
investigation. Future work investigating the selective targeting of PD-L1 to intra-islet 
dendritic cells could also be informative. Subsequent work will be necessary to clarify the 
165 
 
role of intra-islet dendritic cell-specific PD-L1 and beta cell-specific PD-L1 expression in 
controlling diabetes. 
In a second model of diabetes, PD-L1 expression was targeted to a different non-
hematopoietic cell in the pancreas, the peri-islet Schwann cell (pSC). PD-L1 expression 
on pSC was achieved using the glial fibrillary acidic protein (GFAP) promoter (247). 
pSC expression of PD-L1 did not protect mice from developing diabetes (247). These 
failed attempts underscore the complexity of targeting inhibitory pathways in vivo to 
enhance islet-specific tolerance. Future work should be aimed at addressing these issues.  
Lastly, a better understanding of how T cells receive the PD-1 signal in both 
lymphoid and non-lymphoid compartments will be essential to exploit this pathway to re-
establish tolerance and treat autoimmunity since many autoreactive T cells reside in 
peripheral sites and not in secondary lymphoid organs. Work from Blackburn and 
colleagues have shown that PD-1
high
 cells can preferentially survive in the bone marrow 
compared to the spleen during chronic LCMV infection due to low levels of PD-L1 
expressed in this location (248); therefore, understanding the dynamic expression of both 
PD-1 and PD-L1 in various tissues and how that impacts the efficacy of targeting this 
pathway are critical. 
 
Approaches to engage PD-1 in patients to suppress T cell effector functions during 
autoimmunity 
Strategies to engage inhibitory receptors to treat autoimmunity are highly sought 
after clinically due to the antigen-specific manner in which these receptors signal. T cells 
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must receive the PD-1 signal in conjunction with the antigen-specific T cell receptor 
signal to suppress T cell functions (166). Therefore, PD-L1 and peptide/MHC must be 
co-expressed by the same antigen presenting cell (in cis) to signal through PD-1 (166). 
While this signaling requirement is attractive when considering antigen-specific therapies 
because PD-1 will be engaged only on activated T cells and in an antigen dependent 
manner, the clinical feasibility of targeting antigen to the same cells expressing PD-L1 is 
complicated. Using a mouse model of multiple sclerosis (experimental autoimmune 
encephalomyelitis or EAE), Hirata and colleagues developed a strategy to provide the 
PD-1 signal to T cells in cis with T cell receptor engagement (249). In this study dendritic 
cells were engineered to express high levels of PD-L1 and myelin oligodendrocyte 
glycoprotein peptide presented in MHC class II. The engineered dendritic cells 
significantly reduced the severity of EAE and reduced the amount of cellular infiltrate in 
the spinal cord. The results of this study are encouraging and highlight the therapeutic 
potential of engineering dendritic cells as a strategy to engage PD-1 on autoreactive T 
cells in a clinical setting. However, the antigen-specific nature of the PD-1 inhibitory 
signal could also be an obstacle, since the immunodominant epitopes would need to be 
identified prior to treatment. Furthermore, epitope spreading could lead to a wide 
diversity of epitopes as disease progresses, making it difficult to identify newly emerging 
antigenic targets.  
An additional approach to target these receptors is through membrane-bound 
agonists. Membrane-bound agonists are required to induce a signal through inhibitory 
receptors including PD-1 and CTLA-4 because these receptors must be cross-linked 
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through ligand to function. This concept has been most evident through work with 
CTLA-4. Soluble CTLA-4-Ig is not capable of cross-linking CTLA-4 on the surface of T 
cells in vivo; however, expressing a single-chain anti-CTLA-4 construct from the cell 
surface can engage CTLA-4 and deliver an inhibitory signal (250, 251). Using this 
approach, we demonstrated that B cell expression of anti-CTLA-4 single chain 
effectively reduced autoimmune diabetes incidence and decreased insulitis in NOD mice 
(251). This strategy could be pursued for PD-1 engagement to inhibit autoreactive T cells 
in vivo. Further development of this approach to engage PD-1 in clinical applications will 
depend upon efficient gene transfer technology and expression by antigen presenting 
cells in vivo. One strategy for ectopically expressing membrane-bound PD-1 agonists is 
delivery of genes via viral vectors. Ding and colleagues expressed full length murine PD-
L1 in recombinant adenovirus to treat lupus-like syndrome in mice (252). Since the 
authors detected high levels of PD-L1 expression on renal proximal tubular epithelial 
cells, they postulated that PD-L1 was suppressing autoreactive T cells in the autoimmune 
target organ (252). One advantage of using viral vectors is that they can be engineered to 
be highly tissue specific by manipulating the viral capsid or using a tissue-restricted 
promoter to express virally-encoded transgenes. However, caution should be taken to 
ensure patient safety when considering the use of the viral vectors for clinical purposes. 
These findings highlight the complexities of engaging inhibitory receptors to inhibit T 
cell functions.  
 
Can the PD-1 pathway be targeted to restore tolerance in Type 1 Diabetic patients? 
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 In order to engage PD-1 on a T cell to deliver an inhibitory signal, PD-L1 and 
peptide/MHC must be expressed by the same cell, and that cell has to be capable of 
presenting antigen to the T cell of interest. It is likely that due to MHC restriction, CD4
+
 
T cells will be more limited in their ability to receive an inhibitory signal than CD8
+
 T 
cells due to the more restricted expression of MHC class II compared to MHC class I 
(Figure 5-1). CD4
+
 and CD8
+
 T cells are both required during Type 1 Diabetes 
development; however, the specific timing and location in which these cells are required 
for pathogenesis may provide insight into how these cells should be targeted 
therapeutically. At least in NOD mice, CD4
+
 T cells are critical for initiating Type 1 
Diabetes, but CD8
+
 T cells are more important at the later stages of diabetes for directly 
killing the insulin-producing cells. Therefore, it could be reasoned that targeting PD-L1 
to beta cells would be sufficient to protect islets from CD8
+
 T cell-mediated apoptosis 
since these cells also express high levels of MHC class I presenting diabetogenic peptides 
(Figure 5-1). Additional work is needed to define the temporal and spatial requirement 
for islet-reactive CD4
+
 and CD8
+
 T cells in humans to determine the efficacy of targeting 
these populations to protect pancreatic islets. Since immunotherapy will likely be used in 
conjunction with islet replacement therapy such as an islet transplant, PD-L1 or agonist 
anti-PD-1 could be expressed on the islets prior to transplant (e.g. through delivery of 
genes encoding these molecules by a virus) to protect the graft. These therapies hold 
promise for Type 1 Diabetic patients that someday we may have a cure.  
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AUTOIMMUNITY AS A SIDE EFFECT OF USING NEUTRALIZING 
ANTIBODIES TO BLOCK PD-1 IN PATIENTS TO RESTORE PROTECTIVE 
IMMUNITY 
Our long term goal as a lab has been to understand how PD-1 operates to suppress 
T cell functions in the context of autoimmunity with the hope of exploiting this pathway 
therapeutically to suppress diabetogenic T cell responses in patients. However, due to the 
complexities of engaging PD-1 on a T cell to deliver an inhibitory signal, there has been 
limited progress in exploiting this pathway to restore tolerance in patients with 
autoimmunity. Rather, the greatest progress in terms of targeting this pathway for 
therapeutic benefit has been administering neutralizing antibodies to block PD-1 
signaling during chronic viral infections and various malignancies (253-258). In both 
cases, chronic antigen engagement leads to a progressive loss of function and ultimately 
the failure to eliminate the virus or the tumor (148, 159). This loss of function, termed 
exhaustion, has been best defined for CD8
+
 T cell responses, which are essential for 
direct killing of peptide/MHC class I-expressing virus-infected cells or tumor cells (179). 
While PD-1 blockade has been promising to revitalize exhausted CD8
+
 T cells to aid in 
clearance of the tumor or virus, there is substantial concern that anti-PD-1 will elicit an 
autoimmune response in these patients. As immunologists studying the impact of PD-1 
signaling on autoreactive T cells, we have a responsibility to address these issues and 
provide an assessment of risk involved in anti-PD-1 treatment. The goal of this section is 
to address this issue by first outlining how PD-1 blockade is thought to revive CD8
+
 T 
cell responses focusing on chronic viral infections, then examining data from current 
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clinical trials targeting PD-1 and/or CTLA-4, and lastly discussing the risk of anti-PD-1 
eliciting an aberrant autoimmune response in patients considering the data presented in 
Chapter 4 suggesting that PD-1 blockade more potently targets autoreactive effector T 
cells than anergic T cells. 
 
Blocking PD-1 using neutralizing antibodies revitalizes CD8
+
 T cell responses and 
enhances anti-tumor or anti-viral immunity in patients  
In order for PD-1 to deliver an inhibitory signal to a T cell, the T cell receptor 
must simultaneously be engaged by peptide/MHC on the same cell expressing PD-L1 
(166). During chronic viral infections and cancer, antigen-specific PD-1-expressing T 
cells encounter PD-L1 on cognate peptide/MHC-bearing infected cells or tumor cells 
(148). The chronic signaling through PD-1 leads to functional exhaustion of antigen-
specific T cells (148, 158, 259). Because PD-1 and the T cell receptor are persistently 
engaged, administration of anti-PD-1 or anti-PD-L1 can block this inhibitory signal and 
release the cell from negative regulation. Evidence from both mouse and human systems 
has demonstrated that PD-1 blockade can restore function to CD8
+
 T cells, leading to 
enhanced production of inflammatory cytokines and cytotoxic capacity and subsequently 
control of viral titers as well as reduced tumor burden (148, 158, 159, 260). These 
preclinical data have generated substantial interest in targeting this pathway to enhance 
immunity in patients with various malignancies or chronic viral infections. 
Work in mouse models using chronic LCMV infection (Clone 13) has shown that 
while PD-1 blockade can restore T cell effector functions and ultimately lead to enhanced 
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control of the virus, there is a subset of cells that cannot be functionally restored (180). 
What factors dictate whether a cell will be susceptible to being invigorated by PD-1 
blockade are unclear, but is currently an active area of research. One hypothesis is that as 
cells constantly encounter antigen and PD-1 signaling, they become progressively more 
exhausted and subsequently more terminally differentiated (179, 226). Once the cells 
reach a certain threshold, they can no longer be rescued by PD-1 blockade. One approach 
to overcome this limitation and restore function to a greater fraction of the population is 
blocking multiple inhibitory receptors, such as CTLA-4 or LAG-3 (259). Evidence in 
murine models has suggested that there is synergy between multiple inhibitory receptors 
including PD-1 and LAG-3, allowing blockade of multiple receptors to be more effective 
than blocking either molecule individually (259). It should be noted, however, that it 
remains to be determined whether those cells that cannot be rescued by PD-1 blockade 
alone are worth being rescued by combination therapy. It is possible that these cells are in 
such a dysfunctional state that restoration of function would be more detrimental than 
beneficial for the host. Gaining a deeper understanding of exhaustion from other stand 
points than simply effector function, such as metabolism and DNA damage, will be 
essential to determining the importance of these cells to anti-viral or anti-tumor immune 
responses.  
 
Use of neutralizing antibodies to block PD-1 in patients to restore protective immunity 
during malignancies and chronic viral infections  
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Anti-PD-1 or anti-PD-L1 therapy to enhance immunity is currently in clinical 
trials for a variety of malignancies including advanced melanoma, non-small cell lung 
cancer, castration-resistant prostate cancer, renal cell cancer, and colorectal, ovarian, 
pancreatic, gastric, and breast cancers (253-255, 257, 258), and trials are beginning for 
chronic viral infections including hepatitis C (HCV) (256). Trials with anti-PD-1 in 
humans have been highly anticipated due to early successes targeting CTLA-4 with the 
monoclonal antibody ipilimumab (261). Based on work in murine models, PD-1 blockade 
was speculated to be more efficacious at restoring T cell functions than CTLA-4, 
particularly in non-lymphoid tissues where both PD-1 and importantly its ligand PD-L1 
are highly expressed (262). While CTLA-4 is an important regulator of T cell functions, 
it currently hypothesized that CTLA-4 plays more of a role in suppressing functions in 
secondary lymphoid organs than non-lymphoid tissues (262). Early results using anti-PD-
1 in tumors and HCV have been promising. In tumor trials anti-PD-1 has been well 
tolerated and has shown strong evidence of anti-tumor activity. Importantly, in one study 
where patients achieved objective responses during treatment, following cessation of 
therapy these responses were sustained for an additional three years (257). This result 
was exciting because it suggested that the effects of anti-PD-1 were durable and 
subsequently prolonged treatment could be avoided.  In the HCV trial, anti-PD-1 led to a 
substantial reduction in viral load, even in patients that had failed to respond to Type I 
IFN therapy (256). In this study six patients showed signs of immune-related adverse 
events, including low levels of hyperthyroidism. Whether the hyperthyroidism was due to 
pre-existing autoimmunity or a new autoimmune response was unclear. A recent clinical 
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trial was conducted neutralizing both PD-1 (with nivolumab) and CTLA-4 (with 
ipilimumab) in patients with advanced melanoma. In this study, 53% of patients had an 
objective response, all of which experienced at least an 80% reduction in tumor burden 
(263). These results were superior to treating with either agent alone. Additionally, the 
safety profile of this combined therapy was manageable, with adverse effects not more 
severe than either therapy alone (263). These data have generated optimism that 
combination therapy to block inhibitory receptors in patients will be able to eradicate 
tumors and chronic viral infections.  
 
Assessing the risk of eliciting an autoimmune response following anti-PD-1 therapy to 
enhance anti-viral or anti-tumor immunity in patients 
While the early clinical trial data for PD-1 blockade have been promising, there is 
substantial concern for treatment eliciting autoimmunity. While autoimmunity will 
always be a potential risk for immunotherapies aimed at stimulating protective responses, 
relative risk assessments could be made to help patients make informed decisions on 
treatment options based on preclinical models. Based on the data presented in this thesis, 
I speculate that the risk of PD-1 eliciting autoimmunity is going to be very low. By 
studying islet-reactive CD4
+
 T cells under physiological contexts, the role of PD-1 in the 
induction and maintenance of tolerance is not as critical as was originally anticipated 
based on work using highly non-physiological models of Type 1 Diabetes pathogenesis 
(110, 251). PD-1 is important for suppressing autoreactive T cell functions; however, it is 
uniquely involved in suppressing effector phenotype cells rather than anergic cells. I 
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further speculate that anti-PD-1 will not be able to restore functionality to chronically 
stimulated islet-reactive CD4
+
 T cells that arise in the secondary lymphoid organs of 
older NOD mice, though this hypothesis remains to be fully tested. Therefore, I postulate 
that the only patients at risk of developing autoimmunity following anti-PD-1/PD-L1 
treatment are those that have an activated, effector-like population of autoreactive T cells 
(Figure 5-2). All healthy individuals have autoreactive T cells in circulation (121-123). If 
these cells are naïve, blocking PD-1 will not have deleterious effects because it is not 
expressed on naïve T cells (Figure 5-2). If these cells have encountered antigen in a 
tolerogenic context and have been rendered anergic, blocking PD-1 will not have 
deleterious effects because PD-1 is not capable of restoring functionality to these cells 
(Figure 5-2). If these cells became activated but were persistently stimulated for several 
years without causing overt autoimmunity and eventually became functionally exhausted, 
I speculate that anti-PD-1 will also not restore functionality to those cells (Figure 5-2). 
Only if there are activated effector cells will therapeutic PD-1 blockade amplify the 
autoimmune response (Figure 5-2), and improvements on tetramer technology and the 
ability to track these cells in humans will greatly improve our ability to identify these 
patients prior to the initiation of therapy. One issue of particular concern that cannot be 
over-looked is immunopathology, since release of sequestered antigens due to enhanced 
killing by revitalized CD8
+
 T cells may lead to activation of naïve autoreactive T cells, 
and these recently activated cells would be susceptible to enhanced functionality caused 
by PD-1 blockade. On-going results from clinical trials with anti-PD-1 will be 
informative in testing the hypotheses presented above. Ultimately clinical trials targeting 
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PD-1 should move forward despite the concern for eliciting autoimmunity in patients, 
since targeting one inhibitory pathway is unlikely to cause enough amplification of an 
autoimmune response to induce clinical symptoms of autoimmunity. 
  
CONCLUSION 
 The importance of the inhibitory receptor PD-1 interacting with its ligand PD-L1 
in limiting Type 1 Diabetes progression is well established. However, this pathway is not 
sufficient to prevent diabetes in the 60-80% of female mice that eventually develop the 
disease. In this work, I examined the role of PD-1 in regulating islet-reactive CD4
+
 T 
cells using experimental systems that more accurately mimic physiological disease 
progression than previous models. By examining these CD4
+
 T cell populations, it 
became evident that the frequency of pathogenic CD4
+
 T cells in the islet-reactive pool 
was much smaller than originally expected. Following activation in the pancreatic LN, 
the majority of these cells were rendered anergic. The critical finding of this work was 
that PD-1 was not required to induce or maintain this tolerant state. Rather, PD-1 was 
more important for controlling the subset of effector phenotype cells that naturally arises 
in NOD mice. These results have important implications for immunotherapy. In terms of 
inhibiting the on-going islet-specific immune response, it is now appreciated that this 
population is numerically smaller than anticipated, providing renewed hope for patients 
undergoing anti-islet immunotherapy. In terms of targeting PD-1 to induce tolerance, it is 
unclear whether specifically ligating PD-1 on the islet-reactive T cells could provide 
therapeutic benefit. Considering the fact that PD-1 appears to be more important for 
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regulating pathogenic effector cells than anergic cells, PD-1 ligation in the pancreas may 
be effective to suppress the functions of this pathogenic subset. Lastly, I speculate that 
the risk of eliciting an autoimmune response when blocking PD-1 clinically to enhance 
immunity during chronic viral infections and tumors will be very low, since in order for 
therapeutic blockade of PD-1 to amplify an autoimmune response patients would require 
a pre-existing population of activated effector cells that were not being adequately 
restrained by peripheral tolerance (Figure 5-2). Future work addressing what factors 
contribute to the induction and maintenance of the anergic population independently of 
PD-1 will be informative to develop novel therapeutic approaches to promote tolerance 
clinically (Figure 4-18).   
 
FOOTNOTES 
1
Portions of this work have been previously published. Reprinted from Annuals of the 
New York Academy of Sciences, Volume 1217, Brian T. Fife and Kristen E. Pauken, The 
role of the PD-1 pathway in autoimmunity and peripheral tolerance. p. 45-59. 2011. 
Permission pending.  
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